[
    {
        "ticker": "tmo",
        "sector": "Healthcare",
        "data": [
            {
                "index": 0,
                "date": "2023-06-05",
                "press_title": "Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Introduces-Groundbreaking-Mass-Spectrometer-to-Revolutionize-Biological-Discovery/default.aspx",
                "content": "Thermo Scientific Orbitrap Astral mass spectrometer combines high resolution and speed to accelerate the discovery of new proteins and advance precision medicine Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer. The Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer offers accurate and precise quantitation in proteomics laboratories with faster throughput, deeper coverage and higher",
                "1d_change": -1.5108557006,
                "index_price": 0.0200722075,
                "norm_price": -1.5309279081
            },
            {
                "index": 1,
                "date": "2023-05-24",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on July 14, 2023, to shareholders of record as of June 15, 2023. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen,",
                "1d_change": 2.0436428612,
                "index_price": 0.4413054568,
                "norm_price": 1.6023374044
            },
            {
                "index": 2,
                "date": "2023-05-24",
                "press_title": "Thermo Fisher Scientific Hosts 2023 Investor Day",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Hosts-2023-Investor-Day/default.aspx",
                "content": "Highlights include the Company’s Industry-Leading Businesses, Trusted Partner Status with Customers and Outstanding Long-Term Financial Outlook Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses: Life Science Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services. “Science is ad",
                "1d_change": 2.0436428612,
                "index_price": 0.4413054568,
                "norm_price": 1.6023374044
            },
            {
                "index": 3,
                "date": "2023-05-22",
                "press_title": "Thermo Fisher Scientific to Present at Bernstein 39th Annual Strategic Decisions Conference on May 31st, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Present-at-Bernstein-39th-Annual-Strategic-Decisions-Conference-on-May-31st-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31, 2023 at 11:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing",
                "1d_change": -0.4418189079,
                "index_price": -1.0903107932,
                "norm_price": 0.6484918853
            },
            {
                "index": 4,
                "date": "2023-05-19",
                "press_title": "Thermo Fisher Scientific Announces FDA Clearance of Breakthrough Immunoassays to Aid in the Risk Assessment of Preeclampsia",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Announces-FDA-Clearance-of-Breakthrough-Immunoassays-to-Aid-in-the-Risk-Assessment-of-Preeclampsia/default.aspx",
                "content": "First and only blood-based biomarkers for the risk assessment and clinical management of preeclampsia with severe features Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication. Preeclampsia is a life-threatening blood pressure disorder that can occur during pregnancy and the postpartum period. Preeclampsia is the leading cause of maternal and fetal mortality and morbidity worldwide, with incident rates that have increased rapidly in the United States over the last decade. These new assays are designed to be used along with other laboratory tests and clinical assessments to aid in the risk assessment of",
                "1d_change": 1.1303984556,
                "index_price": -0.27476834,
                "norm_price": 1.4051667956
            },
            {
                "index": 5,
                "date": "2023-05-17",
                "press_title": "Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Releases-2022-Corporate-Social-Responsibility-Report/default.aspx",
                "content": "Company highlights colleagues’ commitment to innovation, progress toward ambitious targets, and building a brighter future for all stakeholders Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders and provides insight into its CSR progress and environmental, social and governance (ESG) efforts. “Our Mission to enable our cus",
                "1d_change": 0.2253801197,
                "index_price": 1.7913009738,
                "norm_price": -1.565920854
            },
            {
                "index": 6,
                "date": "2023-05-09",
                "press_title": "Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific--Pfizer-Partner-to-Expand-Localized-Access-to-Next-Generation-Sequencing-Based-Testing-for-Cancer-Patients-in-International-Markets/default.aspx",
                "content": "Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access to localized advanced testing capabilities for breast and lung cancer in more than 30 countries where access to affordable advanced genomic testing is lacking or not available Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient. 1 Cancer is a leading cause of death globally, accounting for nearly 10 million deaths in 2020, or around",
                "1d_change": -0.2886515897,
                "index_price": 0.3236177211,
                "norm_price": -0.6122693108
            },
            {
                "index": 7,
                "date": "2023-05-02",
                "press_title": "Thermo Fisher Scientific to Present at BofA Securities 2023 Healthcare Conference on May 10th, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Present-at-BofA-Securities-2023-Healthcare-Conference-on-May-10th-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 11:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and",
                "1d_change": 1.0119552558,
                "index_price": -1.7930721177,
                "norm_price": 2.8050273736
            },
            {
                "index": 8,
                "date": "2023-04-26",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2023 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Reports-First-Quarter-2023-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023. First Quarter 2023 Highlights Delivered very strong financial results during the first quarter. First quarter revenue was $10.71 billion, 9% lower versus the same quarter last year. Core organic revenue growth was 6%. First quarter GAAP diluted earnings per share (EPS) was $3.32. First quarter adjusted EPS was $5.03. Launched a range of h",
                "1d_change": 2.7660136005,
                "index_price": 1.150327475,
                "norm_price": 1.6156861256
            },
            {
                "index": 9,
                "date": "2023-04-10",
                "press_title": "Thermo Fisher Scientific to Host Investor Day",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Host-Investor-Day/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2023 Investor Day on Wednesday, May 24, starting at 9:00 a.m. (ET)in New York City. The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a QA session. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing",
                "1d_change": 0.6332672178,
                "index_price": 0.5777643522,
                "norm_price": 0.0555028656
            },
            {
                "index": 10,
                "date": "2023-04-04",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 26, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-April-26-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2023 before the market opens on Wednesday, April 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 487376. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, May 12, 2023. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the",
                "1d_change": 1.4606935981,
                "index_price": -0.9204500174,
                "norm_price": 2.3811436155
            },
            {
                "index": 11,
                "date": "2023-03-27",
                "press_title": "Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus. The partnership between Thermo Fisher and UCSF, first announced in 2021 , has the potential to demonstrate that having scientists, clinicians, and patients closer to a manufacturing site may expedite the development of breakthrough treatments. UCSF’s initial focus at the facility will be on treatments for glioblastoma, multiple myeloma, and other cancers using updated approaches to CAR-T and CRISPR technologies. Therapies for other difficult to treat conditions will follow. “Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications,” said Michel Lagarde,",
                "1d_change": -1.7267137348,
                "index_price": -0.2936066309,
                "norm_price": -1.4331071039
            },
            {
                "index": 12,
                "date": "2023-02-28",
                "press_title": "Thermo Fisher Scientific to Present at Cowen 43rd Annual Healthcare Conference on March 6, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Present-at-Cowen-43rd-Annual-Healthcare-Conference-on-March-6-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Cowen Healthcare Conference on Monday, March 6, 2023 at 9:10 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical",
                "1d_change": -0.3509374039,
                "index_price": -0.6529360435,
                "norm_price": 0.3019986396
            },
            {
                "index": 13,
                "date": "2023-02-22",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023. This reflects a 17% increase over the previous dividend payment of $0.30. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our",
                "1d_change": 0.1724292167,
                "index_price": 0.2614445023,
                "norm_price": -0.0890152856
            },
            {
                "index": 14,
                "date": "2023-02-02",
                "press_title": "Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Power-All-Current-U.S.-Sites-With-100-Percent-Renewable-Electricity/default.aspx",
                "content": "Thermo Fisher’s latest net-zero milestone to be achieved through 200-megawatt solar project Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026. The company’s new 20-year virtual power purchasing agreement with EDF Renewables includes the full output of the 200-megawatt (MW) Millers Branch Solar project. The agreement with EDF Renewables will deliver approximately 545,000 MWh of renewable electricity annually from the Millers Branch Solar project in Texas. This project complements Thermo Fisher’s previously announced agreement with Enel North America for the Seven Cowboy wind project. Together, these projects will provide enough renewable power to match all of Thermo Fisher’s current U.S. electricity needs. “Transitioning away from fossil fuels and adopting renewable energy accelerates our progress toward net-zero carbon emissions by 2050,”",
                "1d_change": -0.6652452608,
                "index_price": -0.5366929229,
                "norm_price": -0.1285523379
            },
            {
                "index": 15,
                "date": "2023-02-01",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2022-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 Highlights Fourth quarter revenue grew 7% to $11.45 billion. Fourth quarter GAAP diluted earnings per share (EPS) was $4.01. Fourth quarter adjusted EPS was $5.40. Full year revenue grew 15% to $44.92 billion. Full year GAAP diluted EPS was $17.63. Full year adjusted EPS was $23.24. Dur",
                "1d_change": 0.166924981,
                "index_price": 2.624306262,
                "norm_price": -2.457381281
            },
            {
                "index": 16,
                "date": "2023-01-04",
                "press_title": "Thermo Fisher Scientific to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Present-at-41st-Annual-J.P.-Morgan-Healthcare-Conference-on-January-10-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies,",
                "1d_change": -0.4237411607,
                "index_price": -0.8471418539,
                "norm_price": 0.4234006932
            },
            {
                "index": 17,
                "date": "2023-01-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, February 1, 2023",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-February-1-2023/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, February 1, 2023, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 982319. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, February 17, 2023. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to",
                "1d_change": 1.535814882,
                "index_price": -0.0083070556,
                "norm_price": 1.5441219376
            },
            {
                "index": 18,
                "date": "2023-01-03",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of The Binding Site Group",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Completes-Acquisition-of-The-Binding-Site-Group/default.aspx",
                "content": "Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates. Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022 . “We are very excited to welcome The Binding Site colleagues to Thermo Fisher Scientific,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “The Binding Site",
                "1d_change": 1.535814882,
                "index_price": -0.0083070556,
                "norm_price": 1.5441219376
            },
            {
                "index": 19,
                "date": "2022-12-06",
                "press_title": "Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Raises-Greenhouse-Gas-Emissions-Reduction-Target-on-Path-to-Net-zero-Emissions/default.aspx",
                "content": "Company to achieve 2030 Scope 1 and 2 greenhouse gas emissions reduction target of 30% ahead of schedule; increases ambition to 50% reduction, aligned with 1.5˚C pathway Thermo Fisher Scientific Inc . (NYSE: TMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline. 1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule. (Photo: Business Wire) The company’s new 50% reduction target fulfills its commitment to the Business Ambition to 1.5˚C campaign and aligns its climate strategy with the Paris Agreement and its reduction targets with the 1.5˚C pathway. This represents an important milestone in Thermo Fisher’s pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions. The company has submitted its targets to the Science Based Targets initiative for validation. “Our",
                "1d_change": 1.0212497245,
                "index_price": -1.5940833109,
                "norm_price": 2.6153330353
            },
            {
                "index": 20,
                "date": "2022-11-21",
                "press_title": "Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Present-at-Evercore-ISI-HealthCONx-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing",
                "1d_change": 2.1973408047,
                "index_price": 1.1826939073,
                "norm_price": 1.0146468975
            },
            {
                "index": 21,
                "date": "2022-11-15",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes: €500,000,000 aggregate principal amount of its 3.200% senior notes due 2026 (the “2026 notes”), at the issue price of 99.965% of their principal amount, and €750,000,000 aggregate principal amount of its 3.650% senior notes due 2034 (the “2034 notes” and together with the 2026 notes, the “notes”), at the issue price of 99.637% of their principal amount. The Offering is expected to close on or about November 21, 2022, subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher intends to use the net proceeds from the sale of the notes for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of",
                "1d_change": -1.451461181,
                "index_price": -1.2028895844,
                "norm_price": -0.2485715966
            },
            {
                "index": 22,
                "date": "2022-11-15",
                "press_title": "Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Prices-Offering-of-USD-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of $1.2 billion aggregate principal amount (the “Offering”) of the following notes: $600 million aggregate principal amount of its 4.800% senior notes due 2027 (the “2027 notes”), at the issue price of 99.960% of their principal amount, and $600 million aggregate principal amount of its 4.950% senior notes due 2032 (the “2032 notes” and together with the 2027 notes, the “notes”), at the issue price of 99.797% of their principal amount. The Offering is expected to close on or about November 21, 2022, subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use the net proceeds from the sale of the notes for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its",
                "1d_change": -1.451461181,
                "index_price": -1.2028895844,
                "norm_price": -0.2485715966
            },
            {
                "index": 23,
                "date": "2022-11-10",
                "press_title": "Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Authorizes-4-Billion-of-Share-Repurchases/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo",
                "1d_change": 5.87732312,
                "index_price": 3.3318901493,
                "norm_price": 2.5454329706
            },
            {
                "index": 24,
                "date": "2022-11-10",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-5c9d1c9aa/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders of record as of December 15, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied",
                "1d_change": 5.87732312,
                "index_price": 3.3318901493,
                "norm_price": 2.5454329706
            },
            {
                "index": 25,
                "date": "2022-11-03",
                "press_title": "Thermo Fisher Scientific and Society for Science Launch Junior Innovators Challenge to Inspire More Than 65,000 Future STEM Leaders Nationwide",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-and-Society-for-Science-Launch-Junior-Innovators-Challenge-to-Inspire-More-Than-65000-Future-STEM-Leaders-Nationwide/default.aspx",
                "content": "Educators and school officials encouraged to drive student awareness of state and regional science fairs for a chance to enter nation’s premier middle school STEM competition Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), today announced the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math (STEM) competition. The Society named Thermo Fisher as the new title sponsor of the organization’s middle school STEM competition in August . (Graphic: Business Wire) “Society for Science is very excited to embark on this new partnership with Thermo Fisher Scientific,” said Maya Ajmera, President and CEO of Society for Science and Publisher of Science News . “Our middle school STEM competition, now called the Thermo Fisher Scientific Junior Innovators Challenge, will be impacting and celebrating students at a critical time in their development,",
                "1d_change": 2.3085396628,
                "index_price": 0.989246883,
                "norm_price": 1.3192927799
            },
            {
                "index": 26,
                "date": "2022-10-31",
                "press_title": "Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Continues-to-Execute-Proven-Capital-Deployment-Strategy/default.aspx",
                "content": "Announces $1.0 Billion Share Repurchase Program for Q4 2022 Separately Enters Into Agreement to Acquire The Binding Site Group Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment. Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a $1.0 billion share repurchase program, bringing the total capital deployed on buybacks to $3.0 billion in 2022. Additionally, in a separate press release issued today, Thermo Fisher announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Thermo Fisher continues to execute its disciplined capital deployment strategy through a combination of strategic MA and return of capital to shareholders. Through its proposed acquisition of The Binding Site and",
                "1d_change": 3.3417644419,
                "index_price": -0.6677731218,
                "norm_price": 4.0095375637
            },
            {
                "index": 27,
                "date": "2022-10-31",
                "press_title": "Thermo Fisher Scientific to Acquire The Binding Site Group",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Acquire-The-Binding-Site-Group/default.aspx",
                "content": "Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Serving clinicians and laboratory professionals worldwide, The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite® offering is widely",
                "1d_change": 3.3417644419,
                "index_price": -0.6677731218,
                "norm_price": 4.0095375637
            },
            {
                "index": 28,
                "date": "2022-10-26",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2022 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Reports-Third-Quarter-2022-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights Third quarter revenue was $10.68 billion. Third quarter GAAP diluted earnings per share (EPS) was $3.79. Third quarter adjusted EPS was $5.08. Delivered very strong financial results in the third quarter, with 14% Core organic revenue growth and $0.44 billion of COVID-19 testing revenue. Launched a range of",
                "1d_change": -0.3371281399,
                "index_price": -0.4903716974,
                "norm_price": 0.1532435575
            },
            {
                "index": 29,
                "date": "2022-10-14",
                "press_title": "Thermo Fisher Scientific Prices Offering of Yen-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Prices-Offering-of-Yen-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) the world leader in serving science, announced today that it has priced an offering of ¥109.5 billion aggregate principal amount (the “Offering”) of the following yen-denominated notes, each issued at par: ¥22,300,000,000 aggregate principal amount of its 0.853% Senior Notes due 2025 (the “2025 Notes”), ¥28,900,000,000 aggregate principal amount of its 1.054% Senior Notes due 2027 (the “2027 Notes”), ¥4,700,000,000 aggregate principal amount of its 1.279% Senior Notes due 2029 (the “2029 Notes”), ¥6,300,000,000 aggregate principal amount of its 1.490% Senior Notes due 2032 (the “2032 Notes”), ¥14,600,000,000 aggregate principal amount of its 2.069% Senior Notes due 2042 (the “2042 Notes”), and ¥33,300,000,000 aggregate principal amount of its 2.382% Senior Notes due 2052 (the “2052 Notes” and, collectively with the 2025 Notes, the 2027 Notes, the 2029 Notes, the 2032 Notes and the 2042 Notes, the “Notes”). The Offering is",
                "1d_change": 0.6089996277,
                "index_price": -0.3387746191,
                "norm_price": 0.9477742468
            },
            {
                "index": 30,
                "date": "2022-10-04",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 26, 2022",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-26-2022/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2022 before the market opens on Wednesday, October 26, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 406803. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, November 11, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our",
                "1d_change": 2.8465938408,
                "index_price": 1.5018731873,
                "norm_price": 1.3447206535
            },
            {
                "index": 31,
                "date": "2022-09-29",
                "press_title": "Thermo Fisher Scientific to Source Half of its U.S. Electricity Needs from Wind Power Purchase with Enel North America",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Source-Half-of-its-U.S.-Electricity-Needs-from-Wind-Power-Purchase-with-Enel-North-America/default.aspx",
                "content": "The agreement will deliver renewable energy equal to half of the company’s U.S. electricity consumption Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, recently signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma. Thermo Fisher will purchase approximately 400,000 megawatt hours (MWh) of renewable electricity, equal to half of the company’s current U.S. electricity needs. As part of the company’s emissions-reduction strategy, Thermo Fisher plans to eventually transition most locations globally to renewable energy. Today, more than 60 sites worldwide are fully powered by renewable electricity, including seven facilities that generate 3.5 MW of solar power and 3 MW of wind energy. Another 15 MW of solar power projects are planned. “By sourcing electricity from new wind and solar facilities we can help our customers meet their Scope 3",
                "1d_change": -1.5221097572,
                "index_price": -2.8276808269,
                "norm_price": 1.3055710696
            },
            {
                "index": 32,
                "date": "2022-09-07",
                "press_title": "Thermo Fisher Scientific to Present at Morgan Stanley 2022 Global Healthcare Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Present-at-Morgan-Stanley-2022-Global-Healthcare-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 2022 Global Healthcare Conference on Monday, September 12, 2022, at 9:55 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies,",
                "1d_change": 4.0878273552,
                "index_price": 2.4150188372,
                "norm_price": 1.6728085181
            },
            {
                "index": 33,
                "date": "2022-08-25",
                "press_title": "Thermo Fisher Scientific to Sponsor Nation’s Premier Middle School STEM Competition",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Sponsor-Nations-Premier-Middle-School-STEM-Competition/default.aspx",
                "content": "The Society for Science names Thermo Fisher the new title sponsor for its annual STEM competition, expanding opportunity for thousands of middle school students across the U.S. WALTHAM, Mass., and WASHINGTON, D.C., August 25, 2022  – The Society for Science (Society) and Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Thermo Fisher will be the new title sponsor of the Society’s middle school STEM competition, the nation’s premier STEM (science, technology, engineering and math) competition. Thermo Fisher’s sponsorship begins in 2023, making it only the third title sponsor in the competition’s 25-year history. Thermo Fisher’s sponsorship of the competition continues its longstanding commitment to widespread and equitable access to STEM education. For decades, Thermo Fisher has invested in school-based STEM programs, and colleagues across the company dedicate thousands of volunteer hours each year to support education efforts",
                "1d_change": -2.5970727861,
                "index_price": -2.3560341573,
                "norm_price": -0.2410386288
            },
            {
                "index": 34,
                "date": "2022-08-03",
                "press_title": "Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-and-Structura-Biotechnology-Collaborate-to-Offer-a-Solution-for-Real-Time-Cryo-EM-Data-Analysis/default.aspx",
                "content": "New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura’s CryoSPARC Live, that is designed to integrate with Thermo Fisher’s Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live , will be offered as a subscription. (Graphic: Business Wire) Embedded CryoSPARC Live will enable cryo-electron microscopy (cryo-EM) users of all experience levels to obtain high-quality data while reducing the time it takes to transform raw data into high-quality 3D protein structures from days to hours. Embedded CryoSPARC Live will offer real-time cryo-EM data analysis,",
                "1d_change": -0.0576165882,
                "index_price": 1.0592634067,
                "norm_price": -1.116879995
            },
            {
                "index": 35,
                "date": "2022-07-28",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2022 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Reports-Second-Quarter-2022-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights Second quarter revenue was $10.97 billion. Second quarter GAAP diluted earnings per share (EPS) was $4.22. Second quarter adjusted EPS was $5.51. Delivered very strong financial results in the second quarter, with 13% Core organic revenue growth and $0.63 billion of COVID-19 testing revenue. Launched a range",
                "1d_change": 1.4137288985,
                "index_price": 2.5218605779,
                "norm_price": -1.1081316794
            },
            {
                "index": 36,
                "date": "2022-07-07",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-f3de18cda/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on July 7, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on October 14, 2022, to shareholders of record as of September 15, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo",
                "1d_change": 0.1282416111,
                "index_price": 1.0393905281,
                "norm_price": -0.911148917
            },
            {
                "index": 37,
                "date": "2022-07-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-July-28-2022/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2022 before the market opens on Thursday, July 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 512129. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, August 12, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers",
                "1d_change": 2.9098618579,
                "index_price": 1.3646002069,
                "norm_price": 1.545261651
            },
            {
                "index": 38,
                "date": "2022-06-06",
                "press_title": "Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Showcases-Solutions-for-Accelerating-Next-Generation-Vaccine-and-Therapy-Research-and-Unlocking-Deeper-Analytical-Insights/default.aspx",
                "content": "The company announces new mass spectrometry instruments, workflows, software and industry collaborations during ASMS 2022 Conference Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development. The company will showcase these innovations during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022, in the Minneapolis Convention Center, Minneapolis. “Our newest innovations are focused on improving each of the critical steps in an end-to-end mass spectrometry workflow,” said John Lesica, president, chromatography and mass spectrometry, Thermo Fisher Scientific. “New instruments, consumables, workflows and software solutions enable leading-edge biological research that spans the molecular",
                "1d_change": 0.3049871538,
                "index_price": 0.6239355067,
                "norm_price": -0.3189483529
            },
            {
                "index": 39,
                "date": "2022-06-02",
                "press_title": "Thermo Fisher Scientific Releases Corporate Social Responsibility Report",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Releases-Corporate-Social-Responsibility-Report/default.aspx",
                "content": "Report highlights progress toward environmental, social and governance objectives Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders providing detailed insight into the company’s CSR progress and environmental, social and governance (ESG) efforts. (Graphic: Business Wire) “Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Reducing our impact on the environment, fostering an inclusive culture and being active members of our communities gives our more than 100,000 colleagues the opportunity to make a difference every day.” Highlights from the company’s annual CSR report include: Environment Achieved 12% reduction in absolute Scope 1 and 2 emissions compared",
                "1d_change": 0.6342908686,
                "index_price": 0.3195813313,
                "norm_price": 0.3147095373
            },
            {
                "index": 40,
                "date": "2022-05-19",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific,",
                "1d_change": 2.7290128228,
                "index_price": 0.0604944777,
                "norm_price": 2.6685183451
            },
            {
                "index": 41,
                "date": "2022-05-06",
                "press_title": "Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Present-at-BofA-Securities-2022-Healthcare-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing",
                "1d_change": -4.8319584669,
                "index_price": -3.4307616674,
                "norm_price": -1.4011967994
            },
            {
                "index": 42,
                "date": "2022-04-28",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2022 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Reports-First-Quarter-2022-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights First quarter revenue was $11.82 billion. First quarter GAAP diluted earnings per share (EPS) was $5.61. First quarter adjusted EPS was $7.25. Delivered very strong financial results in the first quarter, with 16% Core organic growth and $1.68 billion of COVID-19 testing revenue. Launched high-impact new prod",
                "1d_change": -1.2316429893,
                "index_price": -2.1938875656,
                "norm_price": 0.9622445763
            },
            {
                "index": 43,
                "date": "2022-04-11",
                "press_title": "Thermo Fisher Scientific to Host Investor Day",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Host-Investor-Day/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2022 Investor Day on Wednesday, May 18, starting at 9:00 a.m. (ET), at the Mandarin Oriental New York, 80 Columbus Circle at 60 th Street, in New York City. The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a QA session. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient",
                "1d_change": -4.8306350927,
                "index_price": -1.482448658,
                "norm_price": -3.3481864347
            },
            {
                "index": 44,
                "date": "2022-04-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 28, 2022",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-April-28-2022/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2022 before the market opens on Thursday, April 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 310385. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Earnings Results.” A replay of the call will be available under “News and Events” through Friday, May 13, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to",
                "1d_change": 0.4323981381,
                "index_price": -2.0374300115,
                "norm_price": 2.4698281496
            },
            {
                "index": 45,
                "date": "2022-03-02",
                "press_title": "Thermo Fisher Scientific to Present at Cowen’s 42nd Annual Healthcare Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Present-at-Cowens-42nd-Annual-Healthcare-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at Cowen’s 42 nd Annual Conference on Monday, March 7, 2022, at 10:30 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing",
                "1d_change": 1.7175014417,
                "index_price": 0.9380146072,
                "norm_price": 0.7794868346
            },
            {
                "index": 46,
                "date": "2022-02-23",
                "press_title": "Thermo Fisher Scientific Elects New Director to Board",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Elects-New-Director-to-Board/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Ruby Chandy has been elected to its board of directors, effective March 1, 2022. Ms. Chandy’s appointment will bring the total number of Thermo Fisher board members to 13. Ruby Chandy (Photo: Business Wire) Ms. Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, Ms. Chandy was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation. Ms. Chandy currently serves on the board of directors of DuPont de Nemours, Inc. (NYSE:DD) and Flowserve Corporation (NYSE: FLS). She also serves on the Advisory Board of Pritzker Private Capital, the MIT Sloan Americas Executive Board and is a mentor-in-residence at the University of Pennsylvania Penn Center for Innovation (PCI). “I am pleased to welcome Ruby to the Thermo Fisher board and look forward to her insights gained",
                "1d_change": 1.5124852451,
                "index_price": -0.844777644,
                "norm_price": 2.3572628891
            },
            {
                "index": 47,
                "date": "2022-02-23",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.30 per common share, payable on April 14, 2022, to shareholders of record as of March 16, 2022. This reflects a 15% increase over the previous dividend payment of $0.26. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical",
                "1d_change": 1.5124852451,
                "index_price": -0.844777644,
                "norm_price": 2.3572628891
            },
            {
                "index": 48,
                "date": "2022-02-23",
                "press_title": "Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Moderna-and-Thermo-Fisher-Scientific-Announce-Long-Term-Strategic-Collaboration/default.aspx",
                "content": "Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a trusted partner, bringing a full range of products and services that have enabled us to deliver innovative medicines at an unprecedented speed and scale,” said Juan Andres, Moderna's chief technical operations and quality officer. “We are pleased to further expand our collaboration with Thermo Fisher as a long-term manufacturing partner that will enable us to continue to build on our mRNA platform and pipeline.” Over the past",
                "1d_change": 1.5124852451,
                "index_price": -0.844777644,
                "norm_price": 2.3572628891
            },
            {
                "index": 49,
                "date": "2022-02-08",
                "press_title": "New Genetic Analyzer Brings Advanced Capabilities to Sanger Sequencing and Fragment Analysis",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/New-Genetic-Analyzer-Brings-Advanced-Capabilities-to-Sanger-Sequencing-and-Fragment-Analysis/default.aspx",
                "content": "Thermo Fisher Scientific expands Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers Capillary electrophoresis (CE), which enables Sanger sequencing and fragment analysis, is an important tool for improving clinical research and advancing scientific discovery. To further enable customers’ cutting-edge research in areas such as gene editing and infectious disease, Thermo Fisher Scientific introduced the new Applied Biosystems SeqStudio Flex Series Genetic Analyzer . The Applied Biosystems SeqStudio Flex Series Genetic Analyzer delivers high-quality Sanger sequencing and fragment analysis data while providing design and technological advancements for enhanced flexibility, usability and connectivity. (Photo: Business Wire) “Labs around the world rely on Applied Biosystems’ CE-based instruments for gold-standard Sanger sequencing and fragment analysis data,” said Kay Eron, vice president and general manager of capillary electrophoresis,",
                "1d_change": 2.0276330908,
                "index_price": 2.3360790757,
                "norm_price": -0.3084459848
            },
            {
                "index": 50,
                "date": "2022-02-02",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2021 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2021-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights Fourth quarter revenue was $10.70 billion. Fourth quarter GAAP diluted earnings per share (EPS) was $4.17. Fourth quarter adjusted EPS was $6.54.  Full year revenue grew 22% to $39.21 billion. Full year GAAP diluted EPS increased 22% to $19.46. Full year adjusted EPS in",
                "1d_change": -1.8842751784,
                "index_price": -1.9866306746,
                "norm_price": 0.1023554962
            },
            {
                "index": 51,
                "date": "2022-01-27",
                "press_title": "Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Earns-Top-Score-for-LGBTQ-Workplace-Equality-for-Seventh-Consecutive-Year/default.aspx",
                "content": "Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the national benchmarking tool measuring policies, practices and benefits pertinent to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees, the CEI is a driving force for LGBTQ+ workplace inclusion. \"We truly believe that embracing diverse backgrounds and perspectives is vital to our long-term success as we work toward our shared mission of enabling our customers to make the world healthier, cleaner and safer,\" said Jennifer Farmer, vice president, global diversity and inclusion at Thermo Fisher Scientific. \"Fostering an inclusive culture and a sense of belonging for our colleagues empowers them to contribute their best ideas and bring their true selves to work each day.\" In 2002, the first year of the CEI, only 13 companies achieved a top-score. A",
                "1d_change": 0.6031155327,
                "index_price": 1.1568536481,
                "norm_price": -0.5537381153
            },
            {
                "index": 52,
                "date": "2022-01-05",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-Completes-Acquisition-of-PeproTech-a-Leader-in-Recombinant-Proteins/default.aspx",
                "content": "Increases capabilities serving the high growth cell and gene therapy market  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion. Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering. \"PeproTech will be an excellent strategic",
                "1d_change": 0.386843376,
                "index_price": -1.9578248424,
                "norm_price": 2.3446682184
            },
            {
                "index": 53,
                "date": "2022-01-04",
                "press_title": "Thermo Fisher Scientific to Present at the 40th Annual J.P. Morgan Healthcare Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Present-at-the-40th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. (EST).  Among other topics, Mr. Casper will provide the company's current perspective on its business and expectations for future financial performance. You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics",
                "1d_change": -3.0362756166,
                "index_price": -2.2109970636,
                "norm_price": -0.825278553
            },
            {
                "index": 54,
                "date": "2022-01-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, February 2, 2022",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2022/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-February-2-2022/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2021 before the market opens on Wednesday, February 2, 2022, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S.  The access code is 986581.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, February 11, 2022. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40",
                "1d_change": -7.2799287098,
                "index_price": 0.3212636636,
                "norm_price": -7.6011923734
            },
            {
                "index": 55,
                "date": "2021-12-30",
                "press_title": "Thermo Fisher Scientific to Present at the 2022 Goldman Healthcare CEOs Unscripted Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-the-2022-Goldman-Healthcare-CEOs-Unscripted-Conference/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 2022 Goldman Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, at 9:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an",
                "1d_change": 0.3821789552,
                "index_price": -0.5885175057,
                "norm_price": 0.9706964609
            },
            {
                "index": 56,
                "date": "2021-12-08",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of PPD, Inc.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Completes-Acquisition-of-PPD-Inc/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. \"We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world.\" As previously announced, the transaction is expected to contribute $1.50 to Thermo Fisher's adjusted earnings per share in 2022. 1 Details of the 2021 impact will be provided during Thermo Fisher's fourth quarter earnings call in early 2022. Thermo Fisher continues to expect to realize",
                "1d_change": 0.9527886331,
                "index_price": -0.5015515322,
                "norm_price": 1.4543401653
            },
            {
                "index": 57,
                "date": "2021-11-29",
                "press_title": "Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Confirms-Detection-of-SARS-CoV-2-in-Samples-Containing-the-Omicron-Variant-with-its-TaqPath-COVID-19-Tests/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results. The Omicron variant, which was designated a \" variant of concern \" by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the",
                "1d_change": -1.1330055804,
                "index_price": -1.3520910882,
                "norm_price": 0.2190855078
            },
            {
                "index": 58,
                "date": "2021-11-18",
                "press_title": "Thermo Fisher Scientific Announces Redemption of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Announces-Redemption-of-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it is giving notice of its intention to redeem the following Senior Notes (the \"Redemption\"), representing an aggregate total principal amount of approximately $2.2 billion, on December 3, 2021 (the \"Redemption Date\"): $1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 (the \"2025 Notes\"); and $1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030 (the \"2030 Notes\" and, together with the 2025 Notes, the \"Notes\"). The Notes will be redeemed at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of the Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 50 basis points in the case of both the 2025 Notes and the 2030 Notes, plus, in each case, accrued and unpaid",
                "1d_change": -0.3741980401,
                "index_price": -0.0587543089,
                "norm_price": -0.3154437312
            },
            {
                "index": 59,
                "date": "2021-11-09",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-c598ef403/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of €2.8 billion aggregate principal amount (the \"Offering\") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly owned finance subsidiary: €1,700,000,000 aggregate principal amount of its floating rate senior notes due 2023 (the \"floating rate notes\"), at the issue price of 100.744% of their principal amount, €550,000,000 aggregate principal amount of its 0.000% senior notes due 2023 (the \"2023 notes\"), at the issue price of 100.321% of their principal amount, and €550,000,000 aggregate principal amount of its 0.000% senior notes due 2025 (the \"sustainability notes\" and together with the floating rate notes and the 2023 notes, the \"notes\"), at the issue price of 99.868% of their principal amount. The Offering is expected to close on or about November 18, 2021, subject to customary closing conditions. The",
                "1d_change": 0.4961310733,
                "index_price": -1.302858142,
                "norm_price": 1.7989892153
            },
            {
                "index": 60,
                "date": "2021-11-04",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-59335130d/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on January 14, 2022, to shareholders of record as of December 15, 2021. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -4.1991009837,
                "index_price": 0.7365490153,
                "norm_price": -4.935649999
            },
            {
                "index": 61,
                "date": "2021-11-01",
                "press_title": "Thermo Fisher Scientific Launches New Mass Spectrometry and Chromatography Solutions at ASMS 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Launches-New-Mass-Spectrometry-and-Chromatography-Solutions-at-ASMS-2021/default.aspx",
                "content": "Advanced mass spectrometry, software and analytical workflow solutions to be showcased at ASMS event ASMS 2021 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is empowering scientists to drive groundbreaking discoveries with the introduction of new-generation mass spectrometry instruments, workflows and software. The company will showcase new additions to its industry-leading offering during the 69 th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held October 31-November 4, in the Pennsylvania Convention Center, Philadelphia, Pennsylvania. \"The life science industry has stepped forward in an unprecedented fashion over the last 18 months, with academia and biopharma making key contributions to respond to the pandemic,\" said Dan Shine, senior vice president and president, analytical instruments, Thermo Fisher Scientific. \"We're honored to have played an essential role in this effort.  The new",
                "1d_change": 0.605166594,
                "index_price": 0.4325480349,
                "norm_price": 0.1726185591
            },
            {
                "index": 62,
                "date": "2021-10-27",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2021 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Reports-Third-Quarter-2021-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended October 2, 2021. Third Quarter 2021 Highlights Third quarter revenue increased 9% to $9.33 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.79. Third quarter adjusted EPS was $5.76. Another quarter of high-impact innovation with a number of product launches, including the Applied Biosystems QuantStudio Absolute Q Digital PCR System to",
                "1d_change": 0.5273625323,
                "index_price": 0.3524418418,
                "norm_price": 0.1749206904
            },
            {
                "index": 63,
                "date": "2021-10-26",
                "press_title": "Thermo Fisher Scientific Publishes 2020 Corporate Social Responsibility Report",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Publishes-2020-Corporate-Social-Responsibility-Report/default.aspx",
                "content": "Report highlights achievements and environmental, social and governance efforts  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published its 2020 Corporate Social Responsibility (CSR) report, reflecting its commitment to society, stakeholders and environmental, social and governance (ESG) efforts. The report provides detailed insight into the company's approach to CSR, outlines future priorities and highlights achievements across four pillars of focus: operations, colleagues, communities and environment. (NYSE: TMO) today published its 2020 Corporate Social Responsibility report reflecting its commitment to ESG efforts. \"Across Thermo Fisher Scientific, we hold ourselves accountable for doing business the right way and delivering on our responsibility to society,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"From our mobilization to assist in the global response to the COVID-19 pandemic, our",
                "1d_change": 0.42952904,
                "index_price": -0.5934020973,
                "norm_price": 1.0229311372
            },
            {
                "index": 64,
                "date": "2021-10-19",
                "press_title": "Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Prices-Offering-of-USD-Denominated-Senior-Notes-62a23e743/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of $5.85 billion aggregate principal amount (the \"Offering\") of the following notes, each issued at par: $1,000,000,000 aggregate principal amount of its 18-month floating rate senior notes due 2023 (the \"18-Month Floating Rate Notes\"), $500,000,000 aggregate principal amount of its floating rate senior notes due 2023 (the \"2023 Floating Rate Notes\"), $500,000,000 aggregate principal amount of its floating rate senior notes due 2024 (collectively with the 18-Month Floating Rate Notes and the 2023 Floating Rate Notes, the \"Floating Rate Notes\"), $1,350,000,000 aggregate principal amount of its 0.797% senior notes due 2023 (the \"2023 Notes\"), and $2,500,000,000 aggregate principal amount of its 1.215% senior notes due 2024 (together with the 2023 Notes, the \"Fixed Rate Notes\" and, collectively with the Floating Rate Notes, the \"Notes\"). The Offering is expected to close on or about",
                "1d_change": 2.4108358948,
                "index_price": 0.8564477713,
                "norm_price": 1.5543881235
            },
            {
                "index": 65,
                "date": "2021-10-19",
                "press_title": "Thermo Fisher Scientific Announces Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Announces-Offering-of-USD-Denominated-Senior-Notes-c7f8c4865/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it intends to offer (the \"Offering\") USD-denominated senior notes (the \"Notes\"). Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the cash consideration payable for the proposed acquisition of PPD, Inc., a Delaware corporation (the \"PPD Acquisition\"). Thermo Fisher may also determine to use a portion of the net proceeds of the Offering for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose. The joint book-running managers for the Offering are Barclays Capital Inc., Morgan Stanley  Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc. and Mizuho Securities USA LLC. The",
                "1d_change": 2.4108358948,
                "index_price": 0.8564477713,
                "norm_price": 1.5543881235
            },
            {
                "index": 66,
                "date": "2021-10-11",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 27, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-27-2021/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2021 before the market opens on Wednesday, October 27, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 6971977.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, November 12, 2021. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is",
                "1d_change": -0.9185569922,
                "index_price": -0.7996515427,
                "norm_price": -0.1189054495
            },
            {
                "index": 67,
                "date": "2021-10-06",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of €5.25 billion aggregate principal amount (the \"Offering\") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly owned finance subsidiary: €1,750,000,000 aggregate principal amount of its 0.800% senior notes due 2030 (the \"2030 notes\"), at the issue price of 99.810% of their principal amount, €1,500,000,000 aggregate principal amount of its 1.125% senior notes due 2033 (the \"2033 notes\"), at the issue price of 99.732% of their principal amount, €1,250,000,000 aggregate principal amount of its 1.625% senior notes due 2041 (the \"2041 notes\"), at the issue price of 98.171% of their principal amount, and €750,000,000 aggregate principal amount of its 2.000% senior notes due 2051 (together with the 2030 notes, the 2033 notes and the 2041 notes, the \"notes\"), at the issue price of 99.331% of their principal",
                "1d_change": 2.7437451063,
                "index_price": 1.8225981799,
                "norm_price": 0.9211469264
            },
            {
                "index": 68,
                "date": "2021-10-01",
                "press_title": "Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Opens-Biologics-Manufacturing-Site-in-Lengnau-Switzerland/default.aspx",
                "content": "State-of-the-art facility provides pathway from development to large-scale biologics production  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited announced last year. The Lengnau site will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join Thermo Fisher. The Lengnau site is a 1.5 million square-foot facility that will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500L bioreactor capacity. This will provide biopharma companies with a pathway from development to large-scale production as manufacturing needs evolve. \"We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new",
                "1d_change": -0.2759193287,
                "index_price": -0.3883350959,
                "norm_price": 0.1124157671
            },
            {
                "index": 69,
                "date": "2021-09-29",
                "press_title": "Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Continues-Support-for-COVID-19-Testing-on-Historically-Black-College-and-University-Campuses/default.aspx",
                "content": "Thermo Fisher Scientific Inc., (NYSE:TMO) the world leader in serving science, today announced continuing support for The Just Project , a national initiative to provide COVID-19 testing to students, faculty and staff across more than 60 historically black colleges and universities (HBCUs) at no cost. A $7.5 million commitment for the 2021-2022 school year will once again provide diagnostic instruments, test kits and related supplies. \"A year after we launched The Just Project, COVID-19 cases are increasing again, and testing is critical to ensuring campus safety,\" said Fred Lowery, senior vice president and president for customer channels at Thermo Fisher Scientific. \"Last year HBCUs nationwide administered more than 50,000 tests under the project, and infection rates at participating schools were below 1% with minimal academic disruption. We hope other schools will join the program as we extend it through the 2021-2022 school year.\" The Just Project, named after pioneering biologist",
                "1d_change": -1.692542805,
                "index_price": -1.2738156045,
                "norm_price": -0.4187272005
            },
            {
                "index": 70,
                "date": "2021-09-23",
                "press_title": "Thermo Fisher Scientific Authorizes $3 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Authorizes-3-Billion-of-Share-Repurchases/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $3 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $500 million was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and",
                "1d_change": 0.4395156377,
                "index_price": 1.0937088862,
                "norm_price": -0.6541932485
            },
            {
                "index": 71,
                "date": "2021-09-21",
                "press_title": "Thermo Fisher Scientific to Present at the JP Morgan 12th Annual U.S. All Stars Conference on September 22, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-the-JP-Morgan-12th-Annual-U.S.-All-Stars-Conference-on-September-22-2021/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the JP Morgan 12 th Annual U.S. All Stars Conference on Wednesday, September 22, 2021 at 9:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.  Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience",
                "1d_change": 2.1660675936,
                "index_price": 0.4820672473,
                "norm_price": 1.6840003464
            },
            {
                "index": 72,
                "date": "2021-09-20",
                "press_title": "Thermo Fisher Scientific Adds Digital PCR to Genetic Analysis Capabilities",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Adds-Digital-PCR-to-Genetic-Analysis-Capabilities/default.aspx",
                "content": "Applied Biosystems QuantStudio Absolute Q Digital PCR System*, the first integrated digital PCR solution, is ideal for oncology, cell and gene therapy development and other research applications Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes. The QuantStudio Absolute Q  provides an industry-best dPCR platform accelerating innovation in cancer research and more. dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays. The dPCR",
                "1d_change": 0.7285867961,
                "index_price": -1.1198467353,
                "norm_price": 1.8484335314
            },
            {
                "index": 73,
                "date": "2021-09-09",
                "press_title": "Thermo Fisher Scientific to Host Virtual Investor Day",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Host-Virtual-Investor-Day/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host a virtual Investor Day on Friday, September 17, 2021, starting at 9:00 a.m. and expected to conclude by 11:00 a.m. (EDT). The virtual format will feature presentations by members of Thermo Fisher Scientific's senior management team and conclude with a QA session. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are",
                "1d_change": -0.3444345513,
                "index_price": -1.2210152213,
                "norm_price": 0.8765806699
            },
            {
                "index": 74,
                "date": "2021-09-08",
                "press_title": "Thermo Fisher Scientific to Further Expand Global Network of Single-Use Technology Manufacturing Sites",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Further-Expand-Global-Network-of-Single-Use-Technology-Manufacturing-Sites/default.aspx",
                "content": "Nashville site will deliver on strategy to enable reliable supply of critical materials used to produce new biologics and vaccines  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to establish a manufacturing facility in Nashville dedicated to the production of single-use technologies (SUT) products. This investment is in addition to the previously announced expansion to address unprecedented demand in the bioprocessing market.  The facility will be one of the world's largest SUT manufacturing sites and will more than double the company's SUT manufacturing capacity in support of its biopharma customers. The first phase of construction will be operational by the second quarter of 2022. Thermo Fisher Scientific to establish facility in Nashville for the production of single-use technologies products. \"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single use platform. This",
                "1d_change": -0.0035040304,
                "index_price": -0.5521592195,
                "norm_price": 0.5486551892
            },
            {
                "index": 75,
                "date": "2021-09-02",
                "press_title": "Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Awarded-192.5-Million-U.S.-Government-Contract-to-Expand-Domestic-Pipette-Tip-Manufacturing/default.aspx",
                "content": "New capacity will help U.S. customers meet current and future demand surges for vital laboratory plastics  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid. In mid-2020, the company announced its own investments to increase pipette tip production capacity to support COVID-19 testing. With the DoD award, issued on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), Thermo Fisher will co-invest with the U.S. government in building a new, state-of-the-art, energy efficient manufacturing facility for pipette tips, which are used in vital disease research and in high volumes for processing of diagnostic tests nationally, including COVID-19, during the pandemic. The new center of excellence",
                "1d_change": 1.1793442054,
                "index_price": 0.0209505003,
                "norm_price": 1.1583937051
            },
            {
                "index": 76,
                "date": "2021-08-09",
                "press_title": "Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Prices-Offering-of-USD-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of $3.1 billion aggregate principal amount (the \"Offering\") of the following notes: $700 million aggregate principal amount of its 1.750% senior notes due 2028, at the issue price of 99.952% of their principal amount, $1.2 billion aggregate principal amount of its 2.000% senior notes due 2031, at the issue price of 98.827% of their principal amount, and $1.2 billion aggregate principal amount of its 2.800% senior notes due 2041, at the issue price of 99.508% of their principal amount. The Offering is expected to close on or about August 23, 2021, subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the cash consideration payable for the pending acquisition of PPD, Inc., a Delaware corporation. The joint book-running managers for the Offering are Barclays",
                "1d_change": -0.6403021738,
                "index_price": -0.0229902413,
                "norm_price": -0.6173119325
            },
            {
                "index": 77,
                "date": "2021-08-09",
                "press_title": "Thermo Fisher Scientific Announces Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Announces-Offering-of-USD-Denominated-Senior-Notes/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it intends to offer USD-denominated senior notes. Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the cash consideration payable for the pending acquisition of PPD, Inc., a Delaware corporation. The joint book-running managers for the offering are Barclays Capital Inc., Morgan Stanley  Co. LLC, BofA Securities, Inc. and Citigroup Global Markets Inc. The Offering is being made pursuant to an effective registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (the \"SEC\"). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the Offering and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and this Offering. These documents are available at no charge by visiting EDGAR on the SEC website at",
                "1d_change": -0.6403021738,
                "index_price": -0.0229902413,
                "norm_price": -0.6173119325
            },
            {
                "index": 78,
                "date": "2021-07-28",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2021 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Reports-Second-Quarter-2021-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 3, 2021. Second Quarter 2021 Highlights Second quarter revenue increased 34% to $9.27 billion. Second quarter GAAP diluted earnings per share (EPS) increased 59% to $4.61. Second quarter adjusted EPS increased 44% to $5.60. Launched a range of new products including the Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer to advance complex s",
                "1d_change": 2.9544535104,
                "index_price": 0.366579713,
                "norm_price": 2.5878737974
            },
            {
                "index": 79,
                "date": "2021-07-27",
                "press_title": "Thermo Fisher Scientific Commits to Achieve Net-Zero Carbon Emissions by 2050",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Commits-to-Achieve-Net-Zero-Carbon-Emissions-by-2050/default.aspx",
                "content": "Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced its commitment to achieve net-zero carbon emissions by 2050. This supports the global goals of the Paris Climate Agreement and the United Nations' Race To Zero campaign and will further advance the company's current strategy to mitigate its impact on the environment. Thermo Fisher's carbon reduction efforts build on its 2030 targets to reduce greenhouse gas (GHG) emissions across its operations (Scopes 1 and 2). Established in 2019, these goals are aligned with the criteria of the Science Based Targets initiative (SBTi). Thermo Fisher's new pledge to reach carbon neutrality by 2050 incorporates additional targets to reduce its value chain emissions (Scope 3), including a commitment to SBTi's most ambitious guidelines. \"To better serve our customers and society overall, we continue to build on our",
                "1d_change": -0.0170089493,
                "index_price": -0.3576694664,
                "norm_price": 0.3406605171
            },
            {
                "index": 80,
                "date": "2021-07-15",
                "press_title": "Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Opens-cGMP-Plasmid-DNA-Manufacturing-Facility-in-Carlsbad-California/default.aspx",
                "content": "Facility will manufacture materials that are vital to production of plasmid-based therapies and vaccines  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines. \"Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally,\" said Marc N. Casper, chairman, president and chief executive officer, Thermo Fisher Scientific. \"Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need.\" The 67,000-square-foot facility, located on Thermo Fisher's Carlsbad campus, is part of an investment strategy to ensure customers",
                "1d_change": 1.8969385591,
                "index_price": -0.9673749473,
                "norm_price": 2.8643135064
            },
            {
                "index": 81,
                "date": "2021-07-13",
                "press_title": "Thermo Fisher Scientific and My Green Lab Collaborate to Expand Use of ACT Label in Driving Environmentally Sustainable Lab Practices",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-and-My-Green-Lab-Collaborate-to-Expand-Use-of-ACT-Label-in-Driving-Environmentally-Sustainable-Lab-Practices/default.aspx",
                "content": "1,200+ products to be identified for environmentally friendly capabilities and sustainability objectives  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of its collaboration with My Green Lab, a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature storage portfolio by the end of 2021. Over time, Thermo Fisher expects to ACT label more than 1,200 additional SKUs, enabling research, pharmaceutical and clinical laboratories to achieve their sustainability objectives by providing a broader range of purchasing options. \"Our customers are committed to adopting more sustainable laboratory practices, and My Green Lab enables them to take proactive steps to meet their objectives,\" said Paul Parker, senior vice president of strategy and corporate",
                "1d_change": -0.6108410257,
                "index_price": -0.1547680734,
                "norm_price": -0.4560729523
            },
            {
                "index": 82,
                "date": "2021-07-08",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-53db824ba/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on October 15, 2021, to shareholders of record as of September 15, 2021. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": 1.0168889625,
                "index_price": 1.1094960038,
                "norm_price": -0.0926070413
            },
            {
                "index": 83,
                "date": "2021-07-07",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 28, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-July-28-2021/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2021 before the market opens on Wednesday, July 28, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 6292118.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, August 13, 2021. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable",
                "1d_change": -0.2641640458,
                "index_price": -0.6987086394,
                "norm_price": 0.4345445936
            },
            {
                "index": 84,
                "date": "2021-07-07",
                "press_title": "Thermo Fisher Scientific Expands Corporate Leadership Team",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Expands-Corporate-Leadership-Team/default.aspx",
                "content": "Alan Sachs, who has served as chief scientific officer (CSO) since 2016, will assume the newly established role of chief medical officer; Karen E. Nelson joins the company as new CSO  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Alan Sachs, who has served as chief scientific officer (CSO) since 2016, will assume the newly established role of chief medical officer (CMO) and will be succeeded by Karen E. Nelson, previously president of the J. Craig Venter Institute. Both will join the company leadership team in August 2021. \"As we continue expanding our capabilities for customers who develop groundbreaking medicines and diagnostics, we have a growing responsibility to support their efforts and serve science overall through our own innovations,\" said Marc N. Casper, chairman, president and chief executive officer, Thermo Fisher. \"With Alan in the newly created role of CMO and Karen joining as CSO, we are reinforcing our commitment",
                "1d_change": -0.2641640458,
                "index_price": -0.6987086394,
                "norm_price": 0.4345445936
            },
            {
                "index": 85,
                "date": "2021-07-07",
                "press_title": "Thermo Fisher Scientific and UC Davis Launch Center of Excellence in Clinical Metabolomics",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-and-UC-Davis-Launch-Center-of-Excellence-in-Clinical-Metabolomics/default.aspx",
                "content": "Center will develop new technologies and reproducible analytical techniques to support rapid, cost-effective clinical research into applications for metabolomics in precision medicine  Thermo Fisher Scientific, (NYSE: TMO) the world leader in serving science, and the University of California, Davis (UC Davis) West Coast Metabolomics Center today announced The Center of Excellence in Clinical Metabolomics, a research collaboration to provide the metabolomics community with innovations, best practices and standard operating procedures to support the rapid scale-up of large cohort studies and clinical research. Metabolomics is an increasingly important field where researchers identify diagnostic biomarkers for disease, discover new drug targets, develop tools to predict drug response, and enable precision medicine overall. Advancements in this area can help ensure that patients receive more targeted medicines and increase the likelihood those therapies will achieve their intended",
                "1d_change": -0.2641640458,
                "index_price": -0.6987086394,
                "norm_price": 0.4345445936
            },
            {
                "index": 86,
                "date": "2021-06-08",
                "press_title": "Thermo Fisher Scientific to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-the-Goldman-Sachs-42nd-Annual-Global-Healthcare-Conference-on-June-10-2021/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 9:40 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and",
                "1d_change": 1.4368250164,
                "index_price": -0.3379567624,
                "norm_price": 1.7747817788
            },
            {
                "index": 87,
                "date": "2021-05-19",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on July 15, 2021, to shareholders of record as of June 15, 2021. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific,",
                "1d_change": 2.8777742772,
                "index_price": 1.4587201179,
                "norm_price": 1.4190541594
            },
            {
                "index": 88,
                "date": "2021-05-19",
                "press_title": "Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-and-University-of-California-San-Francisco-to-Open-Cell-Therapy-cGMP-Manufacturing-and-Collaboration-Center/default.aspx",
                "content": "New facility will provide end-to-end solution to accelerate cell therapy development and manufacturing  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing and collaboration center in leased space on UCSF's Mission Bay campus, which includes biomedical research facilities and hospitals. The site will offer clinical and commercial cGMP cell therapy manufacturing services, along with associated technology development support, to UCSF and other partners. Expected to open in 2022, the facility will also serve as a central location where customers and UCSF researchers will have access to Thermo Fisher's broad portfolio of Cell Therapy Systems (CTS)",
                "1d_change": 2.8777742772,
                "index_price": 1.4587201179,
                "norm_price": 1.4190541594
            },
            {
                "index": 89,
                "date": "2021-05-10",
                "press_title": "Thermo Fisher Scientific to Present at the BofA Securities 2021 Healthcare Conference on May 12, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-the-BofA-Securities-2021-Healthcare-Conference-on-May-12-2021/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 8:45 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical",
                "1d_change": -0.866379022,
                "index_price": -1.8349736185,
                "norm_price": 0.9685945966
            },
            {
                "index": 90,
                "date": "2021-04-29",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2021 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Reports-First-Quarter-2021-Results/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021. First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion. First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88. First quarter adjusted EPS increased 145% to $7.21. Continued significant role in enabling the COVID-19 response, helping to scale vaccine production and supporting testing globally, and accelerated growth in the base business. Strong start to the year in terms of product launches including two Thermo Scientific Orbitrap Exploris Gas Chromatography-Mass Spectrometers , which bring high-resolution analysis to a range of applications, including toxicology and metabolomics, the Thermo Scientific Spectra Ultra electron microscope for improved throughput and workflow in materials science applications, the Kingfisher Apex Purification System for high throughput sample",
                "1d_change": -1.5736952957,
                "index_price": -0.5972064114,
                "norm_price": -0.9764888844
            },
            {
                "index": 91,
                "date": "2021-04-15",
                "press_title": "Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Acquire-PPD-Inc.-a-Leading-Clinical-Research-Organization/default.aspx",
                "content": "Further expands service offering to pharma and biotech customers - Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry - Adds highly complementary services for the company's fastest growing end market - Offers both meaningful cost and revenue synergies which will further accelerate growth - Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close  Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\"), the world leader in serving science, and PPD, Inc. (Nasdaq: PPD) (\"PPD\"), a leading global provider of clinical research services to the pharma and biotech industry, today announced that their boards of directors have approved a definitive agreement under which Thermo Fisher will acquire PPD for $47.50 per share for a total cash purchase price of $17.4 billion plus the assumption of approximately $3.5 billion of net debt. This represents a premium",
                "1d_change": 1.6067539928,
                "index_price": 1.0921221959,
                "norm_price": 0.5146317969
            },
            {
                "index": 92,
                "date": "2021-04-12",
                "press_title": "FDA Authorizes New High-Throughput, Automated System for Leading COVID-19 Test",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/FDA-Authorizes-New-High-Throughput-Automated-System-for-Leading-COVID-19-Test-2021-4-12/default.aspx",
                "content": "The Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit enables laboratories to rapidly scale high-sensitivity PCR testing capacity as schools and employers seek increased testing to support reopening strategies  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the Thermo Fisher Scientific Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit. Amplitude Solution with TaqPath COVID-19 High-Throughput Combo Kit enables labs to scale high-sensitivity PCR testing The Amplitude Solution enables clinical and public health laboratories to scale gold standard PCR testing and process up to 8,000 samples in a single day with minimal staffing resources and a secured supply of kits, reagents and consumables to meet their testing needs. The Amplitude Solution has been implemented globally including labs in Europe",
                "1d_change": 1.3859964798,
                "index_price": 0.4075701228,
                "norm_price": 0.978426357
            },
            {
                "index": 93,
                "date": "2021-04-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 29, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-April-29-2021-2021-4-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2021 before the market opens on Thursday, April 29, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 7956359.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, May 14, 2021. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30",
                "1d_change": 1.8155179457,
                "index_price": 0.9695773764,
                "norm_price": 0.8459405693
            },
            {
                "index": 94,
                "date": "2021-03-24",
                "press_title": "Thermo Fisher Scientific Launches In-Air SARS-CoV-2 Surveillance Solution",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Launches-In-Air-SARS-CoV-2-Surveillance-Solution-2021-3-24/default.aspx",
                "content": "The Thermo Scientific AerosolSense Sampler enables organizations to monitor indoor environments and strengthen facility safety protocols Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the launch of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2. Enables decision makers in hospitals and other facilities to take actions to protect their employees and provide the public with confidence. Individual testing will continue to be a cornerstone in the COVID-19 pandemic response because it enables and informs clinical diagnoses, patient triage and treatment decisions. As society returns to pre-pandemic activities, expanded and complementary monitoring of environments will be key in providing useful insights into virus presence. The AerosolSense Sampler is the next step in providing institutions with highly",
                "1d_change": -1.8517264937,
                "index_price": -0.266270848,
                "norm_price": -1.5854556456
            },
            {
                "index": 95,
                "date": "2021-03-10",
                "press_title": "Thermo Fisher Scientific Investments Support Rapidly Increasing Bioprocessing Production",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Investments-Support-Rapidly-Increasing-Bioprocessing-Production-2021-3-10/default.aspx",
                "content": "More than $600 million in investments will enable reliable supply of critical materials used to produce new vaccines and biologics Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company's current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions. \"As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials. Single-use technologies, cell culture media and purification resins are among those in highest demand,\" said Michel Lagarde, executive vice president of Thermo Fisher Scientific. \"These investments add significant capacity and regional redundancy to further",
                "1d_change": 0.829486,
                "index_price": 1.2019804485,
                "norm_price": -0.3724944485
            },
            {
                "index": 96,
                "date": "2021-02-26",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Mesa Biotech",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Completes-Acquisition-of-Mesa-Biotech-2021-2-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its previously announced acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company. \"Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at the point of care, starting with COVID-19 testing,\" said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. \"By combining Thermo Fisher's operational excellence, access to raw materials and existing distribution and sales channels with Mesa's innovative platform, we can rapidly scale manufacturing volume, drive cost efficiencies and bring much-needed diagnostics to market faster and at greater scale.\" Mesa Biotech has developed the Accula System, an affordable, easy-to-use, point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing",
                "1d_change": 1.0531812506,
                "index_price": 1.5931066825,
                "norm_price": -0.5399254319
            },
            {
                "index": 97,
                "date": "2021-02-24",
                "press_title": "Thermo Fisher Scientific to Present at 41st Annual Cowen Healthcare Conference on March 3, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-41st-Annual-Cowen-Healthcare-Conference-on-March-3-2021-2021-2-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 41 st Annual Cowen Healthcare Conference on Wednesday, March 3, 2021, at 10:20 a.m. (EDT).  You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing",
                "1d_change": -4.2882162669,
                "index_price": -1.1586819668,
                "norm_price": -3.1295343001
            },
            {
                "index": 98,
                "date": "2021-02-23",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend-2021-2-23/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on April 16, 2021, to shareholders of record as of March 16, 2021. This reflects an 18% increase over the previous dividend payment of $0.22. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands,",
                "1d_change": -0.9240950227,
                "index_price": 1.7414618137,
                "norm_price": -2.6655568363
            },
            {
                "index": 99,
                "date": "2021-02-17",
                "press_title": "Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Acquires-Leading-Cell-Sorting-Technology-from-Propel-Labs-2021-2-17/default.aspx",
                "content": "Acquisition broadens the company's cell analysis and flow cytometry portfolio Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has acquired cell sorting technology assets from Propel Labs, a wholly-owned subsidiary of SIDIS Corp. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher's Biosciences business. Propel Labs will continue to operate as a separate entity and serve its existing customers. \"Cell sorting is an essential discovery tool used by many of our customers, allowing for the separation of specific cell types from complex samples. A first-of-its kind, the Bigfoot Spectral Cell Sorter brings more powerful sorting capabilities, faster throughput and novel safety features complementing our already strong flow cytometry offering,\" said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific.",
                "1d_change": -1.7962329866,
                "index_price": -0.1157400116,
                "norm_price": -1.6804929751
            },
            {
                "index": 100,
                "date": "2021-02-11",
                "press_title": "Thermo Fisher Scientific Invests $25 Million to Support Black Communities and Businesses in the U.S.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Invests-25-Million-to-Support-Black-Communities-and-Businesses-in-the-U.S-2021-2-11/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has committed to investing up to $25 million in minority-serving financial institutions. \"Unequal access to capital is hurting Black-owned businesses, Black entrepreneurs and Black communities in the United States,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"Minority-serving financial institutions provide a bridge to empowering historically disenfranchised communities. For Thermo Fisher, supporting these institutions is part of our commitment to addressing inequalities through our business and hiring practices.\" The company has committed $20 million to the Black Economic Development Fund (BEDF), which was launched by the Local Initiatives Support Corporation (LISC) to increase financing to Black-led financial institutions, anchor institutions, and businesses. LISC is one of the nation's oldest and largest Community Development",
                "1d_change": 3.8713704484,
                "index_price": 0.4683855571,
                "norm_price": 3.4029848913
            },
            {
                "index": 101,
                "date": "2021-02-01",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2020-Results-2021-2-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter and Full Year 2020 Highlights Fourth quarter revenue grew 54% to $10.55 billion. Fourth quarter GAAP diluted earnings per share (EPS) increased 151% to $6.24. Fourth quarter adjusted EPS increased 100% to $7.09. Full year revenue grew 26% to $32.22 billion. Full year GAAP diluted EPS increased",
                "1d_change": 0.3259238044,
                "index_price": 2.4864722216,
                "norm_price": -2.1605484172
            },
            {
                "index": 102,
                "date": "2021-01-29",
                "press_title": "Thermo Fisher Scientific Named \"Best Place to Work for LGBTQ Equality\" for Sixth Consecutive Year",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Named-Best-Place-to-Work-for-LGBTQ-Equality-for-Sixth-Consecutive-Year-2021-1-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, was recognized as a \"Best Place to Work for LGBTQ Equality\" for the sixth consecutive year. The company received a perfect score on the 2021 Corporate Equality Index (CEI), the Human Rights Campaign Foundation's 19th annual scorecard on lesbian, gay, bisexual, transgender and queer (LGBTQ) workplace equality. \"At Thermo Fisher, we work together to create an inclusive culture where every colleague feels they belong and are empowered to contribute, collaborate and innovate,\" said Jennifer Farmer, vice president, global diversity and inclusion at Thermo Fisher Scientific. \"Embracing individual differences is critical to our success as a company.\" The CEI is a national benchmarking survey and report on corporate policies and practices related to LGBTQ workplace equality. The report evaluates policies and practices, including non-discrimination workplace protections, domestic partner benefits,",
                "1d_change": 4.1573550317,
                "index_price": -0.1110253504,
                "norm_price": 4.268380382
            },
            {
                "index": 103,
                "date": "2021-01-19",
                "press_title": "Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Acquire-Point-of-Care-Molecular-Diagnostics-Provider-Mesa-Biotech-2021-1-19/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction. Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech's patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. The company is based in San Diego, California and has approximately 500 employees and revenues in 2020 of approximately $45 million. Mesa Biotech's Accula™ Flu A/Flu B, RSV and Strep A",
                "1d_change": 1.1321509981,
                "index_price": 1.8165352511,
                "norm_price": -0.684384253
            },
            {
                "index": 104,
                "date": "2021-01-15",
                "press_title": "Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Acquires-Viral-Vector-Manufacturing-Business-from-Novasep-2021-1-15/default.aspx",
                "content": "Expanded global capacity addresses growing demand for cell and gene therapy  Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash. Novasep's viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep's viral vector business offers more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and",
                "1d_change": 1.9807693622,
                "index_price": 0.2679698091,
                "norm_price": 1.7127995531
            },
            {
                "index": 105,
                "date": "2021-01-06",
                "press_title": "Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-Offers-Financial-Flexibility-with-New-Managed-Equipment-Solutions-2021-1-6/default.aspx",
                "content": "New model for instrument and equipment procurement offers customers subscription-based access to technology, and associated consumables, services and support  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment Solutions , a new subscription-based offering that bundles instrument and equipment procurement with consumables, applications support, software, training and extended service in a convenient and cost-efficient agreement. Managed Equipment Solutions (MES) is ideal for biopharma companies, academic institutions, healthcare organizations and industrial businesses seeking innovative procurement models that offer all the benefits of premium instrument procurement but with increased flexibility. MES gives customers in research, life sciences, specialty diagnostics and applied markets the assurance of long-term, consistent analytical technology performance with predictable subscription costs and a",
                "1d_change": 5.8021713258,
                "index_price": 2.4078639186,
                "norm_price": 3.3943074072
            },
            {
                "index": 106,
                "date": "2021-01-06",
                "press_title": "Thermo Fisher Scientific to Present at 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Present-at-39th-Annual-J.P.-Morgan-Healthcare-Conference-on-January-11-2021-2021-1-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 3:40 p.m. (EDT).  Among other topics, Mr. Casper will provide the company's current perspective on the impact of the COVID-19 pandemic and expectations for future financial performance. You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing",
                "1d_change": 5.8021713258,
                "index_price": 2.4078639186,
                "norm_price": 3.3943074072
            },
            {
                "index": 107,
                "date": "2021-01-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Monday, February 1, 2021",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2021/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Monday-February-1-2021-2021-1-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2020 before the market opens on Monday, February 1, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 9253945.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, February 12, 2021. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue",
                "1d_change": 2.722530405,
                "index_price": 1.3371932341,
                "norm_price": 1.3853371709
            },
            {
                "index": 108,
                "date": "2020-12-30",
                "press_title": "Thermo Fisher Scientific Announces Redemption of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Announces-Redemption-of-Senior-Notes-2020-12-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on December 31, 2020, it will give notice of its intention to redeem the following Senior Notes, representing an aggregate total principal amount of approximately $2.6 billion, on January 15, 2021 (the \"Redemption Date\"): €0.5 billion aggregate principal amount of 2.150% Senior Notes due 2022 (NYSE: TMO 22A) (the \"2022 Notes\") $1.0 billion aggregate principal amount of 3.000% Senior Notes due 2023 (the \"2023 Notes\") $1.0 billion aggregate principal amount of 4.150% Senior Notes due 2024 (the \"2024 Notes\" and, together with the 2022 Notes and the 2023 Notes, the \"Notes\") The Notes will be redeemed at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of the Notes to be redeemed discounted to the Redemption Date (a) on an annual basis at a comparable bond rate",
                "1d_change": 0.098750674,
                "index_price": 0.5292799812,
                "norm_price": -0.4305293073
            },
            {
                "index": 109,
                "date": "2020-11-30",
                "press_title": "Thermo Fisher Scientific to Present at the Evercore ISI HealthCONx Conference on December 1, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Present-at-the-Evercore-ISI-HealthCONx-Conference-on-December-1-2020-2020-11-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the Evercore ISI HealthCONx Conference on Tuesday, December 1, 2020, at 1:00 p.m. (EST).  Among other topics, Mr. Casper will provide the company's current perspective on the impact of the COVID-19 pandemic and expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity",
                "1d_change": 2.9781341758,
                "index_price": 0.7718882144,
                "norm_price": 2.2062459614
            },
            {
                "index": 110,
                "date": "2020-11-20",
                "press_title": "Thermo Fisher Scientific Elects New Director to Board",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Elects-New-Director-to-Board-2020-11-20/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected R. Alexandra \"Alex\" Keith to its board of directors. Ms. Keith's appointment brings the company's total number of board members to 13. Alex is the CEO of Procter  Gamble's (\"PG\") global Beauty business, based in Geneva, Switzerland, and sits on PG's Global Leadership Council. In her current role, she oversees a $13 billion business with 10,000 employees around the world. Alex has spent her entire 30-year career at PG in a variety of roles including manufacturing, logistics, communications and product innovation.   \"Alex is a visionary leader and brand-builder who continuously pushes the boundaries of innovation while staying focused on results,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher",
                "1d_change": -1.513361432,
                "index_price": -0.0480762374,
                "norm_price": -1.4652851946
            },
            {
                "index": 111,
                "date": "2020-11-06",
                "press_title": "Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-and-Innoforce-Partner-to-Establish-Biologics-and-Steriles-Drug-Manufacturing-Facility-in-China-2020-11-6/default.aspx",
                "content": "Joint venture expands global pharma services capacity for drug development and manufacturing Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022. The new state-of-the-art Good Manufacturing Practices (GMP) facility will become part of Thermo Fisher's extensive global pharma services network, which includes leading capabilities for drug product development, biologics manufacturing, sterile fill-finish, clinical trials packaging and logistics. The Hangzhou site will also incorporate stringent quality control processes that meet or exceed regulatory guidelines established by the China National Medical Products Administration (NMPA), the U.S. FDA and appropriate EMEA",
                "1d_change": -6.9259584302,
                "index_price": 1.1874359135,
                "norm_price": -8.1133943437
            },
            {
                "index": 112,
                "date": "2020-11-05",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $2.5 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-and-Authorizes-2.5-Billion-of-Share-Repurchases-2020-11-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.22 per share. The dividend will be paid on January 15, 2021, to shareholders of record as of December 15, 2020. The board also authorized the repurchase of $2.5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $1 billion was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are",
                "1d_change": 0.5041281842,
                "index_price": 0.6753200387,
                "norm_price": -0.1711918545
            },
            {
                "index": 113,
                "date": "2020-10-21",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2020 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Reports-Third-Quarter-2020-Results-2020-10-21/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020. Third Quarter 2020 Highlights Third quarter revenue increased 36% to $8.52 billion. Third quarter GAAP diluted earnings per share (EPS) increased 157% to $4.84. Third quarter adjusted EPS increased 91% to $5.63. Generated $2.0 billion of COVID-19 related revenue in the quarter and returned the base business to growth. Further expanded our global pandemic response, including launching the Amplitude Solution to automate high-throughput PCR-based testing, adding significant capacity for viral transport media production in Europe and introducing two new COVID-19 antibody tests that are available in the U.S. and Europe. Continued to increase our capacity to help governments and biopharma customers globally meet future demand for new therapies and vaccines, most recently partnering with",
                "1d_change": 1.4502302508,
                "index_price": 0.3932276672,
                "norm_price": 1.0570025836
            },
            {
                "index": 114,
                "date": "2020-10-19",
                "press_title": "Thermo Fisher Scientific Increases Availability of COVID-19 Testing with Sample Collection Kit from Everlywell",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Increases-Availability-of-COVID-19-Testing-with-Sample-Collection-Kit-from-Everlywell-2020-10-19/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced it has received an expansion of its Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a leading digital health testing company. The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire. Samples collected using the Everlywell self-collection kit may be processed by CLIA-certified laboratories running Thermo Fisher's TaqMan SARS-CoV-2 RNase P Assay Kit, and the results obtained through the Everlywell online platform. This more convenient home-collection sample processing experience is expected to increase access to highly accurate PCR-based testing and complement other defensive measures including good",
                "1d_change": -0.7758873398,
                "index_price": -1.4678487303,
                "norm_price": 0.6919613904
            },
            {
                "index": 115,
                "date": "2020-10-14",
                "press_title": "Thermo Fisher Scientific Announces Plans to Expand Sterile Filling Capacity for Therapies and Vaccines with New Facility in Singapore",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Announces-Plans-to-Expand-Sterile-Filling-Capacity-for-Therapies-and-Vaccines-with-New-Facility-in-Singapore-2020-10-14/default.aspx",
                "content": "Investment supports global health and preparedness in the Asia-Pacific region  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia-Pacific region for the development and manufacture of therapies and vaccines. Established with the support of the Singapore Economic Development Board (EDB), the US$130M facility will be operated by Thermo Fisher and have the capability to manufacture pharmaceutical products to meet demand in the region and respond effectively to  future health emergencies. \"The COVID-19 pandemic has shown us the importance of government and industry collaboration to protect citizens by ensuring the availability of critical diagnostic tests, therapies and vaccines,\" said Marc N. Casper, chairman, chief executive officer and president of Thermo Fisher Scientific. \"This partnership enables us to expand our sterile fill finish",
                "1d_change": -0.5273865924,
                "index_price": -0.9223871917,
                "norm_price": 0.3950005993
            },
            {
                "index": 116,
                "date": "2020-10-12",
                "press_title": "Thermo Fisher Scientific Further Expands COVID-19 Test Portfolio with Two New Antibody Tests",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Further-Expands-COVID-19-Test-Portfolio-with-Two-New-Antibody-Tests-2020-10-12/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test, and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. These new tests for detecting COVID-19 antibodies expand the company's leading response to the pandemic, which ranges from molecular diagnostic tests and sample collection products, to personal protective equipment, to support of therapy and vaccine development and manufacturing. \"Thermo Fisher is committed to providing a range of innovative solutions, including new serology tests that complement our PCR-based tests,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"The addition of COVID-19 antibody tests to our broad portfolio further enables our support of the pandemic response on multiple fronts.\" OmniPATH COVID-19 Total Antibody ELISA test The OmniPATH COVID-19",
                "1d_change": 0.3742978486,
                "index_price": 0.3391272702,
                "norm_price": 0.0351705784
            },
            {
                "index": 117,
                "date": "2020-10-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-21-2020-2020-10-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter of 2020 before the market opens on Wednesday, October 21, 2020, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 1570827.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, November 6, 2020. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25",
                "1d_change": 1.3209603985,
                "index_price": -0.1874473406,
                "norm_price": 1.5084077391
            },
            {
                "index": 118,
                "date": "2020-09-15",
                "press_title": "Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Further-Expands-Laboratory-Plastics-Production-to-Support-COVID-19-Testing-Therapies-and-Vaccines-2020-9-15/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is investing more than $140 million to further expand its laboratory plastics consumables production to support significant global demand for COVID-19 testing, as well as development and manufacturing of therapies and vaccines. \"Early in the pandemic, we quickly joined forces with governments, public health agencies and industry to increase capacity across our laboratory plastics production facilities and address the growing COVID-19 threat,\" said Fred Lowery, senior vice president and president of Life Sciences Solutions and Laboratory Products at Thermo Fisher Scientific. \"However, demand quickly exceeded those early expansion projects, so we began a series of additional expansions to meet the growing needs of our customers. These investments, along with many others across the company, will ensure that our customers have the supplies they need to continue meeting the",
                "1d_change": -0.4056497562,
                "index_price": -0.6569208681,
                "norm_price": 0.2512711119
            },
            {
                "index": 119,
                "date": "2020-09-14",
                "press_title": "Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 15, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference-on-September-15-2020-2020-9-14/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2020, at 8:00 a.m. (ET). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies,",
                "1d_change": -0.078137127,
                "index_price": 1.1066650923,
                "norm_price": -1.1848022193
            },
            {
                "index": 120,
                "date": "2020-08-27",
                "press_title": "Thermo Fisher Scientific to Host Virtual Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Host-Virtual-Analyst-Meeting-2020-8-27/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host a virtual Analyst Meeting on Thursday, September 10, 2020, starting at 9:00 a.m. and expected to conclude by 11:00 a.m. (EDT). The virtual format will feature presentations by members of Thermo Fisher Scientific's senior management team, to include an update on business conditions, and conclude with a QA session. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and",
                "1d_change": 3.5761434649,
                "index_price": 0.6519399068,
                "norm_price": 2.9242035581
            },
            {
                "index": 121,
                "date": "2020-08-13",
                "press_title": "Thermo Fisher Scientific Announces Results of Offer to Acquire QIAGEN, Lapse of Offer and Termination of Acquisition Agreement",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Announces-Results-of-Offer-to-Acquire-QIAGEN-Lapse-of-Offer-and-Termination-of-Acquisition-Agreement-2020-8-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its offer to acquire all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has lapsed. Based on information provided by the settlement agents for the offer, Deutsche Bank Aktiengesellschaft and American Stock Transfer  Trust Company, 107,546,187 QIAGEN shares, representing 47.02% of the issued and outstanding ordinary shares of QIAGEN, were validly tendered into the offer by the end of the acceptance period at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020. Accordingly, the minimum acceptance threshold condition to the offer has not been satisfied, and the offer has lapsed in accordance with its terms. Thermo Fisher has terminated the acquisition agreement with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of USD 95 million in cash in accordance with",
                "1d_change": 0.4205312189,
                "index_price": -0.0029605086,
                "norm_price": 0.4234917274
            },
            {
                "index": 122,
                "date": "2020-08-12",
                "press_title": "Thermo Fisher Scientific Supports COVID-19 Testing at Historically Black Colleges and Universities Seeking to Provide a Safe Return to Campus",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Supports-COVID-19-Testing-at-Historically-Black-Colleges-and-Universities-Seeking-to-Provide-a-Safe-Return-to-Campus-2020-8-12/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, has committed to supporting the efforts of historically black colleges and universities (HBCUs) in the U.S. to make COVID-19 testing available to all returning students, faculty and staff at the beginning of the fall semester. Through an initiative called \" The Just Project ,\" named after pioneering biologist Ernest Everett Just, Thermo Fisher plans to donate $15 million in diagnostic instruments, test kits and related supplies. The company will also provide technical assistance to HBCUs seeking to establish or expand their laboratories to provide regular on-campus COVID-19 testing throughout the 2020-21 school year. Howard University, Morehouse School of Medicine, Meharry Medical College, Xavier University of Louisiana and Hampton University will be among the first HBCUs to receive donations. Their laboratories, along with those at other HBCUs that are expected to join the initiative over the next several",
                "1d_change": 1.8483007936,
                "index_price": 0.5326913873,
                "norm_price": 1.3156094063
            },
            {
                "index": 123,
                "date": "2020-08-11",
                "press_title": "Thermo Fisher Scientific Provides Process Overview for the Announcement of Final Offer Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Provides-Process-Overview-for-the-Announcement-of-Final-Offer-Results-2020-8-11/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today provided an overview of the process to report the final results from the acceptance period of its offer to acquire all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), which expired at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. Due to German practice regarding the booking by custodian institutions of tenders submitted before the expiration of the offer acceptance period and the calculation and publication of final results, Deutsche Bank Aktiengesellschaft and American Stock Transfer  Trust Company, the settlement agents for the offer, expect to provide Thermo Fisher with a final determination of the number of shares tendered on Thursday, August 13, 2020. As soon as practicable after the determination is made, Thermo Fisher will publicly announce the final results and publish those results",
                "1d_change": 1.6339452034,
                "index_price": 0.2961234628,
                "norm_price": 1.3378217406
            },
            {
                "index": 124,
                "date": "2020-08-05",
                "press_title": "Thermo Fisher Scientific's COVID-19 Response Continues to Expand with New High-Throughput Automated Testing Solution",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientifics-COVID-19-Response-Continues-to-Expand-with-New-High-Throughput-Automated-Testing-Solution-2020-8-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today introduced a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing. The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school. The Thermo Fisher Scientific Amplitude Solution is a molecular diagnostic testing system that leverages the company's Applied Biosystems QuantStudio 7 Flex Real-time PCR instruments along with liquid handling products from Tecan Group, a global leader in laboratory automation and liquid handling. The modular solution delivers test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources. \"Increased testing capability is an essential part of any community's plan to reopen schools and businesses,\" said Marc N. Casper,",
                "1d_change": -0.2838392544,
                "index_price": 0.9491871322,
                "norm_price": -1.2330263866
            },
            {
                "index": 125,
                "date": "2020-08-04",
                "press_title": "Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Confirms-Offer-to-Acquire-QIAGEN-Shares-Expires-on-August-10-2020-8-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. On July 16, 2020, Thermo Fisher and QIAGEN announced that they had entered into an amendment to their acquisition agreement following good faith discussions between the parties. The revised offer price of €43.00 per QIAGEN share represents Thermo Fisher's best and final offer. QIAGEN's Supervisory Board and Managing Board reaffirmed their unanimous support for the offer and unanimously recommend that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period. Each of the members of the Supervisory Board and Managing Board has tendered all of their QIAGEN shares in the offer. If the minimum acceptance",
                "1d_change": 0.2310115414,
                "index_price": 1.1374012457,
                "norm_price": -0.9063897043
            },
            {
                "index": 126,
                "date": "2020-07-22",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2020 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Reports-Second-Quarter-2020-Results-2020-7-22/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020. Second Quarter 2020 Highlights Second quarter revenue increased 10% to $6.92 billion. Second quarter GAAP diluted earnings per share (EPS) increased 5% to $2.90. Second quarter adjusted EPS increased 28% to $3.89. Leveraged our industry-leading scale and expertise to meet strong global demand for COVID-19 products and services. Highlights in the second quarter included: Generated approximately $1.3 billion of COVID-related revenue Received expansion of emergency use authorization (EUA) to run our PCR test on additional instruments and consumables for greater workflow flexibility Designed and built a new facility in Lenexa, Kansas, to manufacture highly specialized viral transport media (VTM) for sample collection under a U.S. government contract Formed a collaboration with WuXi Diagnostics and Mayo Clinic to develop a",
                "1d_change": 0.1559077497,
                "index_price": -0.5933934911,
                "norm_price": 0.7493012408
            },
            {
                "index": 127,
                "date": "2020-07-20",
                "press_title": "Thermo Fisher Scientific's Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientifics-Response-to-COVID-19-Continues-to-Expand-to-Support-Development-and-Production-of-Therapeutics-and-Vaccines-2020-7-20/default.aspx",
                "content": "Leading pharma services network brings unmatched scalability, flexibility and expertise to support the global response  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally. \"Well before the pandemic, we were strategically investing in capacity and capabilities to increase manufacturing and supply chain flexibility for our customers, and this has enabled us to rapidly pivot to also support the COVID-19 response,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"The company is well-positioned to take the lead in supporting development of COVID-19 treatments and vaccines in addition to",
                "1d_change": 1.2875503395,
                "index_price": 1.013416304,
                "norm_price": 0.2741340355
            },
            {
                "index": 128,
                "date": "2020-07-16",
                "press_title": "Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-and-QIAGEN-N.V.-Agree-on-Amended-Terms-to-Acquisition-Agreement-2020-7-16/default.aspx",
                "content": "- Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, today announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN's ordinary shares on the Frankfurt Prime",
                "1d_change": 0.6246743009,
                "index_price": 0.5076354655,
                "norm_price": 0.1170388354
            },
            {
                "index": 129,
                "date": "2020-07-09",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2020-7-9/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per common share, payable on October 15, 2020, to shareholders of record as of September 15, 2020. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -0.7841771478,
                "index_price": 0.278493114,
                "norm_price": -1.0626702618
            },
            {
                "index": 130,
                "date": "2020-07-06",
                "press_title": "Thermo Fisher Scientific Provides Update to Second Quarter Outlook and Will Hold its Q2 Earnings Conference Call on Wednesday, July 22, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Provides-Update-to-Second-Quarter-Outlook-and-Will-Hold-its-Q2-Earnings-Conference-Call-on-Wednesday-July-22-2020-2020-7-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, based on currently available information, it estimates that both reported and organic revenue 1 growth will be approximately 10% for the second quarter ended June 27, 2020. The better-than-expected organic revenue growth was primarily driven by strong global sales of PCR-based tests and other products and services supporting the COVID-19 response, which contributed more than $1.4 billion of revenue in the second quarter and reflects the scale of the company's role in helping customers battle the pandemic. Thermo Fisher will release its financial results for the second quarter on Wednesday, July 22, 2020, before the market opens, and will hold a conference call to discuss those results and provide a business update on the same day at 8:30 a.m. ET. To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 1239877. You may also listen to the",
                "1d_change": 2.6272093531,
                "index_price": -0.3169779382,
                "norm_price": 2.9441872914
            },
            {
                "index": 131,
                "date": "2020-05-27",
                "press_title": "Thermo Fisher Scientific to Showcase New Mass Spectrometry Systems and Software During Virtual ASMS Event",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Showcase-New-Mass-Spectrometry-Systems-and-Software-During-Virtual-ASMS-Event-2020-5-27/default.aspx",
                "content": "Digital programs will enable scientists to broaden mass spectrometry-based research, from proteomics and biotherapeutics to clinical applications Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications.  The company will showcase its newest instruments, software and workflow solutions during a company-hosted virtual event, vLC-MS.com , from May 26-28, 2020, and at the American Society for Mass Spectrometry (ASMS) Reboot Program , from June 1-12, 2020. \"The need for accelerated research has been heightened during the pandemic, and the public is expecting unprecedented progress from the scientific community,\" said Dan Shine, senior vice president and president, analytical instruments. \"A deeper analysis of proteins is critical to understanding disease, including novel viruses.",
                "1d_change": 1.8177091324,
                "index_price": 0.4647304617,
                "norm_price": 1.3529786707
            },
            {
                "index": 132,
                "date": "2020-05-27",
                "press_title": "Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-and-CSL-Enter-Strategic-Partnership-to-Provide-Best-in-Class-Pharma-Services-2020-5-27/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives. Thermo Fisher will support CSL's product portfolio by leveraging its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics. Through a long-term lease agreement with CSL, Thermo Fisher will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in mid-2021. \"We continue to invest to meet the growing need for flexible biologics capacity, and Lengnau will significantly expand our pharma services capacity and capabilities,\" said Michel Lagarde, executive vice president of Thermo Fisher Scientific. \"This",
                "1d_change": 1.8177091324,
                "index_price": 0.4647304617,
                "norm_price": 1.3529786707
            },
            {
                "index": 133,
                "date": "2020-05-20",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2020-5-20/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per common share, payable on July 15, 2020, to shareholders of record as of June 15, 2020. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -2.7669190819,
                "index_price": -0.1736427223,
                "norm_price": -2.5932763596
            },
            {
                "index": 134,
                "date": "2020-05-18",
                "press_title": "Thermo Fisher Scientific's Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientifics-Support-of-COVID-19-Response-Continues-to-Expand-with-U.S.-Government-Contract-for-Products-Used-in-Sample-Collection-2020-5-18/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has received a contract from the U.S. government to provide highly specialized viral transport media (VTM) for COVID-19 sample collection. The VTM is used during collection of patient samples for proper transport to laboratories that can test for the presence of the virus. To ensure accuracy of COVID-19 test results, VTM must be manufactured and dispensed into tubes in an aseptic environment. Thermo Fisher currently produces VTM at its site in Lenexa, Kansas, which meets this requirement, and has ramped production from 50,000 to more than one million VTM-filled tubes per week. Given the significant demand for COVID-19 testing and associated sample collection, Thermo Fisher will expand capacity in Lenexa with a new $40 million facility dedicated to VTM production and quality control. The added capacity and increased efficiencies will allow the company to scale production to more",
                "1d_change": -1.5228417884,
                "index_price": 0.3106404567,
                "norm_price": -1.8334822451
            },
            {
                "index": 135,
                "date": "2020-05-18",
                "press_title": "Thermo Fisher Scientific Publishes Offer Document for Voluntary Tender Offer for All Ordinary Shares of QIAGEN N.V.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Publishes-Offer-Document-for-Voluntary-Tender-Offer-for-All-Ordinary-Shares-of-QIAGEN-N.V-2020-5-18/default.aspx",
                "content": "Acceptance period for cash offer of €39 per QIAGEN share runs from May 18, 2020, to July 27, 2020 Transaction expected to close in the first half of 2021  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published the offer document (the \"Offer Document\") for its voluntary tender offer (the \"Tender Offer\") for all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) at an offer price of €39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority. The period for acceptance of the Tender Offer commenced on May 18, 2020, and is scheduled to end at midnight Frankfurt am Main Local Time or 6:00 PM New York Local Time on July 27, 2020. The Tender Offer is subject to certain customary closing conditions, including, among others, the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at",
                "1d_change": -1.5228417884,
                "index_price": 0.3106404567,
                "norm_price": -1.8334822451
            },
            {
                "index": 136,
                "date": "2020-05-13",
                "press_title": "Thermo Fisher Scientific Response to COVID-19 Expands to Include New Serology Test",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Response-to-COVID-19-Expands-to-Include-New-Serology-Test-2020-5-13/default.aspx",
                "content": "Collaboration with WuXi Diagnostics and Mayo Clinic on serology test will complement Thermo Fisher's widely adopted TaqPath COVID-19 molecular diagnostic test Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher will seek U.S. FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the test over the next few weeks. Once approved for use, the Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test will detect Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to help clinicians determine if a patient has been exposed to SARS-CoV-2. The test is designed to run on an open instrument platform, and the determination of",
                "1d_change": 0.6255751966,
                "index_price": -0.4683648527,
                "norm_price": 1.0939400492
            },
            {
                "index": 137,
                "date": "2020-05-12",
                "press_title": "FDA Further Expands EUA for Thermo Fisher Scientific's COVID-19 Diagnostic Tests",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/FDA-Further-Expands-EUA-for-Thermo-Fisher-Scientifics-COVID-19-Diagnostic-Tests-2020-5-12/default.aspx",
                "content": "Authorization brings more instruments on line, enables workflow flexibility and simplifies methods to increase throughput and allow more labs to run tests Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has further expanded emergency use authorization (EUA) for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS‑CoV‑2, the virus that causes COVID-19. \"Increasing COVID-19 testing is a top priority in re-opening global economies,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"With this expanded authorization, additional instrumentation can be brought on line in labs around the world and the number of tests they can run will increase, which will help to support the need for more testing as people start returning to work.\" Thermo Fisher's Applied Biosystems TaqPath COVID-19 Combo Kit, initially",
                "1d_change": -1.8827225278,
                "index_price": -4.2375886525,
                "norm_price": 2.3548661247
            },
            {
                "index": 138,
                "date": "2020-05-11",
                "press_title": "Thermo Fisher Scientific to Double its Capacity of Viral Vector Manufacturing",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Double-its-Capacity-of-Viral-Vector-Manufacturing-2020-5-11/default.aspx",
                "content": "New Plainville, Massachusetts, site will accelerate commercialization of cell and gene therapies Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is expanding capacity for viral vector development and manufacturing services with construction of a new commercial manufacturing site in Plainville, Mass. The $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines. Construction of the new 290,000-square-foot facility is expected to be completed in 2022. The project will add more than 200 jobs and complement the company's new or recently expanded capacity in Lexington and Cambridge, Mass., and Alachua, Fla. \"The Plainville expansion significantly enhances our 'start here, stay here' strategy, ensuring that customers have an uninterrupted pathway from development through commercialization,\" said Michel Lagarde,",
                "1d_change": 0.114551845,
                "index_price": -1.579719381,
                "norm_price": 1.694271226
            },
            {
                "index": 139,
                "date": "2020-05-06",
                "press_title": "Thermo Fisher Scientific to Present at BofA Securities 2020 Health Care Conference",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Present-at-BofA-Securities-2020-Health-Care-Conference-2020-5-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference   on Wednesday, May 13, 2020, at 8:20 a.m. (EST).  You can access the webcast via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative",
                "1d_change": 0.4571256479,
                "index_price": -0.0676786748,
                "norm_price": 0.5248043227
            },
            {
                "index": 140,
                "date": "2020-04-22",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2020 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Reports-First-Quarter-2020-Results-2020-4-22/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2020. First Quarter 2020 Highlights First quarter revenue increased 2% to $6.23 billion. First quarter GAAP diluted earnings per share (EPS) decreased 2% to $1.97. First quarter adjusted EPS increased 5% to $2.94. Announced agreement to acquire QIAGEN N.V. for $11.5 billion, expanding our specialty diagnostics portfolio with attractive molecular diagnostics capabilities and enhancing our life sciences offering with innovative sample preparation technologies. Commenced permanent financing by raising $3.5 billion through U.S. and European bond offerings. Responded to global demand for COVID-19 diagnostic testing by developing the Applied Biosystems TaqPath COVID-19 Combo Kit, which received Emergency Use Authorization from the U.S. FDA, the CE mark in Europe and subsequent authorizations worldwide. Also introduced the Thermo",
                "1d_change": -0.9484899094,
                "index_price": 0.3542124554,
                "norm_price": -1.3027023648
            },
            {
                "index": 141,
                "date": "2020-04-06",
                "press_title": "Thermo Fisher Scientific Provides COVID-19 Business Update and Will Hold First Quarter Earnings Conference Call on Wednesday, April 22, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Provides-COVID-19-Business-Update-and-Will-Hold-First-Quarter-Earnings-Conference-Call-on-Wednesday-April-22-2020-2020-4-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, due to the evolving COVID-19 pandemic and related customer impact, it is withdrawing 2020 annual guidance, which was provided on January 30, 2020. Thermo Fisher has mobilized to support the global COVID-19 response with products and services that help analyze, diagnose and protect from the virus. However, as the pandemic spread from China to countries worldwide, the company saw a significant reduction in customer activity by late March. Given the ongoing uncertainty of the scope, duration and impact of the pandemic, Thermo Fisher is currently unable to reasonably estimate its annual financial performance. The company believes its long-term prospects remain excellent given the attractive markets served, its industry-leading position and proven growth strategy. The pandemic is also likely to result in additional funding opportunities for its customers in the future. During this",
                "1d_change": 0.6642249891,
                "index_price": 3.0506723481,
                "norm_price": -2.3864473591
            },
            {
                "index": 142,
                "date": "2020-03-30",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2020-3-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of €1.2 billion aggregate principal amount (the \"Offering\") of the following euro-denominated notes: €600 million aggregate principal amount of its 1.750% senior notes due 2027 (the \"2027 notes\"), at the issue price of 99.190% of their principal amount, and €600 million aggregate principal amount of its 2.375% senior notes due 2032 (the \"2032 notes\"), at the issue price of 98.940% of their principal amount. The Offering is expected to close on or about April 2, 2020, subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the consideration for Thermo Fisher's previously announced acquisition of QIAGEN N.V., a public limited liability company organized under the laws of The Netherlands (\"QIAGEN\"), including the repayment of indebtedness of QIAGEN, and for general",
                "1d_change": 1.8723362569,
                "index_price": 0.9908769496,
                "norm_price": 0.8814593073
            },
            {
                "index": 143,
                "date": "2020-03-26",
                "press_title": "Thermo Fisher Scientific Receives CE Mark for its Diagnostic Test to Detect COVID-19",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Receives-CE-Mark-for-its-Diagnostic-Test-to-Detect-COVID-19-2020-3-26/default.aspx",
                "content": "Test will now be available for qualified laboratories across the European Union Company provides update on other designated approvals received to date Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19. \"The CE mark certification is an important step in combatting the outbreak of COVID-19 across Europe,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"We are committed to fighting this disease and we will continue to work with regulatory authorities and customers around the world to expand the availability of diagnostic testing and stem the spread of the coronavirus.\" The Thermo Fisher test, which uses Applied Biosystems TaqPath Assay and real-time PCR technology, is designed to provide patient results within four hours of a sample being",
                "1d_change": -0.1530570368,
                "index_price": 1.5809721186,
                "norm_price": -1.7340291555
            },
            {
                "index": 144,
                "date": "2020-03-23",
                "press_title": "Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Prices-Offering-of-USD-Denominated-Senior-Notes-2020-3-23/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of $2.2 billion aggregate principal amount (the \"Offering\") of the following notes: $1.1 billion aggregate principal amount of its 4.133% senior notes due 2025, at the issue price of 100% of their principal amount, and $1.1 billion aggregate principal amount of its 4.497% senior notes due 2030, at the issue price of 100% of their principal amount. The Offering is expected to close on or about March 25, 2020, subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the consideration for Thermo Fisher's previously announced acquisition of QIAGEN N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (\"QIAGEN\"), including the repayment of indebtedness of QIAGEN to be assumed by Thermo Fisher, and for general",
                "1d_change": 3.4712648095,
                "index_price": 6.3996319331,
                "norm_price": -2.9283671235
            },
            {
                "index": 145,
                "date": "2020-03-16",
                "press_title": "FDA Issued Emergency Use Authorization to Thermo Fisher Scientific for Diagnostic Test Used to Detect COVID-19 on March 13",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/FDA-Issued-Emergency-Use-Authorization-to-Thermo-Fisher-Scientific-for-Diagnostic-Test-Used-to-Detect-COVID-19-on-March-13-2020-3-16/default.aspx",
                "content": "Company Provides Update on Production Rate  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that on March 13, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for its diagnostic test that can be used immediately by CLIA high-complexity laboratories in the U.S. to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19, and not for any other viruses or pathogens. The authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab. The estimated time-to-result also includes time for sample preparation and instrument analysis. On March 13, Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, \"The authorization of our diagnostic test for COVID-19 will help to protect patients and enable medical staff to respond swiftly to treat those who are ill",
                "1d_change": 8.3628541963,
                "index_price": 0.8144842417,
                "norm_price": 7.5483699546
            },
            {
                "index": 146,
                "date": "2020-03-13",
                "press_title": "FDA Issues Emergency Use Authorization to Thermo Fisher Scientific for Diagnostic Test Used to Detect COVID-19",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/FDA-Issues-Emergency-Use-Authorization-to-Thermo-Fisher-Scientific-for-Diagnostic-Test-Used-to-Detect-COVID-19-2020-3-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for  its diagnostic test that can be used immediately by CLIA high-complexity laboratories in the U.S. to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19, and not for any other viruses or pathogens. The authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab. The estimated time-to-result also includes time for sample preparation and instrument analysis. \"The authorization of our diagnostic test for COVID-19 will help to protect patients and enable medical staff to respond swiftly to treat those who are ill and prevent the spread of infection,\" said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. \"At Thermo",
                "1d_change": -6.550908047,
                "index_price": -7.705368796,
                "norm_price": 1.154460749
            },
            {
                "index": 147,
                "date": "2020-03-10",
                "press_title": "Thermo Fisher Scientific Names Paul G. Parker to Head Strategy and Corporate Development",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Names-Paul-G.-Parker-to-Head-Strategy-and-Corporate-Development-2020-3-10/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Paul G. Parker will join the company, effective April 15, 2020, as senior vice president, strategy and corporate development, which also includes corporate social responsibility. Parker will report to Marc N. Casper, chairman, president and chief executive officer, and will be based in Waltham, Mass. Parker joins from Goldman Sachs  Co., where he served for six years as co-chairman of Global Mergers  Acquisitions and as a member of the firm's Partnership Committee. His investment banking career spans 35 years, having held numerous global operating and senior client relationship roles at Goldman Sachs and other leading financial services firms including Barclays, Lehman Brothers and J.P. Morgan. Parker is a graduate of Harvard Business School and The University of North Carolina at Chapel Hill. \"We are pleased to welcome Paul to the Thermo Fisher leadership team as we",
                "1d_change": -5.6603901126,
                "index_price": -2.6300659062,
                "norm_price": -3.0303242065
            },
            {
                "index": 148,
                "date": "2020-03-03",
                "press_title": "Thermo Fisher Scientific to Acquire QIAGEN N.V.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Acquire-QIAGEN-N.V-2020-3-3/default.aspx",
                "content": "- Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing - Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies - Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the",
                "1d_change": 3.3706966978,
                "index_price": 1.0753630848,
                "norm_price": 2.295333613
            },
            {
                "index": 149,
                "date": "2020-02-26",
                "press_title": "Thermo Fisher Scientific President and Chief Executive Officer Marc N. Casper Elected Chairman of the Board of Directors",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-President-and-Chief-Executive-Officer-Marc-N.-Casper-Elected-Chairman-of-the-Board-of-Directors-2020-2-26/default.aspx",
                "content": "Director Thomas Lynch Becomes Lead Independent Director  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has elected president and chief executive officer Marc N. Casper, 51, as chairman, effective immediately. Casper will continue in his role as president and chief executive officer, which he has held since October 2009. The company also announced that Thomas Lynch, 65, has been elected lead independent director, effective immediately. Lynch has been a member of Thermo Fisher's board since May 2009. Casper succeeds Jim Manzi, 68, who has served as a director since May 2000 and as chairman of the board for 15 years. Manzi will continue to serve as a director on the Thermo Fisher board. \"Marc has demonstrated exceptional leadership of Thermo Fisher Scientific, driving the outstanding execution of a growth strategy that has resulted in significant value creation for our customers, colleagues and",
                "1d_change": -3.9248826944,
                "index_price": -5.4096299148,
                "norm_price": 1.4847472204
            },
            {
                "index": 150,
                "date": "2020-02-25",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend-2020-2-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per common share, payable on April 16, 2020, to shareholders of record as of March 16, 2020. This reflects a 16% increase over the previous dividend payment of $0.19. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading",
                "1d_change": -5.0523841231,
                "index_price": -3.9324363463,
                "norm_price": -1.1199477768
            },
            {
                "index": 151,
                "date": "2020-02-24",
                "press_title": "Thermo Fisher Scientific to Present at Cowen and Company's 40th Annual Healthcare Conference on March 2, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Present-at-Cowen-and-Companys-40th-Annual-Healthcare-Conference-on-March-2-2020-2020-2-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at Cowen and Company's 40 th Annual Healthcare Conference in Boston on Monday, March 2, 2020, at 11:20 a.m. (EST).  You can access the webcast via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and",
                "1d_change": -4.7250045744,
                "index_price": -4.1365556692,
                "norm_price": -0.5884489051
            },
            {
                "index": 152,
                "date": "2020-01-30",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2019 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2019-Results-2020-1-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Full Year 2019 Highlights Fourth quarter revenue increased 5% to $6.83 billion. Fourth quarter GAAP diluted earnings per share (EPS) increased 12% to $2.49. Fourth quarter adjusted EPS increased 9% to $3.55.                                       Full year revenue grew 5% to $25.54 billion. Full year GAAP diluted EPS increased 27% to $9.17. Full year adjusted EPS increased 11% to $12.35.                               Delivered another excellent year",
                "1d_change": -2.8129894715,
                "index_price": -0.9589130265,
                "norm_price": -1.854076445
            },
            {
                "index": 153,
                "date": "2020-01-03",
                "press_title": "Thermo Fisher Scientific to Present at 38th Annual J.P. Morgan Healthcare Conference on January 13, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Present-at-38th-Annual-J.P.-Morgan-Healthcare-Conference-on-January-13-2020-2020-1-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2020, at 4:00 p.m. (PST) followed by a QA session at 4:30 p.m. (PST).  You can access the webcast of the presentation and the QA session via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our",
                "1d_change": 1.1256736706,
                "index_price": 0.6136230299,
                "norm_price": 0.5120506407
            },
            {
                "index": 154,
                "date": "2020-01-02",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2020",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2020/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-January-30-2020-2020-1-2/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2019 fourth quarter and full year before the market opens on Thursday, January 30, 2020, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, February 7, 2020. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24",
                "1d_change": -0.9850543654,
                "index_price": -0.3035635013,
                "norm_price": -0.681490864
            },
            {
                "index": 155,
                "date": "2019-11-08",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $2.5 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-and-Authorizes-2.5-Billion-of-Share-Repurchases-2019-11-8/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.19 per share.  The dividend will be paid on January 15, 2020, to shareholders of record as of December 17, 2019. The board also authorized the repurchase of $2.5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $500 million was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver",
                "1d_change": -0.715414911,
                "index_price": 0.1865886326,
                "norm_price": -0.9020035436
            },
            {
                "index": 156,
                "date": "2019-10-23",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2019 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Reports-Third-Quarter-2019-Results-2019-10-23/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2019. Third Quarter 2019 Highlights Third quarter revenue increased 6% to $6.27 billion. Third quarter GAAP diluted earnings per share (EPS) increased 7% to $1.88. Third quarter adjusted EPS increased 12% to $2.94. Launched innovative new products for clinical, life sciences and bioproduction applications, highlighted by the FDA-cleared Thermo Scientific TSQ Altis and Quantis MD mass spectrometers and the Vanquish MD HPLC for clinical diagnostic laboratories, a new Real-time PCR solution for respiratory pathogen detection, the Thermo Scientific Krios G4 compact electron microscope for structural biology and the Thermo Scientific TruBio Discovery bioproduction automation system. Strengthened global capabilities to enhance our unique customer value proposition, including opening a new Center of Excellence for transplant",
                "1d_change": -1.7448016776,
                "index_price": 0.5408126488,
                "norm_price": -2.2856143264
            },
            {
                "index": 157,
                "date": "2019-10-01",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of GSK Manufacturing Site in Cork, Ireland",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Completes-Acquisition-of-GSK-Manufacturing-Site-in-Cork-Ireland-2019-10-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility from GlaxoSmithKline (GSK) for €90 million. Completion of the transaction follows the receipt of all required regulatory approvals. Approximately 400 employees at the Cork, Ireland, site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment. About Thermo Fisher Scientific  Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands",
                "1d_change": -4.3823492309,
                "index_price": -3.3273132594,
                "norm_price": -1.0550359715
            },
            {
                "index": 158,
                "date": "2019-09-30",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-23-2019-2019-9-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter of 2019 before the market opens on Wednesday, October 23, 2019, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, November 8, 2019. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24",
                "1d_change": 0.170489369,
                "index_price": -0.9121696577,
                "norm_price": 1.0826590266
            },
            {
                "index": 159,
                "date": "2019-09-25",
                "press_title": "Thermo Fisher Scientific Prices Offering of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Prices-Offering-of-Senior-Notes-2019-9-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of €4.4 billion aggregate principal amount (the \"Euro Offering\") of euro-denominated notes (collectively, the \"Euro Notes\") and an offering of $900 million aggregate principal amount (the \"USD Offering\" and, together with the Euro Offering, the \"Offerings\") of USD-denominated notes (collectively, the \"USD Notes\"). The following notes were priced: €800 million aggregate principal amount of its 0.125% senior notes due 2025, at the issue price of 99.114% of their principal amount, €800 million aggregate principal amount of its 0.500% senior notes due 2028, at the issue price of 99.060% of their principal amount, €900 million aggregate principal amount of its 0.875% senior notes due 2031, at the issue price of 99.243% of their principal amount, €900 million aggregate principal amount of its 1.500% senior notes due 2039, at the issue price of 99.743% of their principal amount,",
                "1d_change": 0.2475221495,
                "index_price": 0.3113231093,
                "norm_price": -0.0638009597
            },
            {
                "index": 160,
                "date": "2019-09-05",
                "press_title": "Thermo Fisher Scientific Elects New Director to Board",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Elects-New-Director-to-Board-2019-9-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Debora Spar to its board of directors. Ms. Spar's appointment brings the company's total number of board members to 13. Ms. Spar is currently a Professor of Business Administration at Harvard Business School. She served as President of Barnard College from 2008 to 2017, where she led several key initiatives to highlight the leadership and advancement of women. She also served as President and Chief Executive Officer at Lincoln Center for the Performing Arts from 2017 to 2018. Prior to joining Barnard, Ms. Spar was the Spangler Family Professor at Harvard Business School  for 17 years and served as Senior Associate Dean for Faculty Research and Development. Her research has focused on issues related to international political economy, examining how rules are established in new or emerging markets and how firms and governments together shape the evolving global",
                "1d_change": 2.2538304793,
                "index_price": 0.6079767255,
                "norm_price": 1.6458537539
            },
            {
                "index": 161,
                "date": "2019-08-06",
                "press_title": "Thermo Fisher Scientific Showcases New Innovations for the Clinic During AACC 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Showcases-New-Innovations-for-the-Clinic-During-AACC-2019-2019-8-6/default.aspx",
                "content": "AACC 2019 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest instruments, assays and software for improving speed, accuracy and usability across clinical and research labs during the 71st American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2019). Thermo Fisher is exhibiting in booth 2110 at the Anaheim Convention Center, Anaheim, Calif., August 4-8. \"Clinical laboratories play pivotal roles in healthcare as expectations increase for diagnostic speed, accuracy and cost-savings,\" said Patrick Durbin, senior vice president and president, specialty diagnostics for Thermo Fisher Scientific. \"From more effective use of antibiotics to calls for faster lab-supported diagnoses, we're continuously advancing our portfolio to meet the new and unmet needs of healthcare providers who are working to improve patient outcomes.\" Ease of Use, Speed to Result, Improved Diagnosis Thermo",
                "1d_change": 1.2336791614,
                "index_price": 0.7905758356,
                "norm_price": 0.4431033258
            },
            {
                "index": 162,
                "date": "2019-07-24",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2019 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Reports-Second-Quarter-2019-Results-2019-7-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2019. Second Quarter 2019 Highlights Second quarter revenue increased 4% to $6.32 billion. Second quarter GAAP diluted earnings per share (EPS) increased 50% to $2.77. Second quarter adjusted EPS increased 11% to $3.04. Strengthened our mass spectrometry leadership with new instruments, workflows and software, highlighted by two new-generation Thermo Scientific Orbitrap systems – the Exploris 480 and Eclipse Tribrid – and a new workflow to advance biotherapeutics, called the HR Multi-Attribute Method. In genetic analysis, we launched the Applied Biosystems QuantStudio 6 and 7 Pro Real-Time PCR systems to automate qPCR workflows. Continued to expand our bioproduction capabilities to meet customer demand for biologics, committing $50 million to add manufacturing capacity for single-use technologies at our facilities in the U.S. and",
                "1d_change": 0.5437203148,
                "index_price": 0.1631305194,
                "norm_price": 0.3805897954
            },
            {
                "index": 163,
                "date": "2019-07-11",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2019-7-11/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per common share, payable on October 15, 2019, to shareholders of record as of September 17, 2019. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.",
                "1d_change": -2.4747677329,
                "index_price": 0.469508365,
                "norm_price": -2.9442760979
            },
            {
                "index": 164,
                "date": "2019-06-28",
                "press_title": "Thermo Fisher Scientific Completes Sale of Anatomical Pathology Business to PHC Holdings Corporation",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Completes-Sale-of-Anatomical-Pathology-Business-to-PHC-Holdings-Corporation-2019-6-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash. The Anatomical Pathology business, with approximately 1200 employees in the U.S., Europe and Asia, generated approximately $350 million in annual revenue and was part of Thermo Fisher's Specialty Diagnostics Segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory",
                "1d_change": 2.2878459645,
                "index_price": 1.0589285232,
                "norm_price": 1.2289174413
            },
            {
                "index": 165,
                "date": "2019-06-24",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-July-24-2019-2019-6-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter of 2019 before the market opens on Wednesday, July 24, 2019, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, August 9, 2019. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and",
                "1d_change": -0.5689367074,
                "index_price": -1.1668017341,
                "norm_price": 0.5978650267
            },
            {
                "index": 166,
                "date": "2019-06-10",
                "press_title": "Thermo Fisher Scientific and Roper Technologies Announce Termination of Gatan Acquisition",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-and-Roper-Technologies-Announce-Termination-of-Gatan-Acquisition-2019-6-10/default.aspx",
                "content": "Existing Supply Agreement Remains Intact Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Roper Technologies (NYSE: ROP), a leading diversified technology company, today announced that they have mutually terminated the agreement under which Thermo Fisher would have acquired Gatan, Inc., a wholly owned subsidiary of Roper. Both companies have agreed to withdraw from the proposed transaction due to challenges in obtaining regulatory approval in the United Kingdom. The companies noted that an existing long-term supply agreement, under which Gatan supplies filter systems, cameras and software to Thermo Fisher's electron microscopy business, remains intact. ABOUT THERMO FISHER SCIENTIFIC Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers",
                "1d_change": 0.7647470557,
                "index_price": -0.0038155962,
                "norm_price": 0.7685626519
            },
            {
                "index": 167,
                "date": "2019-06-03",
                "press_title": "Thermo Fisher Scientific Extends Industry-leading Mass Spectrometry Portfolio with a New Generation of Intelligence-Driven Instruments and Software",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Extends-Industry-leading-Mass-Spectrometry-Portfolio-with-a-New-Generation-of-Intelligence-Driven-Instruments-and-Software-2019-6-3/default.aspx",
                "content": "ASMS 2019 -  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is accelerating the pace of innovation in the lab with the introduction of a new generation of intelligence-driven mass spectrometry instruments, workflows and software. The company will showcase these new additions to its industry-leading offering during the 67 th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 2-6, in the International Ballroom ABCD at the Omni CNN Center Hotel, Atlanta, Georgia. \"We recognized the ability to transform the mass spectrometry market when our groundbreaking Orbitrap mass analyzer technology was presented 20 years ago at ASMS,\" said Dan Shine, senior vice president and president of analytical instruments for Thermo Fisher Scientific. \"As the demand for high-performance, accurate analytical instruments and innovative software continues to evolve, we are excited to introduce new",
                "1d_change": -0.1194310509,
                "index_price": 1.8457012658,
                "norm_price": -1.9651323167
            },
            {
                "index": 168,
                "date": "2019-05-23",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2019-5-23/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per common share, payable on July 16, 2019, to shareholders of record as of June 14, 2019. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For",
                "1d_change": 1.0522382603,
                "index_price": -0.37649209,
                "norm_price": 1.4287303503
            },
            {
                "index": 169,
                "date": "2019-05-20",
                "press_title": "Thermo Fisher Scientific to Invest $50 Million to Expand Bioproduction Capabilities",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Invest-50-Million-to-Expand-Bioproduction-Capabilities-2019-5-20/default.aspx",
                "content": "Expansion projects will increase single-use capacity to meet growing customer demand Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it is investing more than $50 million in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioprocess container (BPC) systems. Thermo Fisher's single-use technologies are used for critical, sterile liquid-handling applications in the biopharmaceutical industry to help increase productivity and ensure quality in the production of biologic drugs. \"The demand for our bioproduction products and services continues to outpace the market,\" said Cory Stevenson, president of Thermo Fisher's Bioproduction business. \"These investments will expand capabilities across our existing bioproduction network while we look to extend our footprint into new regions to meet increasing customer demand for our industry-leading single-use technologies.\" In Cramlington, U.K.,",
                "1d_change": 1.1983930121,
                "index_price": 0.7827286087,
                "norm_price": 0.4156644034
            },
            {
                "index": 170,
                "date": "2019-05-16",
                "press_title": "Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Acquire-Manufacturing-Site-in-Cork-Ireland-from-GSK-2019-5-16/default.aspx",
                "content": "Expands global footprint for complex API manufacturing  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the site produces highly specialized APIs for treating diseases including childhood cancer, depression and Parkinson's. Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement and plans to expand use of the site to develop and produce complex APIs for other customers as well. The site contains 270 cubic meters of reactor capacity, 10 production buildings, an RD pilot plant and lab infrastructure to support process",
                "1d_change": -1.9867857229,
                "index_price": 0.1304403322,
                "norm_price": -2.117226055
            },
            {
                "index": 171,
                "date": "2019-05-07",
                "press_title": "Thermo Fisher Scientific to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 14, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Present-at-the-Bank-of-America-Merrill-Lynch-2019-Health-Care-Conference-on-May-14-2019-2019-5-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 8:40 a.m. (PT) at the Encore at the Wynn Las Vegas, Las Vegas, Nevada. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -2.2143242982,
                "index_price": -1.1672527222,
                "norm_price": -1.047071576
            },
            {
                "index": 172,
                "date": "2019-05-01",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Brammer Bio",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Completes-Acquisition-of-Brammer-Bio-2019-5-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.  The completion of the transaction follows the receipt of all required regulatory approvals. Brammer Bio has nearly 600 employees at primary locations in Massachusetts and Florida and will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to",
                "1d_change": 0.2267417741,
                "index_price": -1.1931386369,
                "norm_price": 1.419880411
            },
            {
                "index": 173,
                "date": "2019-04-29",
                "press_title": "Thermo Fisher Scientific to Host Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Host-Analyst-Meeting-2019-4-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2019 Analyst Meeting on Wednesday, May 22, starting at 9:00 a.m. (ET), at the Park Hyatt New York, 153 West 57 th Street, in New York City. The meeting will feature presentations by members of Thermo Fisher Scientific's senior management team, including expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient",
                "1d_change": 1.2578997885,
                "index_price": 0.1782180187,
                "norm_price": 1.0796817698
            },
            {
                "index": 174,
                "date": "2019-04-24",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2019 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Reports-First-Quarter-2019-Results-2019-4-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2019. First Quarter 2019 Highlights First quarter revenue increased to $6.12 billion. First quarter GAAP diluted earnings per share (EPS) increased 41% to $2.02. First quarter adjusted EPS increased 12% to $2.81. Launched a range of new products, including two Thermo Scientific instruments for materials analysis – the Nicolet Summit FTIR spectrometer and the Helios 5 DualBeam scanning electron microscope – and in specialty diagnostics, received FDA clearance for a new ImmunoCAP test for peanut allergy. Recently opened new Customer Solution Centers in Beijing and Delhi to help scientists in the food and beverage industry develop advanced analytical workflows that improve food quality and safety. Announced $150 million expansion of our pharma services sites in Italy and North Carolina to increase capacity and capabilities of",
                "1d_change": 1.6954012497,
                "index_price": -0.2675879506,
                "norm_price": 1.9629892003
            },
            {
                "index": 175,
                "date": "2019-04-01",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-April-24-2019-2019-4-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter of 2019 before the market opens on Wednesday, April 24, 2019, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, May 10, 2019. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and",
                "1d_change": -0.1200913438,
                "index_price": 0.649059984,
                "norm_price": -0.7691513278
            },
            {
                "index": 176,
                "date": "2019-03-24",
                "press_title": "Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Acquire-Brammer-Bio-a-Leader-in-Viral-Vector-Manufacturing-2019-3-24/default.aspx",
                "content": "Significantly expands capabilities to support high-growth gene and cell therapy market  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, today announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO), enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies. The business has nearly 600 employees at primary locations in Massachusetts and Florida. Brammer Bio is on track to deliver $250 million of revenue in 2019 and expects to continue to exceed the projected market growth rate of 25 percent over the mid-term. Thermo Fisher expects the business to be accretive to adjusted earnings",
                "1d_change": 1.6836264329,
                "index_price": 0.7965325562,
                "norm_price": 0.8870938767
            },
            {
                "index": 177,
                "date": "2019-03-19",
                "press_title": "Thermo Fisher Scientific Innovations at Pittcon 2019 Enable Workflows Across Life Sciences, Applied and Industrial Markets",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Innovations-at-Pittcon-2019-Enable-Workflows-Across-Life-Sciences-Applied-and-Industrial-Markets-2019-3-19/default.aspx",
                "content": "Pittcon 2019  - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is introducing innovative products, software and services for customers working in biopharma, food safety, environmental quality and industrial applications during the 2019 Pittcon Conference and Exhibition.  The company will showcase analytical workflows that enable fast, precise analyses within booth #2632 at the Philadelphia Convention Center, March 17 - 21, 2019. \"Across many industries, our customers continue to ask for increased speed, improved accuracy and greater ease of use at every stage of their analytical workflows,\" said Dan Shine, senior vice president, analytical instruments, Thermo Fisher Scientific. \"We know how to bring our leading technologies together to help our customers achieve their goals, whether they're a researcher developing new cancer therapies, a food producer testing for dioxins or a medical device manufacturer performing QA/QC.\"",
                "1d_change": 0.4404588178,
                "index_price": -0.5852933157,
                "norm_price": 1.0257521335
            },
            {
                "index": 178,
                "date": "2019-03-18",
                "press_title": "Thermo Fisher Scientific to Invest $150 Million to Expand Pharma Services Capabilities",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Invest-150-Million-to-Expand-Pharma-Services-Capabilities-2019-3-18/default.aspx",
                "content": "Expansion projects will increase capacity to meet growing customer demand for biologics Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it is investing $150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing. Included in the site expansion projects are Monza and Ferentino, Italy, and Greenville, North Carolina. In response to customer requests, each of the sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months. \"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise,\" said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. \"We continue to invest to expand our capabilities and help our",
                "1d_change": 1.0941468203,
                "index_price": 0.3516227559,
                "norm_price": 0.7425240644
            },
            {
                "index": 179,
                "date": "2019-03-04",
                "press_title": "Thermo Fisher Scientific to Present at the Barclays Global Healthcare Conference on March 13, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Present-at-the-Barclays-Global-Healthcare-Conference-on-March-13-2019-2019-3-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019, at 8:00 a.m. (EDT) at the Loews Miami Hotel, Miami, Florida. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and",
                "1d_change": -4.5351134415,
                "index_price": -0.8861404015,
                "norm_price": -3.6489730401
            },
            {
                "index": 180,
                "date": "2019-02-26",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend-2019-2-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.19 per common share, payable on April 16, 2019, to shareholders of record as of March 15, 2019. This reflects a 12% increase over the previous dividend payment of $0.17. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of",
                "1d_change": 2.0876745665,
                "index_price": 0.0007081913,
                "norm_price": 2.0869663752
            },
            {
                "index": 181,
                "date": "2019-01-30",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2018-Results-2019-1-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter and Full Year 2018 Highlights Fourth quarter revenue grew 8% to $6.51 billion. Fourth quarter GAAP diluted earnings per share (EPS) increased 71% to $2.22. Fourth quarter adjusted EPS increased 16% to $3.25. Full year revenue grew 16% to $24.36 billion. Full year GAAP diluted EPS increased 30% to $7.24. Full year adjusted EPS increased 17% to $11.12. Invested $1 billion in RD in 2018 and launched a range of new products that strengthened our leading offering, including the Thermo Scientific Vanquish Duo UHPLC system, Thermo Scientific Q Exactive UHMR mass spectrometer, Ion GeneStudio S5 Series next-generation sequencing systems and the Phadia 200 allergy and autoimmune instrument in Europe. Built on the excellent growth momentum we had all year in Asia-Pacific and Emerging Markets, capped",
                "1d_change": 2.8086553659,
                "index_price": 1.8667940774,
                "norm_price": 0.9418612885
            },
            {
                "index": 182,
                "date": "2019-01-28",
                "press_title": "Thermo Fisher Scientific Signs Agreement to Sell its Anatomical Pathology Business",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-Signs-Agreement-to-Sell-its-Anatomical-Pathology-Business-2019-1-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has signed a definitive agreement to sell its Anatomical Pathology business to PHC Holdings Corporation, a global innovator in healthcare solutions, for approximately $1.14 billion in cash. The Anatomical Pathology business is a provider of microscope slides, instruments and consumables. It has approximately 1,200 employees at locations in the U.S., Europe and China. The business generates approximately $350 million in annual revenue and is part of Thermo Fisher's Specialty Diagnostics Segment. Thermo Fisher anticipates closing the transaction in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals. The company expects the net dilution to 2019 adjusted earnings per share to be approximately $0.10, which will be incorporated into its 2019 financial guidance that will be provided on the January 30, 2019, earnings",
                "1d_change": -0.5023274592,
                "index_price": -0.188256466,
                "norm_price": -0.3140709932
            },
            {
                "index": 183,
                "date": "2019-01-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 30, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-January-30-2019-2019-1-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2018 fourth quarter and full year before the market opens on Wednesday, January 30, 2019, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (877) 273-7122 within the U.S. or (647) 689-5496 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, February 8, 2019. About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20",
                "1d_change": 1.3528256199,
                "index_price": 1.5806069835,
                "norm_price": -0.2277813635
            },
            {
                "index": 184,
                "date": "2019-01-02",
                "press_title": "Thermo Fisher Scientific to Present at 37th Annual J.P. Morgan Healthcare Conference on January 8, 2019",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2019/Thermo-Fisher-Scientific-to-Present-at-37th-Annual-J.P.-Morgan-Healthcare-Conference-on-January-8-2019-2019-1-2/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 4:00 p.m. (PST) at the Westin St. Francis, San Francisco, Calif. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific   Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -3.6244650958,
                "index_price": -1.187556207,
                "norm_price": -2.4369088888
            },
            {
                "index": 185,
                "date": "2018-12-19",
                "press_title": "Gatan Acquisition Requires Further UK Review",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Gatan-Acquisition-Requires-Further-UK-Review-2018-12-19/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Roper Technologies, Inc. (NYSE: ROP), a leading diversified technology company, today announced that Thermo Fisher's pending acquisition of Gatan, Inc., a wholly owned subsidiary of Roper, requires further review by the Competition and Markets Authority (CMA) in the UK. Both parties continue to work cooperatively with the CMA through the review process. All other regulatory approval conditions have been satisfied.  About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our",
                "1d_change": -5.1807281433,
                "index_price": -3.2272628687,
                "norm_price": -1.9534652746
            },
            {
                "index": 186,
                "date": "2018-11-08",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2018-11-8/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share, payable on January 15, 2019, to shareholders of record as of December 17, 2018. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.",
                "1d_change": -0.3121855098,
                "index_price": -0.9122539278,
                "norm_price": 0.600068418
            },
            {
                "index": 187,
                "date": "2018-11-07",
                "press_title": "Thermo Fisher Scientific Elects New Director to Board",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Elects-New-Director-to-Board-2018-11-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Jim Mullen to its board of directors. Mr. Mullen's appointment brings the total number of Thermo Fisher board members to 12. Mr. Mullen previously served as chief executive officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, from February 2011 until the company was acquired by Thermo Fisher in 2017. Prior to that, he was with Biogen Idec, Inc. for 22 years, serving as president and chief executive officer from 2000 to 2010. Mr. Mullen is also currently a director at Insulet Inc. and Editas Medicine Inc. \"We are pleased to welcome Jim to our board,\" said Jim Manzi, chairman of the board of Thermo Fisher Scientific. \"With his extensive experience in the pharmaceutical and biotech industry, his perspective will be highly valuable as we continue to build on our industry-leading capabilities for",
                "1d_change": 2.2681975671,
                "index_price": 1.1650222636,
                "norm_price": 1.1031753035
            },
            {
                "index": 188,
                "date": "2018-10-31",
                "press_title": "Thermo Fisher Scientific to Present at the Jefferies 2018 London Healthcare Conference on November 14, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Present-at-the-Jefferies-2018-London-Healthcare-Conference-on-November-14-2018-2018-10-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018, at 10:40 a.m. (GMT) at the Waldorf Hilton, London, UK. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services",
                "1d_change": -0.4279633164,
                "index_price": 1.2688074254,
                "norm_price": -1.6967707419
            },
            {
                "index": 189,
                "date": "2018-10-29",
                "press_title": "Thermo Fisher Scientific to Present at the Baird 2018 Global Industrial Conference on November 7, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Present-at-the-Baird-2018-Global-Industrial-Conference-on-November-7-2018-2018-10-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Dan Shine, senior vice president and president, Analytical Instruments, will present at the Baird 2018 Global Industrial Conference on Wednesday, November 7, 2018, at 12:30 p.m. (CST) at the Four Seasons Hotel, Chicago, Ill. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher",
                "1d_change": -0.4899541955,
                "index_price": -0.0007462651,
                "norm_price": -0.4892079304
            },
            {
                "index": 190,
                "date": "2018-10-25",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Advanced Bioprocessing from BD",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Completes-Acquisition-of-Advanced-Bioprocessing-from-BD-2018-10-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today completed its previously announced acquisition of the Advanced Bioprocessing business from BD (Becton, Dickinson and Company – NYSE: BDX), a leading global medical technology company, for $477 million in cash, subject to post-closing adjustments. The business will be integrated into Thermo Fisher's Life Sciences Solutions Segment. The Advanced Bioprocessing business has annualized revenue of approximately $100 million, with 160 employees at principal manufacturing locations in Detroit, Mich. and Miami, Fla. \"We are pleased to complete this acquisition and officially welcome our new colleagues from BD to Thermo Fisher,\" said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. \"The addition of Advanced Bioprocessing's complementary cell-culture media products and strong technical services program into our leading bioproduction portfolio will enable our",
                "1d_change": 2.9347729246,
                "index_price": -0.6089443208,
                "norm_price": 3.5437172454
            },
            {
                "index": 191,
                "date": "2018-10-24",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2018 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Reports-Third-Quarter-2018-Results-2018-10-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 29, 2018. Third Quarter 2018 Highlights Grew revenue 16% to $5.92 billion. Increased GAAP diluted earnings per share (EPS) 31% to $1.75. Increased adjusted EPS 13% to $2.62. Launched a number of new instruments for life sciences and specialty diagnostics, highlighted by the Invitrogen EVOS M5000 cell imaging system, Thermo Scientific Phenom Pharos benchtop scanning electron microscope, Thermo Scientific ISQ EM mass spectrometer, and the Phadia 200 allergy and autoimmune system in Europe. Began major expansion of biologics production facility in St. Louis to meet increasing demand for contract development and manufacturing services in North America. Announced agreement to acquire Advanced Bioprocessing business from Becton Dickinson, which will add complementary cell culture products that expand our bioproduction offering to",
                "1d_change": -2.0417923497,
                "index_price": -1.1938352366,
                "norm_price": -0.8479571131
            },
            {
                "index": 192,
                "date": "2018-10-01",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 24, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-24-2018-2018-10-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter before the market opens on Wednesday, October 24, 2018, and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its third quarter financial performance, as well as future expectations.  To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" The webcast will be available under \"Webcasts and Presentations\" through Friday, November 9, 2018. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately",
                "1d_change": 0.7386551299,
                "index_price": -0.0978339652,
                "norm_price": 0.8364890951
            },
            {
                "index": 193,
                "date": "2018-09-07",
                "press_title": "Thermo Fisher Scientific Board Authorizes $2 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Board-Authorizes-2-Billion-of-Share-Repurchases-2018-9-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $2.0 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. The company's previous repurchase authorization of $1.5 billion of shares, approved in July 2016, has $250 million remaining, which the company plans to deplete later this year. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo",
                "1d_change": 0.9233018447,
                "index_price": 0.308288934,
                "norm_price": 0.6150129106
            },
            {
                "index": 194,
                "date": "2018-09-07",
                "press_title": "Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Acquire-Advanced-Bioprocessing-Business-from-BD-2018-9-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement with BD (Becton, Dickinson and Company – NYSE: BDX), a leading global medical technology company, under which Thermo Fisher will acquire BD's Advanced Bioprocessing business. This business combines a strong technical services program with a variety of peptones that enhance cell culture media formulations to improve yield and reduce variability in biopharmaceutical applications. \"Thermo Fisher has a trusted value proposition for customers who are working in biologic drug development and manufacturing,\" said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. \"The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production.\" Patrick Kaltenbach, president of Life Sciences for BD, said \"We are excited that",
                "1d_change": 0.9233018447,
                "index_price": 0.308288934,
                "norm_price": 0.6150129106
            },
            {
                "index": 195,
                "date": "2018-09-04",
                "press_title": "Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference-on-September-12-2018-2018-9-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018, at 2:15 p.m. (ET) at the Grand Hyatt New York, New York. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity",
                "1d_change": -1.0661245732,
                "index_price": -0.2894088139,
                "norm_price": -0.7767157593
            },
            {
                "index": 196,
                "date": "2018-07-31",
                "press_title": "Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Showcases-Innovations-for-Research-and-Clinical-Labs-at-AACC-2018-2018-7-31/default.aspx",
                "content": "AACC  - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research during the 2018 American Association of Clinical Chemistry ( AACC) Annual Scientific Meeting  Clinical Lab Expo (booth 3831), being held July 29 – August 2 at McCormick Place in Chicago.  \"Clinical customers and translational researchers demand analytical platforms that support higher throughput, accuracy and scalability,\" said Patrick Durbin, senior vice president and president of specialty diagnostics for Thermo Fisher Scientific. \"The common goal is actionable data that's delivered with confidence, and we're highlighting our portfolio of leading products at AACC to support their needs, from research to the clinic.\" Comprehensive Laboratory Solutions With more than one billion samples run on its liquid chromatography – mass spectrometry (LC-MS) systems over the past 10 years, Thermo Fisher is",
                "1d_change": 0.9105946454,
                "index_price": 0.1290317206,
                "norm_price": 0.7815629248
            },
            {
                "index": 197,
                "date": "2018-07-25",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2018 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Reports-Second-Quarter-2018-Results-2018-7-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 30, 2018. Second Quarter 2018 Highlights Grew revenue 22% to $6.08 billion. Increased GAAP diluted earnings per share (EPS) 19% to $1.85. Increased adjusted EPS 20% to $2.75. Launched suite of new mass spectrometry systems for life sciences and applied markets – highlighted by the Thermo Scientific Q Exactive UHMR for protein research – as well as new products for clinical research and diagnostics, including the Ion Torrent Oncomine Childhood Cancer Research Assay and the Thermo Scientific B.R.A.H.M.S. Kryptor Gold immunoassay analyzer in Europe. Opened new Precision Medicine Science Center in the U.S., giving customers greater access to the range of technologies and expertise we offer to help them accelerate development of individualized patient treatments. Announced agreement to acquire Gatan Inc., a leading provider of",
                "1d_change": 3.4188049306,
                "index_price": 0.6946388768,
                "norm_price": 2.7241660538
            },
            {
                "index": 198,
                "date": "2018-07-13",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2018-7-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share, payable on October 15, 2018, to shareholders of record as of September 17, 2018. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.",
                "1d_change": -1.5325750874,
                "index_price": 0.053601485,
                "norm_price": -1.5861765724
            },
            {
                "index": 199,
                "date": "2018-06-28",
                "press_title": "Thermo Fisher Scientific Signs Agreement to Acquire Gatan from Roper Technologies",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Signs-Agreement-to-Acquire-Gatan-from-Roper-Technologies-2018-6-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Roper Technologies, Inc. (NYSE: ROP), a leading diversified technology company, today announced that they have entered into a definitive agreement under which Thermo Fisher will acquire Gatan, Inc. , a wholly owned subsidiary of Roper, for approximately $925 million in cash. Gatan is a leading manufacturer of instrumentation and software used to enhance and extend the operation and performance of electron microscopes. Gatan's technologies are used in materials science, electronics and life sciences to enable electron microscopy workflows – from specimen preparation and manipulation to imaging and analysis. These solutions, which are platform agnostic, include filter systems, cameras and proprietary software. With approximately 320 employees globally, Gatan is headquartered in Pleasanton, Calif. , and has key manufacturing operations in Warrendale, Penn. The business is expected",
                "1d_change": 1.9262236877,
                "index_price": 0.7239696926,
                "norm_price": 1.2022539951
            },
            {
                "index": 200,
                "date": "2018-06-26",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 25, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-July-25-2018-2018-6-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter before the market opens on Wednesday, July 25, 2018 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its second quarter financial performance, as well as future expectations.  To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under \"Financial Results.\" The webcast will be available under \"Webcasts and Presentations\" through Friday, August 10, 2018. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately",
                "1d_change": -0.7965371717,
                "index_price": -0.8330858433,
                "norm_price": 0.0365486716
            },
            {
                "index": 201,
                "date": "2018-06-04",
                "press_title": "Thermo Fisher Scientific Opens U.S. Precision Medicine Science Center",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Opens-U.S.-Precision-Medicine-Science-Center-2018-6-4/default.aspx",
                "content": "Supports development of analytical workflows to generate precise molecular profiles of patients   BIO  2018 and ASMS 2018 -   Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today officially opened its U.S. Precision Medicine Science Center (PMSC) in Cambridge, Mass. The Center offers access to advanced \"omics\" technologies and expertise to help collaborators develop analytical workflows that generate precise molecular profiles of patients. This information will ultimately be used in clinical settings to more effectively treat disease. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/83430241-thermo-fisher-us-precision-medicine-science-center/ In addition to providing access to the industry's most advanced analytical technologies, the PMSC's team of in-house scientists helps partners develop standard protocols that enable them to compress RD timelines and quickly progress from",
                "1d_change": 1.2897545416,
                "index_price": 0.2593905277,
                "norm_price": 1.0303640139
            },
            {
                "index": 202,
                "date": "2018-06-04",
                "press_title": "Thermo Fisher Scientific Shows Newest Mass Spectrometry Innovations at ASMS 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Shows-Newest-Mass-Spectrometry-Innovations-at-ASMS-2018-2018-6-4/default.aspx",
                "content": "ASMS 2018 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled advances in its leading mass spectrometry portfolio that make these powerful technologies more accessible to scientists across life sciences and applied markets. New instruments, accessories and software deliver improved ease of use and higher performance to help customers accelerate innovation and enhance productivity. Thermo Fisher will display its newest innovations in booth 708 at the 66 th Annual American Society for Mass Spectrometry (ASMS) Conference , being held June 3-7 at the San Diego Convention Center . \"From proteomic researchers who are discovering biomarkers of disease to forensics experts who are solving crimes, our customers need the capabilities and confidence to push scientific boundaries,\" said Dan Shine , president, analytical instruments, for Thermo Fisher. \"During ASMS, customers will learn how our expanded mass spectrometry offering can help them to",
                "1d_change": 1.2897545416,
                "index_price": 0.2593905277,
                "norm_price": 1.0303640139
            },
            {
                "index": 203,
                "date": "2018-05-24",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2018-5-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share, payable on July 16, 2018 , to shareholders of record as of June 15, 2018 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more",
                "1d_change": -1.6335300938,
                "index_price": -0.3531311162,
                "norm_price": -1.2803989776
            },
            {
                "index": 204,
                "date": "2018-05-09",
                "press_title": "Thermo Fisher Scientific to Present at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Present-at-the-Bank-of-America-Merrill-Lynch-2018-Health-Care-Conference-on-May-16-2018-2018-5-9/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 , at 8:00 a.m. (PT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen,",
                "1d_change": 2.413237752,
                "index_price": 1.6507085768,
                "norm_price": 0.7625291751
            },
            {
                "index": 205,
                "date": "2018-04-30",
                "press_title": "Thermo Fisher Scientific to Host Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Host-Analyst-Meeting-2018-4-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2018 Analyst Meeting on Wednesday, May 23 , starting at 9:00 a.m. (ET) , at the Mandarin Oriental New York, 80 Columbus Circle at 60 th Street, in New York City . The meeting will feature presentations by members of Thermo Fisher Scientific's senior management team, including expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . A replay of the webcast will be available following the presentation. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve",
                "1d_change": -1.1247266099,
                "index_price": -1.0437682849,
                "norm_price": -0.080958325
            },
            {
                "index": 206,
                "date": "2018-04-25",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2018 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Reports-First-Quarter-2018-Results-2018-4-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2018 . First Quarter 2018 Highlights First quarter revenue grew 23% to $5.85 billion . First quarter GAAP diluted earnings per share (EPS) increased 2% to $1.43 . First quarter adjusted EPS increased 20% to $2.50 . Launched new products across our portfolio, including Thermo Scientific Vanquish Duo UHPLC systems for pharma QA/QC, the Thermo Scientific Chromeleon XTR Laboratory Management System and the Ion GeneStudio S5 Series of next-generation sequencing instruments. Held first China-U.S. Precision Medicine Summit in Beijing , convening more than 400 thought leaders across government, academia and industry to promote global collaboration in the prevention, diagnosis and treatment of disease. Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items",
                "1d_change": -1.8752458729,
                "index_price": 1.2006276945,
                "norm_price": -3.0758735674
            },
            {
                "index": 207,
                "date": "2018-04-10",
                "press_title": "Thermo Fisher Scientific Highlights Digital Science Innovations at Analytica 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Highlights-Digital-Science-Innovations-at-Analytica-2018-2018-4-10/default.aspx",
                "content": "Analytica 2018 - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled an expanded portfolio of new instruments and software designed to accelerate discovery and enhance productivity for customers working in pharma and biotech, environmental analysis, academic research and other applications. Digital science highlights on display include instrument connectivity, cloud enablement, and the automation of compliance, consumables procurement and other workflow enhancements. Attendees can learn more about Thermo Fisher's commitment to laboratory innovation in hall 1, booth 101 at the Messe Munchen April 10-13, 2018 , during the 26th International Trade Fair for Laboratory Technology, Analysis, Biotechnology and Analytica conference. \"Our customers want to improve productivity, collaboration and knowledge management by taking an integrated, standardized and unified approach that digitally transforms their labs,\" said Dan Shine , senior vice",
                "1d_change": 0.206774795,
                "index_price": 0.1430642528,
                "norm_price": 0.0637105423
            },
            {
                "index": 208,
                "date": "2018-04-03",
                "press_title": "Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Rapid-Mycoplasma-Testing-Method-Now-Accepted-by-Regulators-for-QA-QC-and-Lot-Release-2018-4-3/default.aspx",
                "content": "MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities Manufacturers of cell-culture-based therapeutics can now rely on a faster method for detecting mycoplasma contamination. The Applied Biosystems MycoSEQ Mycoplasma Detection Kit is a fully integrated solution for real-time PCR-based mycoplasma detection. Used throughout the bioproduction workflow, the MycoSEQ method is an alternative to costly, time-consuming culture-based tests often done externally by contract labs, which can take up to 28 days. Following validation, regulatory review and acceptance, the MycoSEQ assay and method can be used for lot release by manufacturers in different therapeutic modalities including biotherapeutics, cell and gene therapies, vaccines and other cell-culture-based therapeutics. To date, nine global manufacturers of therapies subject to U.S. Food and Drug Administration ,",
                "1d_change": 2.2071637755,
                "index_price": 1.9858668008,
                "norm_price": 0.2212969747
            },
            {
                "index": 209,
                "date": "2018-04-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 25, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-April-25-2018-2018-4-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter before the market opens on Wednesday, April 25, 2018 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its first quarter financial performance, as well as future expectations.  To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" The webcast will be available under \"Webcasts and Presentations\" through Friday, May 11, 2018 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000",
                "1d_change": 2.2071637755,
                "index_price": 1.9858668008,
                "norm_price": 0.2212969747
            },
            {
                "index": 210,
                "date": "2018-02-27",
                "press_title": "Thermo Fisher Scientific Innovations Offer Greater Connectivity and Ease of Use",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Innovations-Offer-Greater-Connectivity-and-Ease-of-Use-2018-2-27/default.aspx",
                "content": "Pittcon 2018 –  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled an expanded portfolio of analytical instruments, consumables, software and services to make technology more available to scientists worldwide, enabling faster, more informed decisions based on advanced scientific data. The Pittcon 2018 Conference and Exhibition provides a backdrop for new instruments and software that are easier to use and more accessible, allowing customers to accelerate innovation and improve productivity in pharma and biotech, environmental analysis, academic research and other applications. The company is exhibiting within booth 2353 at the Orange County Convention Center's West Building in Orlando , Feb. 27 – March 1, 2018 . \"The ecosystem that exists today around cloud computing, big data and machine learning allows more scientists globally to experience the power of our extensive offering,\" said Dan Shine , senior vice president, analytical",
                "1d_change": -2.5601799048,
                "index_price": -2.4548284575,
                "norm_price": -0.1053514473
            },
            {
                "index": 211,
                "date": "2018-01-31",
                "press_title": "Thermo Fisher Scientific Uses Tax Reform Benefit to Make Additional Investments in Colleagues, Customers and Communities",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Uses-Tax-Reform-Benefit-to-Make-Additional-Investments-in-Colleagues-Customers-and-Communities-2018-1-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will make additional investments totaling $50 million as a result of the benefit of recently enacted Federal tax reform legislation in the U.S. This investment includes: $34 million for a one-time bonus of $500 to be paid to each of the company's approximately 68,000 eligible non-executive employees globally $16 million to accelerate key breakthrough RD programs and also to increase the impact of the company's sustainability initiatives and philanthropic activities in support of STEM (Science, Technology, Engineering and Math) education. \"Thermo Fisher will benefit from tax reform, so we chose to use this unique opportunity to recognize the commitment of our colleagues who work hard every day to fulfill our Mission – to enable our customers to make the world healthier, cleaner and safer,\" said Marc N. Casper , president and chief executive officer, Thermo Fisher Scientific . \"We also plan to",
                "1d_change": -0.4947118739,
                "index_price": -0.3695962308,
                "norm_price": -0.1251156431
            },
            {
                "index": 212,
                "date": "2018-01-31",
                "press_title": "Thermo Fisher Scientific Increases Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Increases-Quarterly-Dividend-2018-1-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.17 per common share, payable on April 16, 2018 , to shareholders of record as of March 15, 2018 . This reflects a 13% increase over the previous dividend payment of $0.15 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination",
                "1d_change": -0.4947118739,
                "index_price": -0.3695962308,
                "norm_price": -0.1251156431
            },
            {
                "index": 213,
                "date": "2018-01-31",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2017 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2017-Results-2018-1-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2017 . Fourth Quarter and Full Year 2017 Highlights Fourth quarter revenue grew 22% to $6.05 billion .  Full year revenue grew 14% to $20.92 billion .  Fourth quarter GAAP diluted earnings per share (EPS) decreased 18% to $1.30 . Full year GAAP diluted EPS increased 10% to $5.59 . GAAP results include a one-time tax provision of $204 million associated with the recent enactment of tax reform legislation in the U.S.  Fourth quarter adjusted EPS increased 16% to $2.79 . Full year adjusted EPS increased 15% to $9.49 .  Invested $0.9 billion in RD during the year and launched high-impact products across all segments, highlighted by the Thermo Scientific Q-Exactive HF-X mass spectrometer, Thermo Scientific Krios G3i cryo transmission electron microscope,",
                "1d_change": -0.4947118739,
                "index_price": -0.3695962308,
                "norm_price": -0.1251156431
            },
            {
                "index": 214,
                "date": "2018-01-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-January-31-2018-2018-1-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2017 fourth quarter and full year before the market opens on Wednesday, January 31, 2018 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its fourth quarter financial performance, as well as future expectations.  To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Thursday, February 1, 2018 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more",
                "1d_change": 1.3417590253,
                "index_price": 0.5961285232,
                "norm_price": 0.7456305021
            },
            {
                "index": 215,
                "date": "2018-01-02",
                "press_title": "Thermo Fisher Scientific to Present at 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2018/Thermo-Fisher-Scientific-to-Present-at-36th-Annual-J.P.-Morgan-Healthcare-Conference-on-January-9-2018-2018-1-2/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 , at 3:00 p.m. (PST) at the Westin St. Francis , San Francisco, Calif. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems ,",
                "1d_change": 2.9106442915,
                "index_price": 1.0810699908,
                "norm_price": 1.8295743008
            },
            {
                "index": 216,
                "date": "2017-11-21",
                "press_title": "Thermo Fisher Scientific Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Recommends-Shareholders-Reject-Mini-Tender-Offer-by-TRC-Capital-Corporation-2017-11-21/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it received notice of an unsolicited \"mini-tender\" offer by TRC Capital Corporation (TRC) to purchase up to 1,000,000 shares of Thermo Fisher's common stock at a price of $181.75 per share in cash. TRC's offer price is approximately 4.43% lower than the $190.17 closing price of Thermo Fisher's common stock on November 17, 2017 , the last closing price prior to commencement of the offer. The offer is for approximately 0.249% of Thermo Fisher's outstanding shares of common stock as of the offer date. Thermo Fisher does not endorse TRC's unsolicited mini-tender offer and recommends that shareholders not tender their shares because the offer is at a price below the current market price of Thermo Fisher's shares and is subject to numerous conditions. Thermo Fisher is not affiliated or associated in any way with TRC, its mini-tender offer or the mini-tender offer documentation. TRC has made",
                "1d_change": 0.7263123716,
                "index_price": 0.3045788352,
                "norm_price": 0.4217335364
            },
            {
                "index": 217,
                "date": "2017-11-09",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2017-11-9/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 15, 2018 , to shareholders of record as of December 15, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more",
                "1d_change": -3.8887335511,
                "index_price": -0.0658308926,
                "norm_price": -3.8229026585
            },
            {
                "index": 218,
                "date": "2017-10-30",
                "press_title": "Thermo Fisher Scientific to Present at the Baird 2017 Global Industrial Conference on November 7, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Present-at-the-Baird-2017-Global-Industrial-Conference-on-November-7-2017-2017-10-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Baird 2017 Global Industrial Conference on Tuesday, November 7, 2017 , at 1:30 p.m. (CST) at the Four Seasons Hotel , Chicago, Ill. You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen,",
                "1d_change": 1.0937619603,
                "index_price": -0.0966888868,
                "norm_price": 1.190450847
            },
            {
                "index": 219,
                "date": "2017-10-25",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2017 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Reports-Third-Quarter-2017-Results-2017-10-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 30, 2017 . Third Quarter 2017 Highlights Reported revenue of $5.1 billion . Reported GAAP diluted earnings per share (EPS) of $1.34 . Reported adjusted EPS of $2.31 . Launched four new electron microscopy systems for structural biology and materials science research, released the new iQ Series air-quality monitoring platform, and enabled the first FDA -approved gene therapy, which uses our proprietary magnetic bead technology. Opened Precision Medicine Customer Experience Center in Guangzhou, China , to showcase our range of technologies and services for advancing personalized healthcare. Completed acquisition of Patheon, adding leading contract development and manufacturing outsourcing services to significantly enhance our value proposition for biopharma customers. Adjusted EPS, adjusted operating income, adjusted operating",
                "1d_change": 0.9931222882,
                "index_price": -0.2390297384,
                "norm_price": 1.2321520266
            },
            {
                "index": 220,
                "date": "2017-10-06",
                "press_title": "Winners of 2017 Nobel Prize in Chemistry Helped Spark \"New Era\" in Biochemistry",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Winners-of-2017-Nobel-Prize-in-Chemistry-Helped-Spark-New-Era-in-Biochemistry-2017-10-6/default.aspx",
                "content": "Cryo-electron microscopes are used to \"see the molecules inside the cell and how they interact\"  The 2017 Nobel Prize in Chemistry recognizes the pioneering work of three scientists, Jacques Dubochet, Joachim Frank and Richard Henderson , whose breakthrough developments in cryo-electron microscopy (cryo-EM) have helped to broaden the use of this technology within the structural biology community. The winners worked with systems manufactured by Thermo Fisher Scientific . Scientists can now routinely produce highly resolved, three-dimensional images of protein structures that lead to a better understanding of biological function and, ultimately, the development of new therapies. According to the Nobel committee's announcement , cryo-EM has moved biochemistry into \"a new era\" where it's \"now facing an explosive development and is all set for an exciting future.\" The work of the three winners spans decades, and their individual contributions helped spark follow-on efforts",
                "1d_change": -0.0620851749,
                "index_price": -0.1064930644,
                "norm_price": 0.0444078896
            },
            {
                "index": 221,
                "date": "2017-09-28",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 25, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-25-2017-2017-9-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter before the market opens on Wednesday, October 25, 2017 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its third quarter financial performance, as well as future expectations.  To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S.  You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, November 3, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately",
                "1d_change": 0.7452194705,
                "index_price": 0.63310502,
                "norm_price": 0.1121144505
            },
            {
                "index": 222,
                "date": "2017-09-13",
                "press_title": "Thermo Fisher Scientific Completes Subsequent Offering Period of Tender Offer Following Acquisition of Patheon N.V.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Completes-Subsequent-Offering-Period-of-Tender-Offer-Following-Acquisition-of-Patheon-N.V-2017-9-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. The company completed the acquisition of Patheon on August 29, 2017 . The subsequent offering period expired at 12:01 a.m. , New York City time, on September 13, 2017 . Based on information provided by American Stock Transfer  Trust Company, LLC , the depositary for the tender offer, a total of 143,781,162 Patheon ordinary shares (including Patheon ordinary shares tendered during the initial offering period), representing approximately 99% of the outstanding Patheon ordinary shares, had been validly tendered as of 12:01 a.m. , New York City time, on September 13, 2017. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., immediately accepted for payment and has promptly paid (or will promptly",
                "1d_change": -0.9433340116,
                "index_price": 0.0693304481,
                "norm_price": -1.0126644597
            },
            {
                "index": 223,
                "date": "2017-09-05",
                "press_title": "Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 11, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference-on-September-11-2017-2017-9-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2017 , at 1:05 p.m. (EDT) at the Grand Hyatt New York, New York . You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen,",
                "1d_change": 1.8689974289,
                "index_price": -0.1950914817,
                "norm_price": 2.0640889106
            },
            {
                "index": 224,
                "date": "2017-08-29",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Patheon",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Completes-Acquisition-of-Patheon-2017-8-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion . Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. \"We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders,\" said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . \"By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the",
                "1d_change": 2.8751213879,
                "index_price": 1.0437113419,
                "norm_price": 1.831410046
            },
            {
                "index": 225,
                "date": "2017-08-23",
                "press_title": "Thermo Fisher Scientific Announces Receipt of All Required Regulatory Approvals for Proposed Acquisition of Patheon",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Announces-Receipt-of-All-Required-Regulatory-Approvals-for-Proposed-Acquisition-of-Patheon-2017-8-23/default.aspx",
                "content": "Tender Offer Scheduled to Expire at 5:00 p.m., New York City Time, on August 28, 2017   Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that all required antitrust clearances have been obtained for the previously announced all-cash tender offer by its wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., to purchase all of the outstanding ordinary shares of Patheon N.V. (NYSE: PTHN). Competition authorities in Brazil approved the transaction on August 7, 2017 , initiating a 15 calendar-day comment period, which expired on August 22, 2017 . Additionally, the European Commission approved the transaction today. As a result of the antitrust approvals, Thermo Fisher expects to complete the tender offer promptly following the expiration of the offer, which is scheduled to expire at 5:00 p.m. , New York City time, on August 28 , 2017.  Completion of the tender offer is subject to the satisfaction of conditions described in the",
                "1d_change": -0.1989001646,
                "index_price": -0.2423118029,
                "norm_price": 0.0434116383
            },
            {
                "index": 226,
                "date": "2017-08-10",
                "press_title": "Thermo Fisher Scientific Prices Offering of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Prices-Offering-of-Senior-Notes-2017-8-10/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has priced an offering of $1.5 billion aggregate principal amount of the following notes: $750 million aggregate principal amount of its 3.200% senior notes due 2027, at an issue price of 99.263% of their principal amount and $750 million aggregate principal amount of its 4.100% senior notes due 2047, at an issue price of 98.825% of their principal amount. The issuance of the notes is expected to close on August 14, 2017 , subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use all of the net proceeds of the offering to fund a portion of the consideration payable for its acquisition of Patheon N.V. (NYSE: PTHN), including the repayment of indebtedness of Patheon N.V. to be assumed by Thermo Fisher. As previously announced, Thermo Fisher now expects to complete the transaction around the end of the third quarter of 2017, subject to the satisfaction of",
                "1d_change": 0.7504401864,
                "index_price": -0.985524789,
                "norm_price": 1.7359649754
            },
            {
                "index": 227,
                "date": "2017-08-08",
                "press_title": "Thermo Fisher Scientific Prices Offering of Common Stock",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Prices-Offering-of-Common-Stock-2017-8-8/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has priced its underwritten public offering of 8,771,930 shares of common stock at a price of $171.00 per share for expected gross proceeds of approximately $1.5 billion , before the underwriting discount and expenses. Thermo Fisher has also granted the underwriters a 30-day option to purchase up to an additional 1,315,789 shares of its common stock. The issuance of the shares is expected to close on August 11, 2017 , subject to customary closing conditions. Thermo Fisher intends to use all of the net proceeds of the offering to fund a portion of the consideration payable for its acquisition of Patheon N.V. (NYSE: PTHN), including the repayment of indebtedness of Patheon N.V. to be assumed by Thermo Fisher. As previously announced, Thermo Fisher now expects to complete the transaction around the end of the third quarter of 2017, subject to the satisfaction of customary closing conditions, including the receipt of",
                "1d_change": -1.8757961875,
                "index_price": -0.1750219518,
                "norm_price": -1.7007742357
            },
            {
                "index": 228,
                "date": "2017-08-07",
                "press_title": "Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Announces-1.5-Billion-Offering-of-Common-Stock-2017-8-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has commenced an underwritten public offering of $1.5 billion of its common stock. Thermo Fisher also intends to grant the underwriters an option for a period of 30 days to purchase up to $225.0 million of additional shares of its common stock. All of the shares in the offering are to be sold by Thermo Fisher. Thermo Fisher intends to use all of the net proceeds of the offering to fund a portion of the consideration payable for its acquisition of Patheon N.V. (NYSE: PTHN), including the repayment of indebtedness of Patheon N.V. to be assumed by Thermo Fisher. As announced in a separate press release issued today, Thermo Fisher now expects to complete the transaction around the end of the third quarter of 2017, subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals and completion of Thermo Fisher's tender offer to acquire all of the issued and outstanding",
                "1d_change": -1.3563858494,
                "index_price": -0.0896986882,
                "norm_price": -1.2666871613
            },
            {
                "index": 229,
                "date": "2017-08-07",
                "press_title": "Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer Timing with Two Remaining Regulatory Approvals",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Extends-Cash-Tender-Offer-for-All-Outstanding-Shares-of-Patheon-to-Coordinate-Offer-Timing-with-Two-Remaining-Regulatory-Approvals-2017-8-7/default.aspx",
                "content": "Offer Now Scheduled to Expire at 5:00 p.m., New York City Time, on August 28, 2017   Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that its wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has extended the offering period of its previously announced all-cash tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. (NYSE: PTHN). The tender offer is being extended to coordinate with the timing of the two remaining regulatory approvals in the European Union and Brazil . The company's anti-trust filing was submitted to the European Union on July 19, 2017 , initiating the 25 business-day review period (which is expected to expire August 25 ). In Brazil , competition authorities approved the transaction today, initiating a 15 calendar-day comment period (which is expected to expire August 22 ). Thermo Fisher previously received clearances from regulatory authorities in the U.S. and Canada . Based on",
                "1d_change": -1.3563858494,
                "index_price": -0.0896986882,
                "norm_price": -1.2666871613
            },
            {
                "index": 230,
                "date": "2017-07-31",
                "press_title": "Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Advances-Innovation-for-the-Clinic-at-AACC-2017-2017-7-31/default.aspx",
                "content": "AACC  - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest advancements in clinical and research-based solutions during the 2017 American Association of Clinical Chemistry ( AACC) Annual Scientific Meeting  Clinical Lab Expo , being held July 31 – August 3 at the San Diego Convention Center. Among the products displayed within booth #4039 is a preview of the new Thermo Scientific Cascadion SM Clinical Analyzer , (in development and not available for sale), the world's first fully integrated laboratory analyzer that combines the ease of use of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology.* \"Advances in clinical diagnostics have the potential to improve healthcare by expanding the use of highly sensitive analytical tools that provide valuable patient information faster and more accurately,\" said Marc N. Casper ,",
                "1d_change": -0.6496562674,
                "index_price": 0.0165629347,
                "norm_price": -0.6662192021
            },
            {
                "index": 231,
                "date": "2017-07-26",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2017 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Reports-Second-Quarter-2017-Results-2017-7-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2017 . Second Quarter 2017 Highlights Reported revenue of $4.99 billion . Reported GAAP diluted earnings per share (EPS) of $1.56 . Reported adjusted EPS of $2.30 . Strengthened innovation leadership, highlighted by a new Q Exactive Orbitrap mass spectrometer to advance protein research, the new SeqStudio Genetic Analyzer for a range of sequencing applications, and FDA clearance of our B.R.A.H.M.S. PCT assay to support antibiotic stewardship. Made significant progress in precision medicine initiatives, including receiving FDA pre-market approval for our Oncomine Dx Target Test – the first next-generation sequencing-based companion diagnostic for non-small cell lung cancer. Opened Center of Excellence for electron microscopy in Saudi Arabia to enable scientific collaboration in the region and continue to increase our presence in",
                "1d_change": 0.0570613622,
                "index_price": -0.1838091706,
                "norm_price": 0.2408705328
            },
            {
                "index": 232,
                "date": "2017-07-18",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2017-7-18/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") announced today that it has priced an offering of €2.6 billion aggregate principal amount of the following notes: €500 million aggregate principal amount of its floating rate senior notes due 2019, at the issue price of 100.205% of their principal amount €700 million aggregate principal amount of its 1.400% senior notes due 2026, at the issue price of 99.526% of their principal amount €700 million aggregate principal amount of its 1.950% senior notes due 2029 (the\"2029 notes\"), at the issue price of 99.282% of their principal amount €700 million aggregate principal amount of its 2.875% senior notes due 2037 (the \"2037 notes\") at the issue price of 99.760% of their principal amount. The issuance of the notes is expected to close on or about July 24, 2017 , subject to customary closing conditions. The floating rate notes will pay interest on a quarterly basis, and the fixed rate notes will pay interest on an annual",
                "1d_change": -0.2498069402,
                "index_price": 0.7256034063,
                "norm_price": -0.9754103464
            },
            {
                "index": 233,
                "date": "2017-07-12",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2017-7-12/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on October 16, 2017 , to shareholders of record as of September 15, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit",
                "1d_change": 0.4554578234,
                "index_price": 0.4935014989,
                "norm_price": -0.0380436755
            },
            {
                "index": 234,
                "date": "2017-07-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 26, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-July-26-2017-2017-7-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter before the market opens on Wednesday, July 26, 2017 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its second quarter financial performance, as well as future expectations.  To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the \"Investors\" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under \"Financial Results.\" A replay of the call will be available under \"Webcasts and Presentations\" through Friday, August 7, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000",
                "1d_change": -0.1656812591,
                "index_price": -0.8980140088,
                "norm_price": 0.7323327497
            },
            {
                "index": 235,
                "date": "2017-06-05",
                "press_title": "Thermo Fisher Scientific Raises the Bar in Mass Spectrometry Innovation at ASMS 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Raises-the-Bar-in-Mass-Spectrometry-Innovation-at-ASMS-2017-2017-6-5/default.aspx",
                "content": "ASMS 2017 –  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, strengthened its leadership in mass spectrometry by launching new technologies to advance cutting-edge research and improve results in applied markets during the 65 th Annual American Society for Mass Spectrometry (ASMS) Conference . Visitors can learn about the company's latest technologies in Booth 601 at the Indiana Convention Center from June 4-8 or the White River Ballroom F-J at the JW Marriott , Indianapolis . \"Thermo Fisher has been the undisputed leader in mass spectrometry for more than 50 years, and this year is no exception,\" said Dan Shine , senior vice president and president, analytical instruments. \"During ASMS, customers will learn how our new innovations in mass spectrometry are advancing biological research, translational medicine, and food and environmental analysis.\" Accelerating Proteomics Research The new Thermo Scientific Q Exactive HF-X Quadrupole Orbitrap",
                "1d_change": -0.1079149591,
                "index_price": -0.3498906994,
                "norm_price": 0.2419757403
            },
            {
                "index": 236,
                "date": "2017-05-18",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2017-5-18/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 17, 2017 , to shareholders of record as of June 15, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com .",
                "1d_change": 0.2915115518,
                "index_price": 1.1353108574,
                "norm_price": -0.8437993056
            },
            {
                "index": 237,
                "date": "2017-05-15",
                "press_title": "Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organization (CDMO)",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Acquire-Patheon-a-Leading-Contract-Development-and-Manufacturing-Organization-CDMO-2017-5-15/default.aspx",
                "content": "- Patheon Provides Entry into the Attractive, High-growth CDMO Market - Combination Significantly Strengthens Thermo Fisher's Unique Value Proposition for Pharmaceutical and Biotech Customers by Adding Highly Complementary Services - Creates Substantial Synergies and Positions Combined Company to Further Accelerate Growth - Expected to be Immediately and Significantly Accretive to Adjusted Earnings Per Share (EPS)   Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon . Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transaction represents a purchase price of approximately $7.2 billion , which includes the",
                "1d_change": 0.4469787769,
                "index_price": 0.2786697724,
                "norm_price": 0.1683090046
            },
            {
                "index": 238,
                "date": "2017-05-05",
                "press_title": "Thermo Fisher Scientific to Host Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Host-Analyst-Meeting-2017-5-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2017 Analyst Meeting on Wednesday, May 17 , starting at 9:00 a.m. (ET) , at the Mandarin Oriental New York, 80 Columbus Circle at 60 th Street, in New York City . The meeting will feature presentations by members of Thermo Fisher Scientific's senior management team, including expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . An audio archive of the webcast will be available through Friday, June 16, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex",
                "1d_change": 0.1819637108,
                "index_price": 0.2921490538,
                "norm_price": -0.110185343
            },
            {
                "index": 239,
                "date": "2017-04-26",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2017 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Reports-First-Quarter-2017-Results-2017-4-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2017 . First Quarter 2017 Highlights Reported revenue of $4.77 billion .  Reported GAAP diluted earnings per share (EPS) of $1.40 . Reported adjusted EPS of $2.08 .  Launched innovative new products across our technology portfolio, including the iCAP triple-quadrupole mass spectrometry system, the first cloud-connected electronic pipette and the microarray-based CarrierScan Assay for the detection of inherited diseases.  Achieved strong growth in Asia-Pacific markets, particularly China , India and South Korea . Opened new customer demonstration center for electron microscopy in partnership with Tsinghua University in Beijing to advance structural biology applications.    Completed two strategic bolt-on acquisitions – Finesse Solutions, which adds measurement and control",
                "1d_change": 2.7414260811,
                "index_price": -0.0087894999,
                "norm_price": 2.750215581
            },
            {
                "index": 240,
                "date": "2017-04-19",
                "press_title": "Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Multi-Center-Clinical-Study-Confirms-Decreased-Levels-of-Procalcitonin-as-an-Independent-Predictor-of-Mortality-in-Patients-with-Severe-Sepsis-and-Septic-Shock-2017-4-19/default.aspx",
                "content": "WALTHAM, Mass. , April 19, 2017 /PRNewswire/ - Thermo Fisher Scientific Inc . today announced that results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been published in the May 2017 print issue of Critical Care Medicine . Researchers from the study, titled \"Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study,\" investigated the use of the B·R·A·H·M·S PCT (procalcitonin) assay to assess risk for 28 day all-cause mortality for patients diagnosed with severe sepsis or septic shock in 13 U.S. investigational sites. Results from the multi-center study showed that patients with a decrease in PCT less than or equal to 80 percent during the first four days following diagnosis of severe sepsis or septic shock had a two-fold increased risk of death as compared to those who experienced a decrease in PCT greater than 80 percent 1 . The study also found that a baseline PCT",
                "1d_change": 0.8946914783,
                "index_price": 0.3841537834,
                "norm_price": 0.5105376949
            },
            {
                "index": 241,
                "date": "2017-04-18",
                "press_title": "New X-ray Machine Handles Heavy Products in Washdown Environments",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/New-X-ray-Machine-Handles-Heavy-Products-in-Washdown-Environments-2017-4-18/default.aspx",
                "content": "Thermo Scientific NextGuard Pro enables inspection/detection of up to 50 kg/110 lbs in IP65 plants  A new X-ray machine from Thermo Fisher Scientific engineered to handle heavy product weights of up to 50 kilograms/110 pounds in IP65 washdown environments will make its debut at Interpack 2017 , May 4-10 in Düsseldorf, Germany , Messe Dusseldorf, Hall 8a, Stand C77. The Thermo Scientific NextGuard Pro X-ray inspection system—the latest model in the Thermo Scientific NextGuard X-ray inspection platform—features an extended, rugged, washdown conveyor that is capable of handling multiple large packages while also incorporating a complete rejection system. \"The NextGuard Pro is cost-effective and ideal for processors with larger, heavier products such as bagged rice or dog food, blocks of cheese, larger boxes and other dense products that are too heavy for a typical conveyor to accommodate. In addition, those looking for a complete food safety system on one frame will prefer the new",
                "1d_change": 0.919347654,
                "index_price": -0.1864752164,
                "norm_price": 1.1058228704
            },
            {
                "index": 242,
                "date": "2017-04-18",
                "press_title": "Thermo Fisher Scientific Establishes Institute of Pathology at University Hospital Basel as Center of Excellence Partner",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Establishes-Institute-of-Pathology-at-University-Hospital-Basel-as-Center-of-Excellence-Partner-2017-4-18/default.aspx",
                "content": "CARLSBAD, Calif. , April 18, 2017 /PRNewswire/ - Thermo Fisher Scientific has signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland , to establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program, a new initiative designed to develop and refine Thermo Fisher's NGS-based research assays from its Oncomine™ oncology portfolio with the intent to eventually introduce them into the clinic as companion diagnostics. As part of the agreement, both organizations will work together to form global alliances and strategic partnerships with biopharma groups and others in an effort to accelerate oncology and immune-oncology trials. Additionally, the Institute of Medical Genetics and Pathology , managed by Markus Tolnay , MD, will serve as one of the NGS Companion Dx Center of Excellence Program's global sites focused on conducting research and validation of Thermo",
                "1d_change": 0.919347654,
                "index_price": -0.1864752164,
                "norm_price": 1.1058228704
            },
            {
                "index": 243,
                "date": "2017-03-31",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 26, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-April-26-2017-2017-3-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter before the market opens on Wednesday, April 26, 2017 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its first quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, May 12, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees",
                "1d_change": 0.76980599,
                "index_price": -0.2535136019,
                "norm_price": 1.0233195918
            },
            {
                "index": 244,
                "date": "2017-03-07",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2017-3-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €500 million aggregate principal amount of 1.450% senior notes due 2027 at an issue price of 98.824% of the principal amount. The issuance of the notes is expected to close on or about March 16, 2017 , subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher intends to use approximately $508 million of the net proceeds of the offering to redeem all of the outstanding $500 million aggregate principal amount of its 1.850% senior notes that mature on January 15, 2018 and to pay accrued interest, fees and expenses associated with the redemption. Thermo Fisher intends to use any remaining net proceeds for general corporate purposes. The joint book-running managers for the offering are Credit Suisse Securities (Europe) Limited and HSBC Bank plc . The offering is being made pursuant to an effective registration statement on Form S-3, as amended by the",
                "1d_change": 0.323804057,
                "index_price": -0.3283993021,
                "norm_price": 0.6522033591
            },
            {
                "index": 245,
                "date": "2017-03-07",
                "press_title": "Thermo Fisher Scientific to Present at the Barclays Global Healthcare Conference on March 14, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Present-at-the-Barclays-Global-Healthcare-Conference-on-March-14-2017-2017-3-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 , at 10:15 a.m. (EDT) at the Loews Miami Hotel , Miami, Fla. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an",
                "1d_change": 0.323804057,
                "index_price": -0.3283993021,
                "norm_price": 0.6522033591
            },
            {
                "index": 246,
                "date": "2017-03-06",
                "press_title": "Thermo Fisher Scientific Showcases Integrated Analytical Workflows During Pittcon 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Showcases-Integrated-Analytical-Workflows-During-Pittcon-2017-2017-3-6/default.aspx",
                "content": "New technologies anchor application-specific workflows for life sciences and applied markets Pittcon 2017 - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a line-up of new products at the 2017 Pittcon Conference and Exhibition that enable application-specific workflows for pharma/biopharma, materials science, and environmental and food safety markets. The company’s leading portfolio of integrated instruments, consumables, software and services is featured in booth 3021 in the West Hall of McCormick Place in Chicago , March 5-9, 2017 . “Customers want application-specific workflows anchored by analytical instruments that are easy to use, yet powerful,” said Dan Shine , senior vice president, analytical instruments, Thermo Fisher Scientific . “We’re excited to introduce advanced instruments and tailored workflows that help more technicians and individuals across an enterprise quickly, and confidently, turn samples into knowledge.”",
                "1d_change": -0.9220142041,
                "index_price": -0.2888075106,
                "norm_price": -0.6332066934
            },
            {
                "index": 247,
                "date": "2017-03-01",
                "press_title": "Thermo Fisher Scientific Elects New Director to Board",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Elects-New-Director-to-Board-2017-3-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Dion Weisler to its board of directors, effective today. Mr. Weisler’s appointment brings the total number of Thermo Fisher board members to 12. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170301005757/en/ Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Dion Weisler to its board of directors, effective March 1, 2017 . (Photo: Business Wire) Mr. Weisler has been president and chief executive officer of HP Inc. since November 2015 , following the separation of Hewlett-Packard into two independent companies. He also serves on the HP board of directors. Prior to that, Mr. Weisler was executive vice president of Hewlett-Packard’s Printing and Personal Systems Business for four years. During his more than 25 years of experience in the information",
                "1d_change": -0.1696345813,
                "index_price": 0.0751511017,
                "norm_price": -0.244785683
            },
            {
                "index": 248,
                "date": "2017-02-28",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2017-2-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 17, 2017 , to shareholders of record as of March 15, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com .",
                "1d_change": 1.0136677838,
                "index_price": 1.2470944131,
                "norm_price": -0.2334266293
            },
            {
                "index": 249,
                "date": "2017-02-14",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Completes-Acquisition-of-Finesse-Solutions-Inc-2017-2-14/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today completed its previously announced acquisition of Finesse Solutions, Inc. , a leader in the development of scalable control automation systems and software for bioproduction. The business will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. Terms of the transaction were not disclosed. Based in Santa Clara, California , Finesse Solutions is a leader in bioprocess management technology, generating approximately $50 million in revenue in 2016. Its proprietary Smart™ technology, which consists of sensors, controllers and software, is designed to optimize the bioproduction workflow. The company has been a technology partner of Thermo Fisher Scientific since 2013. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to",
                "1d_change": 1.4659385267,
                "index_price": 0.9845645552,
                "norm_price": 0.4813739715
            },
            {
                "index": 250,
                "date": "2017-02-13",
                "press_title": "Thermo Fisher Scientific Receives Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Finesse Solutions, Inc.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Receives-Early-Termination-of-Hart-Scott-Rodino-Waiting-Period-for-Acquisition-of-Finesse-Solutions-Inc-2017-2-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its pending acquisition of Finesse Solutions, Inc. , a leader in the development of scalable control automation systems and software for bioproduction, has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Thermo Fisher expects to complete the acquisition in the coming days. Based in Santa Clara, California , Finesse Solutions is a leader in bioprocess management technology, generating approximately $50 million in revenue in 2016. Its proprietary Smart™ technology, which consists of sensors, controllers and software, is designed to optimize the bioproduction workflow. The business will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. Terms of the transaction were not disclosed. “Finesse Solutions has been a technology partner since 2013, and we are pleased to add their complementary",
                "1d_change": 1.4496840891,
                "index_price": 0.6784840259,
                "norm_price": 0.7712000633
            },
            {
                "index": 251,
                "date": "2017-01-31",
                "press_title": "Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2016-Results-2017-1-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2016 . Fourth Quarter and Full Year 2016 Highlights Fourth quarter revenue increased 6% to $4.95 billion . Full year revenue grew 8% to $18.27 billion . Fourth quarter GAAP diluted earnings per share (EPS) increased 6% to $1.59 . Fourth quarter adjusted EPS grew 14% to $2.41 . Full year GAAP diluted EPS increased 3% to $5.09 . Full year adjusted EPS grew 12% to $8.27 . Invested more than $750 million in RD in 2016, and launched significant new products, including Q Exactive BioPharma mass spectrometry and Integrion chromatography systems, TSX laboratory freezers, Ion Torrent cancer assays, and new tests for drugs-of-abuse and autoimmune disease. Strengthened capabilities in Shanghai , Seoul and Singapore during the year to build on industry-leading presence in Asia-Pacific and emerging markets and",
                "1d_change": 4.1127248628,
                "index_price": 0.2425930196,
                "norm_price": 3.8701318432
            },
            {
                "index": 252,
                "date": "2017-01-06",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Tuesday, January 31, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Tuesday-January-31-2017-2017-1-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2016 fourth quarter and full year before the market opens on Tuesday, January 31, 2017 , and will hold a conference call on the same day at 8:30 a.m. EST . During the call, the company will discuss its fourth quarter and full year financial performance, as well as future expectations, including initial 2017 financial guidance. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, February 17, 2017 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving",
                "1d_change": 1.4984299753,
                "index_price": -0.0987258289,
                "norm_price": 1.5971558041
            },
            {
                "index": 253,
                "date": "2017-01-03",
                "press_title": "Thermo Fisher Scientific to Present at 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2017/Thermo-Fisher-Scientific-to-Present-at-35th-Annual-J.P.-Morgan-Healthcare-Conference-on-January-10-2017-2017-1-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the 35 th Annual J. P. Morgan Healthcare Conference on Tuesday, January 10, 2017 , at 2:30 p.m. (PST) at the Westin St. Francis , San Francisco, Calif. You can access the live webcast of the presentations via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity",
                "1d_change": 1.9082178434,
                "index_price": 0.8446518393,
                "norm_price": 1.0635660041
            },
            {
                "index": 254,
                "date": "2016-11-10",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2016-11-10/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 16, 2017 , to shareholders of record as of December 15, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information,",
                "1d_change": -1.6859595444,
                "index_price": -0.1404531928,
                "norm_price": -1.5455063516
            },
            {
                "index": 255,
                "date": "2016-10-28",
                "press_title": "Thermo Fisher Scientific to Present at Baird’s 2016 Industrial Conference on November 8, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Present-at-Bairds-2016-Industrial-Conference-on-November-8-2016-2016-10-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Thomas W. Loewald , senior vice president and chief commercial officer, will present at Baird’s 2016 Industrial Conference on Tuesday, November 8, 2016 , at 11:00 a.m. (CST) at the Four Seasons Hotel , Chicago, Ill. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab",
                "1d_change": -1.6799068705,
                "index_price": -0.2859665783,
                "norm_price": -1.3939402922
            },
            {
                "index": 256,
                "date": "2016-10-27",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2016 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Reports-Third-Quarter-2016-Results-2016-10-27/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter of 2016, ended October 1, 2016 . Third Quarter 2016 Highlights Revenue increased 9% to $4.49 billion . GAAP diluted earnings per share (EPS) increased 1% to $1.19 . Adjusted EPS grew 13% to $2.03 . Strengthened presence in clinical markets by receiving FDA clearance to launch new DRI Hydrocodone assay and two new EliA IgG thyroid tests as well as extend use of BRAHMS PCT sepsis test to the emergency room. Increased capabilities to support biopharma growth in Asia-Pacific markets with new clinical packaging and supplies facility in Seoul, South Korea , and expansion of cryogenic storage and logistics operations in Tokyo, Japan . Completed acquisition of FEI Company , adding leading electron microscopy products that strengthen offerings for attractive structural biology and materials science markets, and significantly enhance our customer value",
                "1d_change": -3.2470617769,
                "index_price": -0.8300444041,
                "norm_price": -2.4170173727
            },
            {
                "index": 257,
                "date": "2016-10-20",
                "press_title": "Thermo Fisher Scientific Partners with Boys & Girls Clubs of America to Bring STEM Education to the Next Generation of Employees and Leaders",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Partners-with-Boys--Girls-Clubs-of-America-to-Bring-STEM-Education-to-the-Next-Generation-of-Employees-and-Leaders-2016-10-20/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will partner with Boys  Girls Clubs of America (BGCA) to extend science, technology, engineering and math (STEM) education to thousands of children and teens across the country. Thermo Fisher’s initial contribution and in-kind support is valued at $340,000 , with an additional investment over a three-year period after a successful pilot year. “Our philanthropic focus is to inspire the next generation of scientists and engineers by introducing them to STEM subjects in a way that is engaging and fun,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “Boys  Girls Clubs of America and Thermo Fisher share the same commitment to STEM. Together we will have a greater impact in making math and science education accessible so that young students gain the skills needed to compete in a global economy.” The U.S. Bureau of Labor Statistics reports",
                "1d_change": -0.763280345,
                "index_price": -0.063054499,
                "norm_price": -0.700225846
            },
            {
                "index": 258,
                "date": "2016-10-17",
                "press_title": "Thermo Fisher Scientific Joins Cancer Moonshot Effort",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Joins-Cancer-Moonshot-Effort-2016-10-17/default.aspx",
                "content": "Commitment to Vice President Biden’s initiative is part of larger precision medicine effort Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has joined the Cancer Moonshot, an initiative led by Vice President Joe Biden aimed at making more therapies available to more patients while also improving cancer detection at early stages and, ultimately, preventing the disease. Initially, Thermo Fisher will join a liquid biopsy-based precision oncology pilot, called the Blood Profiling Atlas designed to make it easier for oncologists to access databases of liquid biopsy information when diagnosing patients. “The Cancer Moonshot is an ambitious, all-hands initiative that requires the best minds and best technologies working collaboratively,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “As part of our broader focus on precision medicine, which includes investments to accelerate the development of more effective cancer",
                "1d_change": -0.1186377927,
                "index_price": 0.3108125902,
                "norm_price": -0.4294503829
            },
            {
                "index": 259,
                "date": "2016-10-03",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, October 27, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-October-27-2016-2016-10-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2016 before the market opens on Thursday, October 27, 2016 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its third quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, November 11, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000",
                "1d_change": -0.2411840183,
                "index_price": -0.6435783451,
                "norm_price": 0.4023943268
            },
            {
                "index": 260,
                "date": "2016-09-19",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of FEI Company",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Completes-Acquisition-of-FEI-Company-2016-9-19/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of FEI Company, Inc. (NASDAQ: FEIC), the leader in high-performance electron microscopy, for $107.50 per share in cash, or a total purchase price of approximately $4.2 billion . The completion of the transaction follows the receipt of all required regulatory approvals. The business will become part of Thermo Fisher’s Analytical Instruments Segment. “We are pleased to complete this transaction and officially welcome our new colleagues from FEI to Thermo Fisher,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “With FEI’s leading electron microscopy platform, we’re now in an even stronger position to help our life sciences customers accelerate advancements in structural biology. FEI’s products also create new opportunities for us to serve customers in materials science markets that increasingly rely on",
                "1d_change": 0.9497591336,
                "index_price": -0.1976848081,
                "norm_price": 1.1474439417
            },
            {
                "index": 261,
                "date": "2016-09-14",
                "press_title": "Thermo Fisher Scientific Prices Offering of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Prices-Offering-of-Senior-Notes-2016-9-14/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of $1.2 billion aggregate principal amount of its 2.950% senior notes due 2026 at the issue price of 98.787% of the principal amount. The issuance of the notes is expected to close on or about September 19, 2016 , subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use a portion of the net proceeds of the offering to redeem all of the outstanding $900 million aggregate principal amount of its 1.30% senior notes due 2017, which mature on February 1, 2017 . The company plans to use the remaining net proceeds for general corporate purposes. The joint book-running managers for the offering are J.P. Morgan Securities LLC , Citigroup Global Markets Inc. and Deutsche Bank Securities Inc. The offering is being made pursuant to an effective registration statement on Form S-3, as amended by the post-effective amendment thereto (including a",
                "1d_change": 3.3266223489,
                "index_price": 0.9034724372,
                "norm_price": 2.4231499117
            },
            {
                "index": 262,
                "date": "2016-09-07",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2016-9-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €1.0 billion aggregate principal amount of its 0.750% senior notes due 2024 and €600 million aggregate principal amount of its 1.375% senior notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively. The issuance of the notes is expected to close on or about September 12, 2016 , subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher intends to use the net proceeds of the offering to finance a portion of the estimated $4.2 billion purchase price for its acquisition of FEI Company and to pay certain associated costs. The FEI acquisition is expected to close by December 31, 2016 , subject to the satisfaction of customary closing conditions, including applicable regulatory approvals. The joint book-running managers for the offering are J.P. Morgan Securities plc , Barclays Bank PLC, Mizuho",
                "1d_change": 0.0132864991,
                "index_price": -0.1774113125,
                "norm_price": 0.1906978116
            },
            {
                "index": 263,
                "date": "2016-09-06",
                "press_title": "Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 14, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference-on-September-14-2016-2016-9-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 , at 8:10 a.m. (EDT) at the Grand Hyatt New York, New York . You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab",
                "1d_change": -0.4983475012,
                "index_price": 0.2081185673,
                "norm_price": -0.7064660685
            },
            {
                "index": 264,
                "date": "2016-08-01",
                "press_title": "Thermo Fisher Scientific Expands Offering for Clinical Applications at AACC 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Expands-Offering-for-Clinical-Applications-at-AACC-2016-2016-8-1/default.aspx",
                "content": "New products and applications designed to accelerate innovation and increase productivity in research and clinical settings AACC 2016 – Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, will exhibit its expanded offering of new assays, instruments and software at the 2016 American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo being held July 31 - August 4 at the Pennsylvania Convention Center . Designed specifically for customers working in research and clinical settings, these innovative new products will be on display in booths #2334 and #2145. “Today’s healthcare and clinical service providers are on the front line of a rapidly changing diagnostic landscape,” said Marc. N Casper, president and chief executive officer of Thermo Fisher Scientific . “Our commitment to innovation in specialty diagnostics enables these customers to meet the growing demand for more rapid, sensitive and cost-effective tests that lead to better",
                "1d_change": -1.476630708,
                "index_price": -0.7473179709,
                "norm_price": -0.7293127371
            },
            {
                "index": 265,
                "date": "2016-07-28",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2016 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Reports-Second-Quarter-2016-Results-2016-7-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter of 2016, ended July 2, 2016 . Second Quarter 2016 Highlights Revenue increased 6% to $4.54 billion . GAAP diluted earnings per share (EPS) increased 2% to $1.30 . Adjusted EPS grew 10% to $2.03 . Strengthened leadership in analytical instruments by launching a suite of software and Cloud-based solutions for research and applied markets, and introducing new products to accelerate drug discovery, including our flagship Q Exactive BioPharma mass spectrometer. Delivered strong performance in emerging markets, led by China , South Korea and India . Announced agreement to acquire FEI Company for $4.2 billion , adding leading electron microscopy technologies to significantly increase capabilities for structural biology applications and create new growth opportunities in attractive materials science markets. Adjusted EPS, adjusted operating income,",
                "1d_change": 1.05765982,
                "index_price": 0.3473522492,
                "norm_price": 0.7103075708
            },
            {
                "index": 266,
                "date": "2016-07-07",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $1.5 Billion of Share Repurchases",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-and-Authorizes-1.5-Billion-of-Share-Repurchases-2016-7-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on October 17, 2016 , to shareholders of record as of September 15, 2016 . The board also authorized the repurchase of $1.5 billion of shares of the company’s common stock in the open market or in negotiated transactions. The new repurchase authorization has no expiration date. The company’s previous repurchase authorization was completed in the first quarter of 2016. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory",
                "1d_change": 2.5214117145,
                "index_price": 1.3841016865,
                "norm_price": 1.137310028
            },
            {
                "index": 267,
                "date": "2016-07-05",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-July-28-2016-2016-7-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2016 before the market opens on Thursday, July 28, 2016 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its second quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, August 26, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000",
                "1d_change": 0.6102785152,
                "index_price": 0.222882546,
                "norm_price": 0.3873959692
            },
            {
                "index": 268,
                "date": "2016-06-13",
                "press_title": "Thermo Fisher Scientific and West China Hospital Partner on Joint Research Platform for Precision Medicine",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-and-West-China-Hospital-Partner-on-Joint-Research-Platform-for-Precision-Medicine-2016-6-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a partnership with West China Hospital of Sichuan University , one of the largest single-site hospitals in the world, to develop a joint platform to research precision medicine. The partners shared the news during the seventh round of the China-U.S. High-Level Consultation on People-to-People Exchange (CPE) held in Beijing on June 6-7 . \"Our company mission – to enable our customers to make the world healthier, cleaner and safer – is perfectly aligned with the priorities in China's 5-year plan,\" said Marc N. Casper , president and chief executive officer of Thermo Fisher. \"We share a commitment to advancing precision medicine, and we're excited about strengthening our collaboration with West China Hospital to provide technologies and expertise that will ultimately improve patient care.\" “We are exploring opportunities to collaborate with renowned, industry-leading international companies to",
                "1d_change": -2.3787286245,
                "index_price": -0.7916818177,
                "norm_price": -1.5870468068
            },
            {
                "index": 269,
                "date": "2016-06-06",
                "press_title": "Thermo Fisher Scientific Strengthens Life Sciences Leadership with New Instruments Launched at ASMS 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Strengthens-Life-Sciences-Leadership-with-New-Instruments-Launched-at-ASMS-2016-2016-6-6/default.aspx",
                "content": "Thermo Fisher Scientific Inc. , (NYSE: TMO), the world leader in serving science, strengthened its industry-leading analytical instruments platform with innovative systems designed to help pharmaceutical and biologics producers more efficiently discover and develop candidate drugs. These new products will be on display at the 64 th Annual American Society for Mass Spectrometry (ASMS) Conference , June 5-9 in Texas Ballroom D at the Grand Hyatt Hotel . “The success of our innovation strategy is based on continuous collaboration with our customers,” said Marc N. Casper , president and chief executive officer Thermo Fisher Scientific . “Our mission is to enable our customers to make the world healthier, cleaner and safer, and we are committed to providing them with the most advanced analytical technologies to help them facilitate research and accelerate discovery. This year’s ASMS showing is another great example of how we continue to leverage our technology leadership to raise the",
                "1d_change": -0.0720377857,
                "index_price": 0.5349957301,
                "norm_price": -0.6070335158
            },
            {
                "index": 270,
                "date": "2016-05-27",
                "press_title": "Thermo Fisher Scientific to Acquire FEI Company",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Acquire-FEI-Company-2016-5-27/default.aspx",
                "content": "Leading Electron Microscopy Platform Complements Mass Spectrometry Leadership to Accelerate Advancements in Structural Biology Creates New Opportunities to Expand Presence in Attractive Materials Science Market Proprietary, Global Services Business Generates High-Margin, Recurring Revenue Stream Delivers Attractive Financial Benefits; Expected to be Immediately Accretive to Adjusted Earnings Per Share (EPS) Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and FEI Company (NASDAQ:FEIC), the leader in high-performance electron microscopy, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of FEI for $107.50 per share in cash. The transaction represents a purchase price of approximately $4.2 billion . FEI designs, manufactures and supports high-performance electron microscopy workflows that provide images and information at micro-, nano- and picometer scales. Through its industry-leading offering, FEI enables",
                "1d_change": 0.164720157,
                "index_price": 0.3285673353,
                "norm_price": -0.1638471783
            },
            {
                "index": 271,
                "date": "2016-05-18",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2016-5-18/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 15, 2016 , to shareholders of record as of June 15, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit",
                "1d_change": -0.006743463,
                "index_price": -0.2127392471,
                "norm_price": 0.2059957841
            },
            {
                "index": 272,
                "date": "2016-05-10",
                "press_title": "Thermo Fisher Scientific Reports Progress on Global Corporate Social Responsibility",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Reports-Progress-on-Global-Corporate-Social-Responsibility-2016-5-10/default.aspx",
                "content": "Thermo Fisher Scientific , (NYSE: TMO), the world leader in serving science, today released its 2015 Corporate Social Responsibility (CSR) Report. The report highlights progress in the areas of business sustainability, employee involvement and philanthropic giving. “Everything we do starts with our mission: to enable our customers to make the world healthier, cleaner and safer,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “Our CSR strategy enables employees worldwide to fulfill this mission by getting involved at work and in our communities. We are proud of our progress over the last year and we’re committed to doing more.” Business Sustainability Thermo Fisher’s PPI Business System (practical process improvement) empowers every employee to drive profitable growth by continuously improving quality, productivity and customer allegiance. In 2015, the PPI Business System delivered significant results including a reduction in hazardous solvent",
                "1d_change": -0.2635546584,
                "index_price": 0.0886468209,
                "norm_price": -0.3522014793
            },
            {
                "index": 273,
                "date": "2016-05-04",
                "press_title": "Thermo Fisher Scientific to Host Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Host-Analyst-Meeting-2016-5-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2016 Analyst Meeting on Wednesday, May 18 , starting at 9:00 a.m. (EDT) , at the Mandarin Oriental New York , 80 Columbus Circle at 60 th Street, in New York City . The meeting will feature presentations by members of Thermo Fisher Scientific’s senior management team, including expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . An audio archive of the webcast will be available through Friday, June 24, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve",
                "1d_change": 1.3159856203,
                "index_price": -0.4715705207,
                "norm_price": 1.787556141
            },
            {
                "index": 274,
                "date": "2016-05-02",
                "press_title": "Thermo Fisher Scientific to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Present-at-the-Bank-of-America-Merrill-Lynch-2016-Health-Care-Conference-on-May-10-2016-2016-5-2/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 , at 10:40 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific",
                "1d_change": -0.0966720791,
                "index_price": -0.184155264,
                "norm_price": 0.0874831849
            },
            {
                "index": 275,
                "date": "2016-04-28",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2016 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Reports-First-Quarter-2016-Results-2016-4-28/default.aspx",
                "content": "Raises Full-year 2016 Guidance Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter of 2016, ended April 2, 2016 . First Quarter 2016 Highlights Reported adjusted earnings per share (EPS) of $1.80 and GAAP diluted EPS of $1.01 . Reported record revenue of $4.29 billion . Strengthened our Thermo Scientific analytical instrument offering for applied markets with new product launches at Pittcon, highlighted by the Integrion high-pressure ion chromatography system (HPIC) for environmental, food safety and industrial markets. Delivered strong performance in emerging markets, led by double-digit growth in China and India . Completed $1.3 billion acquisition of Affymetrix, enhancing our customer value proposition by strengthening our leadership in biosciences and expanding our opportunities in genetic analysis. Deployed $1 billion of capital on share buybacks in the quarter. Adjusted EPS, adjusted operating",
                "1d_change": -2.0519413078,
                "index_price": -1.2409762362,
                "norm_price": -0.8109650715
            },
            {
                "index": 276,
                "date": "2016-04-04",
                "press_title": "Thermo Fisher Scientific Prices Offering of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Prices-Offering-of-Senior-Notes-2016-4-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of $1.0 billion aggregate principal amount of 3.000% senior notes due 2023 at an issue price of 99.512% of the principal amount. The issuance of the notes is expected to close on or about April 13, 2016 , subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher plans to use the net proceeds of the offering and cash on hand to redeem all of the outstanding $1.0 billion aggregate principal amount of its 2.250% senior notes that mature on August 15, 2016 . The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner  Smith Incorporated ; Goldman, Sachs  Co. and Morgan Stanley  Co. LLC . The offering will be made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the Securities and Exchange Commission (the “SEC”). Prospective investors should read the prospectus forming a",
                "1d_change": -0.5658228155,
                "index_price": -1.3700522137,
                "norm_price": 0.8042293982
            },
            {
                "index": 277,
                "date": "2016-04-04",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 28, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-April-28-2016-2016-4-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2016 before the market opens on Thursday, April 28, 2016 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its first quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, May 13, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries.",
                "1d_change": -0.5658228155,
                "index_price": -1.3700522137,
                "norm_price": 0.8042293982
            },
            {
                "index": 278,
                "date": "2016-03-31",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by Affymetrix Stockholders",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Completes-Acquisition-of-Affymetrix-Following-Approval-of-Transaction-by-Affymetrix-Stockholders-2016-3-31/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Affymetrix, Inc. (NASDAQ:AFFX), a leading provider of cellular and genetic analysis products, today announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion . Completion of the transaction follows approval of the merger agreement by Affymetrix stockholders at the special meeting held today. “We are pleased to announce the completion of this transaction and officially welcome the Affymetrix team to Thermo Fisher,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific . “This is a great outcome for both companies. With Affymetrix , we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets. Our combined capabilities will benefit our",
                "1d_change": 1.3457815548,
                "index_price": 0.4346823898,
                "norm_price": 0.911099165
            },
            {
                "index": 279,
                "date": "2016-03-28",
                "press_title": "Thermo Fisher Scientific Agrees with Affymetrix that Merger Agreement Remains Superior",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Agrees-with-Affymetrix-that-Merger-Agreement-Remains-Superior-2016-3-28/default.aspx",
                "content": "Prepared to Close the Transaction Immediately Following Affymetrix Stockholder Approval Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today issued the following statement regarding Affymetrix , Inc.’s (NASDAQ: AFFX) press release dated March 28, 2016 : “We are pleased that the Affymetrix board of directors has concluded that our merger agreement remains superior and continues to recommend that Affymetrix stockholders vote in favor of the transaction at the March 31, 2016 , stockholder meeting,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “We are confident that Affymetrix stockholders will show their resounding support for our fully financed, all cash merger by voting in favor of our merger agreement. We look forward to completing the transaction immediately following the vote and welcoming our new Affymetrix colleagues to Thermo Fisher.” JP Morgan is acting as financial advisor to Thermo Fisher, and",
                "1d_change": 0.3996170728,
                "index_price": 0.8330857288,
                "norm_price": -0.433468656
            },
            {
                "index": 280,
                "date": "2016-03-23",
                "press_title": "Thermo Fisher Scientific Remains Confident That Origin Technologies’ Proposal is Not Likely to Result in a Superior Proposal",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Remains-Confident-That-Origin-Technologies-Proposal-is-Not-Likely-to-Result-in-a-Superior-Proposal-2016-3-23/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today issued the following statement regarding Origin Technologies’ most recent proposal to acquire Affymetrix, Inc. (NASDAQ: AFFX) (“Affymetrix”): “The Thermo Fisher transaction, which has been unanimously approved by both boards of directors, provides Affymetrix shareholders with a significant premium, is fully-financed, and received all required regulatory approvals,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “In contrast, Origin Technologies has still not addressed the fundamental flaws of its proposal, which has remained from its first announcement highly contingent, uncertain and insufficient. “We fully expect that the Affymetrix board of directors will promptly conclude that our transaction remains the only bona fide alternative for Affymetrix stockholders and, as contemplated by the terms of our merger agreement, will definitively recommend against",
                "1d_change": 0.0143674935,
                "index_price": -0.6193752166,
                "norm_price": 0.6337427101
            },
            {
                "index": 281,
                "date": "2016-03-22",
                "press_title": "Thermo Fisher Scientific Issues Open Letter to Affymetrix Stockholders",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Issues-Open-Letter-to-Affymetrix-Stockholders-2016-3-22/default.aspx",
                "content": "Remains Confident that Thermo Fisher Merger Agreement is Superior to Origin Technologies’ Proposal Urges Affymetrix Stockholders to Vote Their Shares in Favor of the Thermo Fisher Acquisition Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today commented on the press release of Origin Technologies Corporation, LLC dated March 21, 2016 , that was issued in response to the Affymetrix board of directors’ determination that Origin Technologies’ March 18, 2016 , unsolicited proposal does not constitute, and could not reasonably be expected to lead to, a “Superior Proposal” as defined in the Agreement and Plan of Merger between Thermo Fisher and Affymetrix (the “Merger Agreement”). In connection with this, Thermo Fisher reiterated its belief that the Merger Agreement is superior and remains in the best interest of Affymetrix and its stockholders. “We are confident that our Merger Agreement continues to be superior to the proposal put forth to Affymetrix by",
                "1d_change": -0.2377290604,
                "index_price": -0.5857452396,
                "norm_price": 0.3480161792
            },
            {
                "index": 282,
                "date": "2016-03-20",
                "press_title": "Thermo Fisher Scientific Issues Open Letter to Affymetrix Stockholders",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Issues-Open-Letter-to-Affymetrix-Stockholders-2016-3-20/default.aspx",
                "content": "Agrees with Affymetrix that Acquisition Proposal from Origin Technologies Does Not Constitute, and Could Not Reasonably be Expected to Lead to, a Superior Proposal Reiterates Commitment to Completing Affymetrix Transaction as Quickly as Possible, which is in the Best Interests of All Affymetrix Stockholders Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science, today commented on the press release of Affymetrix, Inc. that responded to the unsolicited, non-binding proposal received on March 18, 2016 , from Origin Technologies Corporation, LLC (the “Origin Proposal”). Thermo Fisher agrees with Affymetrix and its board of directors that the Origin Proposal does not constitute, and could not reasonably be expected to lead to, a “Superior Proposal” as defined in the Agreement and Plan of Merger between Thermo Fisher and Affymetrix (the “Merger Agreement”) and that Affymetrix and its board of directors could not reasonably determine otherwise. Thermo Fisher continues to",
                "1d_change": -0.4681069499,
                "index_price": 0.0936698165,
                "norm_price": -0.5617767664
            },
            {
                "index": 283,
                "date": "2016-03-09",
                "press_title": "Thermo Fisher Scientific to Present at the Barclays Global Healthcare Conference on March 15, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Present-at-the-Barclays-Global-Healthcare-Conference-on-March-15-2016-2016-3-9/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016, at 8:00 a.m. (EDT) at the Loews Miami Hotel, Miami, Fla. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer",
                "1d_change": -1.2249873329,
                "index_price": 0.4086312672,
                "norm_price": -1.6336186001
            },
            {
                "index": 284,
                "date": "2016-03-07",
                "press_title": "Thermo Fisher Scientific Continues to Expand Leading Analytical Instruments Offering for Customers in Applied Markets",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Continues-to-Expand-Leading-Analytical-Instruments-Offering-for-Customers-in-Applied-Markets-2016-3-7/default.aspx",
                "content": "Pittcon 2016 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled new products across its instrument, consumables, software and services portfolio that make advanced analysis more accessible to customers in applied markets. The company will showcase its depth of capabilities for applications such as biopharma, food safety and environmental analysis at the Pittcon Conference and Exhibition in Booth 2239 at the Georgia World Congress Center from March 7-10, 2016 . “In today’s economic environment, our customers rely on us more than ever to help them accelerate results and improve productivity,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “We are committed to developing new products that make our industry-leading technologies available to a broader base of customers and set new standards for detection and quantification in applied markets.” Expanding Leadership in Analytical Technologies Building on",
                "1d_change": 0.2588035513,
                "index_price": -0.8513270365,
                "norm_price": 1.1101305878
            },
            {
                "index": 285,
                "date": "2016-02-25",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2016-2-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 15, 2016 , to shareholders of record as of March 15, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information,",
                "1d_change": 0.5431639186,
                "index_price": 0.8305769003,
                "norm_price": -0.2874129817
            },
            {
                "index": 286,
                "date": "2016-01-28",
                "press_title": "Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-Reports-Record-Fourth-Quarter-and-Full-Year-2015-Results-2016-1-28/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2015 . Fourth Quarter and Full Year 2015 Highlights Grew fourth quarter adjusted earnings per share (EPS) by 7% to $2.12 and full year adjusted EPS by 6% to $7.39 . Increased fourth quarter revenue by 4% to $4.65 billion . Expanded fourth quarter adjusted operating margin by 40 basis points to 23.2%. Launched significant new products in 2015 for research, clinical and applied markets, highlighted by the QuantStudio 3 and 5 qPCR systems, Orbitrap Fusion Lumos Tribrid mass spectrometer and the Ion S5 and S5 XL next-generation sequencing instruments. Leveraged increasing scale in Asia-Pacific and emerging markets to deliver strong growth, led by outstanding performance in China and significant contributions from India and South Korea . Successfully integrated the Life Technologies acquisition, which strengthened our",
                "1d_change": 0.9086759284,
                "index_price": 2.835732683,
                "norm_price": -1.9270567546
            },
            {
                "index": 287,
                "date": "2016-01-08",
                "press_title": "Thermo Fisher Scientific to Acquire Affymetrix",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Acquire-Affymetrix-2016-1-8/default.aspx",
                "content": "Strengthens Leadership in Biosciences and Genetic Analysis Significantly Expands Portfolio of Antibodies and Assays for High-Growth Flow Cytometry and Single-Cell Biology Applications Adds Complementary Genetic Analysis Products Serving Research, Clinical and Applied Markets Offers Opportunity to Leverage Thermo Fisher’s Commercial and Geographic Scale Creates Attractive Financial Benefits; Expected to be Immediately Accretive to Adjusted Earnings per Share (EPS) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Affymetrix Inc. (NASDAQ: AFFX), a leading provider of cellular and genetic analysis products, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion . Affymetrix’s technologies enable parallel and multiplex analysis of biological systems at the cellular, protein and genetic level,",
                "1d_change": -0.5338222227,
                "index_price": -1.1592386557,
                "norm_price": 0.6254164331
            },
            {
                "index": 288,
                "date": "2016-01-04",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 28, 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2016/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-January-28-2016-2016-1-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2015 fourth quarter and full year before the market opens on Thursday, January 28, 2016 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its fourth quarter and full year financial performance, as well as future expectations, including initial 2016 financial guidance. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through March 1, 2016 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with",
                "1d_change": -0.6786488662,
                "index_price": -1.065596474,
                "norm_price": 0.3869476078
            },
            {
                "index": 289,
                "date": "2015-12-29",
                "press_title": "Thermo Fisher Scientific to Present at Upcoming Investor Conferences",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-Upcoming-Investor-Conferences-2015-12-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the following investor conferences in January: Goldman Sachs Healthcare CEOs Unscripted: A View from the Top, on Tuesday, January 5, 2016 , at 8:45 a.m. (EST) at the InterContinental Boston , Boston, Mass. 34 th Annual J. P. Morgan Healthcare Conference on Tuesday, January 12, 2016 , at 8:00 a.m. (PST) at the Westin St. Francis , San Francisco, Calif. You can access the live webcast of the presentations via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve",
                "1d_change": 0.8959914284,
                "index_price": 0.1366735913,
                "norm_price": 0.7593178371
            },
            {
                "index": 290,
                "date": "2015-12-04",
                "press_title": "Company Profile for Thermo Fisher Scientific",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Company-Profile-for-Thermo-Fisher-Scientific-2015-12-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com .   Company: Thermo Fisher Scientific   Headquarters Address: 81 Wyman Street Waltham, MA 02451   Main Telephone: 781-622-1000   Website: thermofisher.com   Twitter: http://twitter.com/thermofisher   Facebook: https://www.facebook.com/thermofisher   LinkedIn:",
                "1d_change": 1.4387726023,
                "index_price": 1.2435824154,
                "norm_price": 0.1951901869
            },
            {
                "index": 291,
                "date": "2015-11-30",
                "press_title": "Thermo Fisher Scientific Prices Offering of Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Prices-Offering-of-Senior-Notes-2015-11-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of $450 million aggregate principal amount of 2.150% senior notes due 2018 at an issue price of 99.997% of the principal amount and $350 million aggregate principal amount of 3.650% senior notes due 2025 at an issue price of 99.858% of the principal amount. The issuance of the notes is expected to close on or about December 9, 2015 , subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher plans to use the net proceeds of the offering to redeem all of the outstanding $900 million aggregate principal amount of its 3.20% senior notes that mature on March 1, 2016 . The joint book-running managers for the offering are Goldman, Sachs  Co. , J.P. Morgan Securities LLC and Mizuho Securities USA Inc. The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and",
                "1d_change": -1.4022519085,
                "index_price": 0.5554915649,
                "norm_price": -1.9577434734
            },
            {
                "index": 292,
                "date": "2015-11-13",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2015-11-13/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €425 million aggregate principal amount of 1.50% senior notes due 2020 at an issue price of 99.971% of the principal amount. The issuance of the notes is expected to close on or about November 24, 2015 , subject to customary closing conditions. The notes will pay interest on an annual basis. The company plans to use a portion of the net proceeds of the offering to redeem all of the outstanding $400 million aggregate principal amount of 3.50% senior notes issued by Life Technologies Corporation prior to its acquisition by Thermo Fisher, which mature on January 15, 2016 , and the remainder for general corporate purposes. The joint book-running managers for the offering are Deutsche Bank AG , London Branch and HSBC Bank plc. The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission (“SEC”).",
                "1d_change": 2.1174463861,
                "index_price": 0.4164216172,
                "norm_price": 1.7010247689
            },
            {
                "index": 293,
                "date": "2015-11-12",
                "press_title": "Thermo Fisher Scientific Authorizes $1 Billion of Share Repurchases and Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Authorizes-1-Billion-of-Share-Repurchases-and-Declares-Quarterly-Dividend-2015-11-12/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $1 billion of shares of its common stock in the open market or in negotiated transactions. The new share repurchase authorization replaces the existing authorization, in which there was approximately $410 million remaining. The company intends to resume share repurchases in 2016. The board also declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 15, 2016 , to shareholders of record as of December 15, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges,",
                "1d_change": -1.1184365608,
                "index_price": -2.4344550305,
                "norm_price": 1.3160184697
            },
            {
                "index": 294,
                "date": "2015-11-03",
                "press_title": "Thermo Fisher Scientific to Present at Baird’s 2015 Industrial Conference on November 10, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-Bairds-2015-Industrial-Conference-on-November-10-2015-2015-11-3/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Thomas Loewald , senior vice president and president analytical instruments, will present at Baird’s 2015 Industrial Conference on Tuesday, November 10, 2015 , at 8:30 a.m. (CST) at the Four Seasons Hotel , Chicago, Ill. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity",
                "1d_change": 0.8650740085,
                "index_price": -0.01521299,
                "norm_price": 0.8802869985
            },
            {
                "index": 295,
                "date": "2015-10-21",
                "press_title": "Thermo Fisher Scientific Reports Third Quarter 2015 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Reports-Third-Quarter-2015-Results-2015-10-21/default.aspx",
                "content": "Raises Full-year Revenue and Earnings Guidance Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter of 2015, ended September 26, 2015 . Third Quarter 2015 Highlights Grew adjusted earnings per share (EPS) by 5% to $1.80 . Delivered revenue of $4.12 billion . Expanded adjusted operating margin by 70 basis points to 22.6%. Launched Ion S5 and Ion S5 XL to enable targeted next-generation sequencing, including gene panels as well as small genomes, exomes, transcriptomes and custom assays, on a single platform. Strengthened clinical offering by introducing a range of new Thermo Scientific products at AACC, including new immunodiagnostic tests and instruments, and a high-throughput HPLC; obtained CE marks for clinical use of HPLC, mass spectrometry and related software in Europe . Achieved strong revenue growth in China , driven by customer demand in biopharma, environmental and food safety markets.",
                "1d_change": -3.8145300602,
                "index_price": 0.9276465874,
                "norm_price": -4.7421766476
            },
            {
                "index": 296,
                "date": "2015-10-01",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-October-21-2015-2015-10-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2015 before the market opens on Wednesday, October 21, 2015 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its third quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, November 6, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000",
                "1d_change": 1.4378386389,
                "index_price": 1.6250185089,
                "norm_price": -0.18717987
            },
            {
                "index": 297,
                "date": "2015-09-30",
                "press_title": "Thermo Fisher Scientific Completes Acquisition of Alfa Aesar to Significantly Expand Laboratory Chemicals Offering",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Completes-Acquisition-of-Alfa-Aesar-to-Significantly-Expand-Laboratory-Chemicals-Offering-2015-9-30/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Alfa Aesar, a leading global manufacturer of research chemicals, from Johnson Matthey Plc , for £256 million (or approximately $400 million ) in cash. “With the close of the transaction, we now have the opportunity to fully leverage our combined capabilities in laboratory chemicals to drive growth,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “The addition of Alfa Aesar products to our existing chemicals portfolio offers customers greater access to a broad offering that serves virtually every laboratory application – from research to production.” Alfa Aesar has approximately 480 employees at key locations in the United Kingdom , United States , Germany , China , South Korea and India . The business generated sales of approximately £78 million in 2014 and will be integrated into Thermo Fisher’s Laboratory",
                "1d_change": 1.3349687379,
                "index_price": 1.9066197807,
                "norm_price": -0.5716510428
            },
            {
                "index": 298,
                "date": "2015-09-15",
                "press_title": "Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 16, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference-on-September-16-2015-2015-9-15/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2015 , at 2:50 p.m. (EDT) at the Grand Hyatt New York, New York . You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab",
                "1d_change": 2.7003354476,
                "index_price": 2.0152298052,
                "norm_price": 0.6851056424
            },
            {
                "index": 299,
                "date": "2015-07-27",
                "press_title": "Thermo Fisher Scientific Unveils New Solutions to Advance the Use of Clinical Testing and Improve Patient Outcomes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Unveils-New-Solutions-to-Advance-the-Use-of-Clinical-Testing-and-Improve-Patient-Outcomes-2015-7-27/default.aspx",
                "content": "New product innovations and enhanced services for diagnostic laboratories at AACC 2015 AACC 2015 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced new instruments and assays to expand the use of clinical testing, enhance laboratory productivity and ultimately improve patient outcomes. The new solutions were unveiled today at the 2015 AACC Annual Meeting and Clinical Lab Expo , Booth 3135, being held at the Georgia World Congress Center in Atlanta , July 26 - 30 . “As healthcare systems face the issue of improving patient care while reducing costs, the clinical laboratory becomes increasingly important in aiding diagnosis and treatment,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “Our role is to provide the tools to help our customers achieve rapid and more accurate results, while increasing laboratory productivity.” For laboratories performing allergy and autoimmunity testing, the fully",
                "1d_change": 0.8438562803,
                "index_price": 0.7194581915,
                "norm_price": 0.1243980888
            },
            {
                "index": 300,
                "date": "2015-07-22",
                "press_title": "Thermo Fisher Scientific Reports Second Quarter 2015 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Reports-Second-Quarter-2015-Results-2015-7-22/default.aspx",
                "content": "Raises Full-year Revenue and Earnings Guidance Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter of 2015, ended June 27, 2015 . Second Quarter 2015 Highlights Grew adjusted earnings per share (EPS) by 7% to $1.84 . Delivered revenue of $4.27 billion . Expanded adjusted operating margin by 90 basis points to 22.3%. Launched a number of new products, including the Orbitrap Fusion Lumos Tribrid mass spectrometer for proteomics, Q Exactive GC-MS/MS for research and applied markets, and the cloud-enabled QuantStudio 3 and 5 real-time PCR systems for genomics applications. Increased presence in emerging markets by opening a Customer Experience Center in Dubai to serve growing life sciences, healthcare and food safety markets across the Middle East . Expanded bioproduction capabilities in the U.K. with a state-of-the-art facility for manufacturing dry powder media to capitalize on increasing global",
                "1d_change": 0.2702753716,
                "index_price": -0.7639825578,
                "norm_price": 1.0342579295
            },
            {
                "index": 301,
                "date": "2015-07-16",
                "press_title": "Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Prices-Offering-of-Euro-Denominated-Senior-Notes-2015-7-16/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €500 million aggregate principal amount of 2.150% Senior Notes due 2022 at an issue price of 99.788% of the principal amount. The issuance of the notes is expected to close on or about July 21, 2015 , subject to customary closing conditions. The notes will pay interest on an annual basis. Thermo Fisher plans to use the net proceeds of the offering for general corporate purposes. The joint book-running managers for the offering are BNP Paribas and HSBC Bank plc . The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission (“SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and",
                "1d_change": -0.0294463602,
                "index_price": 0.7565852501,
                "norm_price": -0.7860316103
            },
            {
                "index": 302,
                "date": "2015-07-10",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2015-7-10/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on October 15, 2015 , to shareholders of record as of September 15, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information,",
                "1d_change": 3.3881937386,
                "index_price": 2.2318586989,
                "norm_price": 1.1563350397
            },
            {
                "index": 303,
                "date": "2015-07-01",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 22, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-July-22-2015-2015-7-1/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2015 before the market opens on Wednesday, July 22, 2015 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its second quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, August 14, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000",
                "1d_change": 0.2138145233,
                "index_price": 0.4709227342,
                "norm_price": -0.2571082109
            },
            {
                "index": 304,
                "date": "2015-06-25",
                "press_title": "Thermo Fisher Scientific Signs Agreement to Acquire Research Chemicals Leader Alfa Aesar",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Signs-Agreement-to-Acquire-Research-Chemicals-Leader-Alfa-Aesar-2015-6-25/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals and part of Johnson Matthey Plc , for £256 million (or approximately $405 million ) in cash. Based in Heysham, U.K. , Alfa Aesar has 480 employees and operates in key research hubs in the United States , Germany , China , South Korea and India . The business generated sales of approximately £78 million (or $125 million ) in 2014. “The acquisition of Alfa Aesar enhances our existing portfolio of chemicals, solvents and reagents to support virtually every laboratory application – from research, to drug discovery and development, to production,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “In addition, customers will benefit from greater access to these products through our extensive global commercial reach.” The transaction, which is",
                "1d_change": 1.5127361746,
                "index_price": -0.4030459694,
                "norm_price": 1.915782144
            },
            {
                "index": 305,
                "date": "2015-06-08",
                "press_title": "Thermo Fisher Scientific to Present at the Goldman Sachs 36th Annual Global Healthcare Conference on June 9, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-the-Goldman-Sachs-36th-Annual-Global-Healthcare-Conference-on-June-9-2015-2015-6-8/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Goldman Sachs 36 th Annual Global Healthcare Conference on Tuesday, June 9, 2015 , at 8:00 a.m. (PDT) at the Terranea Resort , Rancho Palos Verdes, Calif. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific",
                "1d_change": -0.5289054765,
                "index_price": -0.586024379,
                "norm_price": 0.0571189025
            },
            {
                "index": 306,
                "date": "2015-05-21",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2015-5-21/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 15, 2015 , to shareholders of record as of June 15, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please",
                "1d_change": -0.030243275,
                "index_price": 0.0239884929,
                "norm_price": -0.0542317679
            },
            {
                "index": 307,
                "date": "2015-05-05",
                "press_title": "Thermo Fisher Scientific to Host Analyst Meeting",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Host-Analyst-Meeting-2015-5-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2015 Analyst Meeting on Wednesday, May 20 , from 9:00 a.m. to noon (EDT), at the New York Hilton Midtown, 1335 Avenue of Americas , New York City . The meeting will feature presentations by members of Thermo Fisher Scientific’s senior management team, including expectations for future financial performance. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.",
                "1d_change": 1.1828460286,
                "index_price": -1.5614249931,
                "norm_price": 2.7442710217
            },
            {
                "index": 308,
                "date": "2015-05-04",
                "press_title": "Thermo Fisher Scientific to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-the-Bank-of-America-Merrill-Lynch-2015-Health-Care-Conference-on-May-13-2015-2015-5-4/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 , at 11:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nevada . You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher",
                "1d_change": -1.2554301369,
                "index_price": -0.9940376901,
                "norm_price": -0.2613924468
            },
            {
                "index": 309,
                "date": "2015-04-22",
                "press_title": "Thermo Fisher Scientific Reports First Quarter 2015 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Reports-First-Quarter-2015-Results-2015-4-22/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter of 2015, ended March 28, 2015 . First Quarter 2015 Highlights Grew adjusted earnings per share (EPS) by 7% to $1.63 . Increased revenue to $3.92 billion . Expanded adjusted operating margin by 60 basis points to 21.9%. Strengthened technology leadership with a number of new products, highlighted by the Gemini handheld chemical analyzer, Q Exactive Focus mass spectrometer and the latest release of Sample Manager LIMS all launched at Pittcon, as well as the new PDM3700 personal coal dust monitor, TSX ultralow-temperature freezer and the Ion Torrent AmpliSeq RNA Fusion panel. Expanded commercial capabilities to better penetrate analytical instrument markets in Asia by acquiring two channel partners covering Singapore , Malaysia and South Korea . Acquired Advanced Scientifics, Inc. (ASI) for $300 million , adding complementary single-use systems and",
                "1d_change": 0.2856146529,
                "index_price": 0.6938191319,
                "norm_price": -0.408204479
            },
            {
                "index": 310,
                "date": "2015-04-07",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 22, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Wednesday-April-22-2015-2015-4-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2015 before the market opens on Wednesday, April 22, 2015 , and will hold a conference call on the same day at 8:30 a.m. EDT . During the call, the company will discuss its first quarter financial performance, as well as future expectations. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, May 15, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000",
                "1d_change": -0.8583011617,
                "index_price": 0.0533101174,
                "norm_price": -0.911611279
            },
            {
                "index": 311,
                "date": "2015-03-09",
                "press_title": "Thermo Fisher Scientific Strengthens Technology Leadership in Applied Markets at Pittcon 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Strengthens-Technology-Leadership-in-Applied-Markets-at-Pittcon-2015-2015-3-9/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will showcase new products designed to help customers in applied markets accelerate innovation and maximize productivity during the 2015 Pittsburgh Conference and Exhibition , being held March 8 - 12 at the Ernest N. Morial Convention Center in New Orleans . “We continue to extend the use of our industry-leading analytical instruments and software to customers in applied markets who need greater sensitivity and speed,” said Marc N. Casper , president and chief executive officer of Thermo Fisher Scientific . “Our new products being launched at Pittcon this year reflect our ongoing commitment to technology innovation and our focus on giving customers in a range of industries the tools they need to achieve their goals.” An example of this versatility is the company’s newest ultra high-performance liquid chromatography system, the Thermo Scientific Vanquish UHPLC , which is making its Pittcon debut. It offers",
                "1d_change": -1.2280767135,
                "index_price": -1.3741568835,
                "norm_price": 0.14608017
            },
            {
                "index": 312,
                "date": "2015-02-26",
                "press_title": "Thermo Fisher Scientific Declares Quarterly Dividend",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Declares-Quarterly-Dividend-2015-2-26/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 15, 2015 , to shareholders of record as of March 16, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please",
                "1d_change": -0.5845982429,
                "index_price": -0.4471329109,
                "norm_price": -0.137465332
            },
            {
                "index": 313,
                "date": "2015-02-24",
                "press_title": "Thermo Fisher Scientific to Present at the Cowen and Company 35th Annual Health Care Conference on March 3, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Present-at-the-Cowen-and-Company-35th-Annual-Health-Care-Conference-on-March-3-2015-2015-2-24/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper , president and chief executive officer, will present at the Cowen and Company 35 th Annual Health Care Conference on March 3, 2015 , at 10:40 a.m. (EST) at the Boston Marriott Copley Place Hotel , Boston, Mass. You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems , Invitrogen, Fisher Scientific and Unity Lab",
                "1d_change": 0.1906810633,
                "index_price": 0.2251809261,
                "norm_price": -0.0344998627
            },
            {
                "index": 314,
                "date": "2015-02-17",
                "press_title": "Thermo Fisher Scientific’s Chief Financial Officer to Retire in Early 2016",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientifics-Chief-Financial-Officer-to-Retire-in-Early-2016-2015-2-17/default.aspx",
                "content": "Stephen Williamson to Become Chief Financial Officer, Effective August 2015 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Peter M. Wilver , senior vice president and chief financial officer, has decided to retire, effective March 31, 2016 . The company’s board of directors has elected Stephen Williamson , currently vice president of financial operations, as his successor, effective August 1, 2015 . Williamson will report to Marc N. Casper, president and chief executive officer of Thermo Fisher. Wilver, age 55, has led Thermo Fisher’s global finance organization as CFO since 2004. He joined the company in 2000 as vice president of financial operations. Wilver will work with Williamson during the ensuing months to ensure a smooth transition of responsibilities, and will remain an active member of the Company Leadership Team until his retirement in March 2016 . “Pete has done an incredible job as our CFO during a time of tremendous",
                "1d_change": 0.7656468902,
                "index_price": 0.1528785835,
                "norm_price": 0.6127683067
            },
            {
                "index": 315,
                "date": "2015-02-05",
                "press_title": "Thermo Fisher Scientific Strengthens Bioproduction Offering by Acquiring Advanced Scientifics, Inc.",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Strengthens-Bioproduction-Offering-by-Acquiring-Advanced-Scientifics-Inc-2015-2-5/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has acquired Advanced Scientifics, Inc. (ASI), a global provider of single-use technologies for customized bioprocessing solutions, for $300 million in cash. ASI designs, manufactures and delivers customized single-use systems and equipment for the preparation, processing, storage and transportation of biopharmaceuticals. The company has 380 employees and operations in Pennsylvania and Mexico . “ASI’s intense customer focus has led to the development of innovative solutions that complement our existing single-use technologies and expand our offering across the bioprocessing workflow,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific . “We see this acquisition as a great opportunity to meet customer demand for quality and productivity in bioprocessing, and plan to leverage our global reach to bring these innovative products to a larger customer base.”",
                "1d_change": -1.570542815,
                "index_price": 0.5847820548,
                "norm_price": -2.1553248699
            },
            {
                "index": 316,
                "date": "2015-01-29",
                "press_title": "Thermo Fisher Scientific Reports Strong Fourth Quarter and Full Year 2014 Results",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-Reports-Strong-Fourth-Quarter-and-Full-Year-2014-Results-2015-1-29/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2014 . Fourth Quarter and Full Year 2014 Highlights Grew fourth quarter adjusted earnings per share (EPS) by 39% to $1.99 and full year adjusted EPS by 28% to $6.96 . Increased revenue in the fourth quarter by 30% to $4.49 billion . Expanded fourth quarter adjusted operating margin by 280 basis points to 22.8%. Generated free cash flow of $2.25 billion for the full year. Expanded global Centers of Excellence during the year, including the October opening of a new facility in Fremont, California , to enhance our strategic position in specialty diagnostics. Launched significant new products throughout 2014 to expand our offering for clinical applications, strengthen our leadership in analytical instruments for research and applied markets, and build momentum in next-generation sequencing. Delivered more than $100",
                "1d_change": 1.4775044212,
                "index_price": -0.3739347553,
                "norm_price": 1.8514391765
            },
            {
                "index": 317,
                "date": "2015-01-07",
                "press_title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2015",
                "release_url": "https://ir.thermofisher.com/investors/news-events/news/news-details/2015/Thermo-Fisher-Scientific-to-Hold-Earnings-Conference-Call-on-Thursday-January-29-2015-2015-1-7/default.aspx",
                "content": "Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the 2014 fourth quarter and full year before the market opens on Thursday, January 29, 2015 , and will hold a conference call on the same day at 8:30 a.m. EST . During the call, the company will discuss its fourth quarter and full year financial performance, as well as future expectations, including initial 2015 financial guidance. To listen, call (877) 201-0168 within the U.S. or (647) 788-4901 outside the U.S. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, February 27, 2015 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc.  (NYSE:TMO) is the world leader in serving",
                "1d_change": 2.8479599799,
                "index_price": 2.7442291357,
                "norm_price": 0.1037308443
            }
        ]
    }
]